{
  "dataset": "ist3",
  "total_mechanisms_analyzed": 15,
  "total_abstracts_retrieved": 292,
  "overall_support_count": 7,
  "overall_conflict_count": 3,
  "overall_neutral_count": 282,
  "mechanism_results": [
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Higher NIHSS scores indicate more severe cerebral injury, which can limit the efficacy of reperfusion therapies like alteplase.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"reperfusion\" OR \"therapies\" OR \"alteplase\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions baseline stroke severity (NIHSS) only as an adjustment variable in regression models and reports no heterogeneity of treatment effect across subgroups, but it does not present specific analyses of how differing NIHSS levels (i.e., stroke severity) modify the efficacy of reperfusion therapies such as alteplase or thrombectomy. Therefore, it neither directly supports nor contradicts the proposed mechanism that higher NIHSS, indicating more severe injury, limits the efficacy of reperfusion therapies.",
          "key_findings": "Baseline NIHSS was included as an adjustment covariate in mixed-effects ordinal logistic regression for treatment effect of endovascular thrombectomy vs control; subgroup analyses showed no heterogeneity of treatment effect across prespecified subgroups, but the abstract does not report NIHSS-stratified efficacy results or specific interactions between stroke severity and response to reperfusion therapies like alteplase.",
          "pmid": "26898852",
          "title": "Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares tenecteplase with alteplase for acute ischaemic stroke and reports functional and safety outcomes, but does not analyze or report results stratified by NIHSS, nor does it discuss how baseline stroke severity (as measured by NIHSS) affects the efficacy of alteplase or other reperfusion therapy. Therefore, it neither supports nor contradicts the proposed mechanism that higher NIHSS scores (greater severity) limit the efficacy of alteplase.",
          "key_findings": "The trial showed that tenecteplase 0.25 mg/kg is non-inferior to alteplase 0.9 mg/kg for achieving mRS 0\u20131 at 90\u2013120 days, with similar rates of symptomatic intracerebral hemorrhage and mortality. Eligibility criteria included disabling neurological deficit and presentation within 4.5 hours, but no data are provided on NIHSS distributions or interaction between NIHSS severity and treatment efficacy.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses thrombolytic agents, adjunct therapies, and systems-of-care improvements for acute ischemic stroke but does not mention NIHSS scores, stroke severity stratification, or how initial neurological deficit modifies the efficacy of alteplase or other reperfusion therapies.",
          "key_findings": "The abstract states that alteplase is the only approved thrombolytic, introduces tenecteplase as a potential alternative (especially for large vessel occlusion), mentions adjunct therapies and intra-arterial thrombolysis after thrombectomy, and highlights the role of mobile stroke units and advanced imaging in expanding thrombolysis eligibility. No data or claims are presented about NIHSS severity influencing treatment efficacy.",
          "pmid": "36907201",
          "title": "Thrombolysis for acute ischaemic stroke: current status and future perspectives.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-stroke depression, its incidence, risk factors (including stroke severity), mechanisms of depression, and treatments. It does not address NIHSS scores, cerebral injury severity in relation to thrombolytic/reperfusion efficacy, or alteplase outcomes. Therefore it neither supports nor conflicts with the proposed mechanism about NIHSS-modulated efficacy of reperfusion therapy.",
          "key_findings": "Post-stroke depression affects about one-third of stroke survivors, with an incidence of 11\u201341% within 2 years. Risk factors include history of depression, stroke severity, and lesion location. Proposed mechanisms involve HPA axis dysregulation, inflammation, monoamine decrease, glutamate excitotoxicity, and abnormal neurotrophic responses. No data are presented on NIHSS or on how stroke severity affects alteplase or other reperfusion therapy efficacy.",
          "pmid": "34052887",
          "title": "The advances of post-stroke depression: 2021 update.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports NIHSS as a secondary outcome (\u22658\u2011point improvement at 48 hours) but does not analyze how baseline NIHSS severity affects the efficacy of alteplase or endovascular reperfusion. It focuses on ASPECTS-defined infarct size and compares endovascular therapy plus medical care versus medical care alone, with alteplase used similarly (~27%) in both groups. No data are presented on treatment effect modification by NIHSS level or on whether higher NIHSS scores limit alteplase efficacy.",
          "key_findings": "1) Trial included patients with large infarctions (ASPECTS 3\u20135), randomized to endovascular therapy plus medical care vs medical care alone. 2) About 27% in each arm received alteplase (0.6 mg/kg). 3) Endovascular therapy improved functional outcome: mRS 0\u20133 at 90 days in 31.0% vs 12.7% (RR 2.43). 4) NIHSS was used as a secondary outcome: \u22658\u2011point NIHSS improvement at 48 hours occurred in 31.0% vs 8.8% (RR 3.51). 5) The study does not evaluate whether higher baseline NIHSS scores reduce the efficacy of reperfusion therapy, including alteplase.",
          "pmid": "35138767",
          "title": "Endovascular Therapy for Acute Stroke with a Large Ischemic Region.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions NIHSS only as a stratification variable in the randomisation algorithm and does not analyze how baseline NIHSS (stroke severity) modifies the efficacy of alteplase or other reperfusion therapies. No results are presented relating NIHSS score to treatment response, penumbra salvage, or clinical outcome, so the proposed mechanism about higher NIHSS limiting alteplase efficacy is neither supported nor refuted.",
          "key_findings": "Patients were randomized to tenecteplase or alteplase with minimisation including NIHSS, but all reported outcomes (penumbra salvaged, hemorrhage rates, serious adverse events, neurological and radiological outcomes) compare drugs overall and do not examine the relationship between NIHSS severity and treatment efficacy.",
          "pmid": "25726502",
          "title": "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The mechanism concerns how higher NIHSS (greater stroke severity) may limit alteplase efficacy. This trial restricts enrollment to patients with minor deficits (NIHSS 0\u20135) and does not analyze or compare alteplase efficacy across different NIHSS severity strata beyond this narrow range. The primary analysis is adjusted for NIHSS but does not report differential treatment effect by NIHSS level, so it neither supports nor contradicts the idea that higher NIHSS scores reduce alteplase effectiveness.",
          "key_findings": "PRISMS randomized 313 patients with minor, nondisabling stroke (NIHSS 0\u20135; median NIHSS 2) to alteplase vs aspirin within 3 hours. Favorable 90-day outcome (mRS 0\u20131) was 78.2% with alteplase vs 81.5% with aspirin (adjusted risk difference \u22121.1%; 95% CI \u22129.4% to 7.3%), with higher sICH in the alteplase group (3.2% vs 0%). No analysis is presented of alteplase efficacy across different NIHSS levels beyond this minor-stroke range.",
          "pmid": "29998337",
          "title": "Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ischemic stroke epidemiology, risk factors, and the availability of acute medical and endovascular therapies in general terms, but it does not mention NIHSS scores, stroke severity scales, or how baseline severity affects the efficacy of reperfusion therapies like alteplase.",
          "key_findings": "Ischaemic stroke is common worldwide; modifiable risk factors include lifestyle behaviors and medical comorbidities; acute ischaemic stroke can now be treated with medical and endovascular therapies to reduce infarct volume; future advances are expected in prevention and recovery. No data are provided on NIHSS or severity-dependent treatment efficacy.",
          "pmid": "28800170",
          "title": "Ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke in cancer patients, thrombolysis safety, endovascular procedures, and prognosis predictors including initial stroke severity and metastasis, but it does not analyze how NIHSS score (as a measure of stroke severity) specifically alters the efficacy of reperfusion therapies like alteplase. There is no explicit link between baseline NIHSS and treatment response/effectiveness.",
          "key_findings": "The abstract notes that: (1) acute treatment with intravenous thrombolysis is considered safe in non-metastatic cancer patients; (2) early results from endovascular procedures are reassuring but show more frequent arterial reocclusion in cancer patients; and (3) prognosis is worse in patients with cancer and depends on predictors such as initial stroke severity and presence of metastasis. However, it does not report any data on how higher NIHSS scores influence the efficacy of alteplase or other reperfusion therapies.",
          "pmid": "37024364",
          "title": "Stroke and cancer.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses urinary incontinence as a marker of stroke severity and its association with poorer outcomes, but does not address NIHSS scores, cerebral injury severity metrics, reperfusion therapies, or alteplase efficacy. Therefore it neither supports nor contradicts the specific mechanism that higher NIHSS scores limit the efficacy of reperfusion therapy.",
          "key_findings": "Post-stroke urinary incontinence is common, correlates with greater stroke severity, and is associated with poorer functional outcomes, increased institutionalization, and higher mortality; better continence management and recovery are linked to better outcomes. No data on NIHSS scores or reperfusion therapy effectiveness are presented.",
          "pmid": "23834208",
          "title": "Post-stroke urinary incontinence.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on intrathecal therapies for vasospasm after aneurysmal subarachnoid hemorrhage and their effects on vasospasm, delayed cerebral ischemia, infarction, and functional outcome. It does not mention NIHSS scores, alteplase, reperfusion therapy, or how baseline stroke severity modifies response to such therapies. Therefore, it neither supports nor conflicts with the proposed mechanism about higher NIHSS limiting alteplase efficacy.",
          "key_findings": "Intrathecal treatments (CSF drainage via lumbar drain, intraventricular nimodipine, cisternal magnesium) reduced vasospasm, delayed cerebral ischemia, and cerebral infarction, and improved functional outcomes in aSAH patients, but no data are presented on NIHSS scores, alteplase use, or severity-dependent treatment effects.",
          "pmid": "35231885",
          "title": "Update on intrathecal management of cerebral vasospasm: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates overall efficacy of endovascular stent-retriever therapy versus medical management and examines modifiers such as time to treatment, age, gender, stroke severity, and IV tPA use. It states there were no significant differences in the beneficial effects across categories of stroke severity, but it does not analyze how higher NIHSS (more severe injury) specifically affects the efficacy of alteplase or reperfusion therapies mechanistically. The proposed mechanism about NIHSS-limited efficacy of alteplase is not directly tested or substantiated.",
          "key_findings": "Endovascular therapy with stent-retrievers improved functional outcome versus medical management; benefits were greater with shorter onset-to-groin puncture and onset-to-reperfusion times; there were no significant differences in beneficial effects across categories of stroke severity, gender, age, CT ischemic changes, or IV tPA administration.",
          "pmid": "26807742",
          "title": "Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The mechanism concerns how stroke severity (higher NIHSS) may limit the efficacy of reperfusion therapy (alteplase). This abstract focuses on time-to-thrombolysis effects and comparison of tenecteplase vs alteplase, only mentioning baseline NIHSS as a descriptive difference between time windows. It does not analyze how NIHSS modifies alteplase efficacy or outcomes, nor whether higher NIHSS attenuates benefit from thrombolysis.",
          "key_findings": "Patients treated in the 3\u20134.5 hour window had lower median baseline NIHSS (7 vs 10) and fewer large vessel occlusions than those treated within 0\u20133 hours, but outcomes were analyzed primarily in relation to onset-to-needle and door-to-needle times and thrombolytic type. Faster treatment was associated with better 90-day mRS outcomes, and tenecteplase showed a similar time\u2013outcome relationship as alteplase. No effect modification analysis of treatment efficacy by baseline NIHSS was reported.",
          "pmid": "37800372",
          "title": "Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "low",
          "reasoning": "The provided abstract text contains only the title and no substantive content about NIHSS scores, severity of cerebral injury, or response to reperfusion therapy such as alteplase. Without methods, results, or conclusions, there is no mechanistic evidence to assess whether higher NIHSS limits alteplase efficacy.",
          "key_findings": "No specific findings are available beyond the title; NIHSS, cerebral injury severity, and alteplase/reperfusion outcomes are not described.",
          "pmid": "33130478",
          "title": "Stroke and Thromboprophylaxis in the Era of COVID-19.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports clinical outcomes (NIHSS, mRS, ADL) and safety of argatroban (alone or with r-tPA) versus controls, but it does not analyze how baseline NIHSS severity modifies the efficacy of reperfusion therapy or whether higher NIHSS reflects injury that limits treatment response. No interaction, subgroup, or mechanistic analysis relating NIHSS level to treatment efficacy is presented.",
          "key_findings": "Argatroban, as monotherapy or adjunct to r-tPA, did not significantly improve NIHSS at 7 days, ADL, or mRS 0\u20131/0\u20132 at 90 days compared with placebo, standard therapy, or endovascular r-tPA, and did not significantly increase adverse events including symptomatic intracranial hemorrhage or major systemic bleeding.",
          "pmid": "38176219",
          "title": "Efficacy and safety of argatroban in the management of acute ischemic stroke: A systematic literature review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The proposed mechanism concerns baseline stroke severity measured by NIHSS limiting alteplase efficacy. This abstract evaluates cerebral microbleeds (baseline burden, new CMBs after alteplase) and their association with NIHSS change and mRS outcomes. While it shows that new microbleeds are associated with NIHSS worsening and that high CMB burden may worsen alteplase outcomes, it does not analyze how baseline NIHSS severity per se affects alteplase efficacy. NIHSS is used only as an outcome/change measure, not as a predictor or mechanistic determinant of treatment effect.",
          "key_findings": "1) New cerebral microbleeds developed only in the alteplase group (11%) within ~28 hours and were associated with mixed distribution and \u22655 baseline cerebral microbleeds. 2) New cerebral microbleeds were associated with an increase in NIHSS score (p=0.023). 3) In patients with \u22655 baseline cerebral microbleeds, alteplase treatment was associated with a numerical shift toward worse functional outcomes on mRS compared to those with <5 microbleeds. 4) The interaction between baseline \u22655 microbleeds and treatment group on ordinal mRS was significant (p interaction=0.042). These findings relate microbleeds to NIHSS change and alteplase outcomes, but not baseline NIHSS severity to alteplase efficacy.",
          "pmid": "34282985",
          "title": "Cerebral microbleeds development after stroke thrombolysis: A secondary analysis of the THAWS randomized clinical trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on cell adhesion molecules, inflammation, and their modulation of ischemic stroke injury and reperfusion, including widening the therapeutic window for thrombolysis. It does not discuss NIHSS scores, stroke severity scales, or how baseline clinical severity modifies the efficacy of reperfusion therapies like alteplase. Therefore it neither supports nor contradicts the proposed mechanism linking higher NIHSS scores (greater injury) to reduced efficacy of reperfusion therapy.",
          "key_findings": "Beta2-integrins, ICAM, and P-selectin contribute to leukocyte and platelet recruitment in post-ischemic cerebral microvasculature; blocking these molecules (via immunoblockade or genetic deletion) reduces infarct volume, edema, behavioral deficits, and/or mortality in animal stroke models. Anti-adhesion agents may widen the therapeutic window for thrombolytic therapy in experimental models. Clinical trials of anti-adhesion therapies have so far failed to show efficacy, partly due to immune reactions, and further trials with humanized or non-immunogenic agents are needed. Adhesion-blocking strategies seem particularly effective at reperfusion and may be combined with thrombolytics.",
          "pmid": "18826804",
          "title": "Cell adhesion molecules and ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that predictive nursing, combined with alteplase, improves NIHSS scores and other outcomes, but it does not analyze how baseline NIHSS severity modifies the efficacy of alteplase. There is no stratification or interaction analysis relating initial NIHSS to treatment response, so the proposed mechanism\u2014that higher NIHSS indicates more severe cerebral injury which limits alteplase efficacy\u2014is neither directly supported nor refuted.",
          "key_findings": "In ischemic stroke patients treated with alteplase, adding predictive nursing shortened Door-to-Needle Time, improved NIHSS, FMA, MMSE, and MoCA scores, enhanced venous blood flow parameters, and reduced recurrence of ischemic stroke, DVT, and gingival bleeding compared with routine nursing alone. No data are presented on how differing baseline NIHSS levels impact the effectiveness of alteplase.",
          "pmid": "36738135",
          "title": "Effects of predictive nursing intervention on cognitive impairment and neurological function in ischemic stroke patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how prior antiplatelet use affects safety and functional outcomes after intravenous alteplase and includes analyses adjusted for age and admission NIHSS, but it does not analyze or report how different NIHSS levels themselves modify alteplase efficacy. NIHSS is treated solely as a confounder, not as the mechanistic variable of interest, so the study provides no direct evidence on whether higher NIHSS (greater stroke severity) limits the effectiveness of alteplase.",
          "key_findings": "In a meta-analysis of 7 RCTs (4376 patients), antiplatelet pretreatment was initially associated with higher symptomatic ICH, higher mortality, and lower 3\u2011month functional independence in unadjusted analyses. After adjustment for age and admission NIHSS, antiplatelet pretreatment was no longer associated with symptomatic ICH, 3\u2011month functional independence, or death. The study does not stratify outcomes by NIHSS level or examine an interaction between NIHSS severity and alteplase efficacy.",
          "pmid": "28550481",
          "title": "Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses polymorphonuclear neutrophils, their role in ischemic brain injury, reperfusion deficits, and recovery, but does not mention NIHSS scores, stroke severity scales, or the differential efficacy of reperfusion therapies like alteplase as a function of stroke severity. Therefore it neither supports nor contradicts the proposed mechanism about higher NIHSS limiting alteplase efficacy.",
          "key_findings": "PMNs are rapidly recruited after ischemic stroke and exacerbate injury via ROS, proteases, and proinflammatory cytokines; they may worsen microvascular injury and contribute to reperfusion deficits; experimental PMN depletion or blockade of brain entry reduces infarct volume and neurological deficits in animal models; elevated peripheral PMN responses in humans are associated with larger infarcts and poorer outcomes; however, clinical trials targeting PMN brain infiltration did not improve or worsened outcomes; PMNs also have roles in post-ischemic angiogenesis and brain remodeling. None of these findings directly address NIHSS-based stroke severity or altered efficacy of reperfusion therapy such as alteplase.",
          "pmid": "35087539",
          "title": "Roles of Polymorphonuclear Neutrophils in Ischemic Brain Injury and Post-Ischemic Brain Remodeling.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Severe strokes may be less responsive to thrombolysis if there is extensive tissue damage beyond recovery even with restored blood flow.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"thrombolysis\" OR \"responsive\" OR \"extensive\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 12,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 12,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on IV tPA dosing, ethnic differences, and functional outcomes/safety across Asian populations. It does not analyze how baseline stroke severity or extent of irreversibly damaged tissue affects responsiveness to thrombolysis, nor does it examine cases where reperfusion fails to yield benefit due to extensive non-salvageable tissue.",
          "key_findings": "18 Asian thrombolysis publications (9300 patients) show: (1) low-dose IV-tPA in Japanese patients appears comparable in efficacy and safety to standard dose; (2) functional outcomes with low-dose IV-tPA in non-Japanese Asian populations were similar to Japanese studies; (3) with standard-dose IV-tPA, better functional outcomes were observed without increased symptomatic intracerebral hemorrhage; (4) variable-dose regimens are used without robust evidence, and establishing a uniform regimen is recommended. No data are presented on differential response to thrombolysis based on severity or extent of irreversible tissue damage.",
          "pmid": "22111797",
          "title": "Current status of intravenous thrombolysis for acute ischemic stroke in Asia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The proposed mechanism concerns reduced responsiveness to thrombolysis in severe strokes due to extensive irrecoverable tissue damage, predicting poorer benefit from reperfusion. This meta-analysis compares outcomes of endovascular therapy versus IV thrombolysis overall and in a severe-stroke subgroup, but it does not examine tissue viability, extent of irreversible damage, or differential responsiveness of severe strokes to thrombolysis per se. The finding that endovascular therapy may have better outcomes than IV thrombolysis in severe strokes addresses treatment comparisons, not whether severe strokes are intrinsically less responsive to thrombolysis because of non-salvageable tissue.",
          "key_findings": "Five randomized trials (1197 patients) comparing endovascular therapy (ET) to IV thrombolysis showed no overall superiority of ET. In subgroup analysis of severe strokes (NIHSS \u226520), ET showed better outcomes than IV thrombolysis, with additional absolute improvements of 4%, 7%, and 13% in excellent, good, and fair outcomes, respectively. Evidence was limited by sample size.",
          "pmid": "24079677",
          "title": "Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates erythropoietin and its analogues as neuroprotective agents in animal stroke models, focusing on infarct size reduction, dose, and timing (earlier than 6 hours vs later). It does not investigate thrombolysis, responsiveness to thrombolytic therapy, recanalization, or the impact of baseline stroke severity or extent of irreversibly damaged tissue on thrombolytic efficacy. Therefore, it neither supports nor contradicts the proposed mechanism that severe strokes with extensive irrecoverable damage are less responsive to thrombolysis.",
          "key_findings": "Erythropoietin and its analogues, when given after onset of ischemia, reduced infarct size by 32% and improved neurobehavioral deficits in animal models. Higher doses were associated with smaller infarct volumes, and treatment initiated earlier than 6 hours was more effective than later initiation. Both hematopoietic and nonhematopoietic analogues showed efficacy. The abstract calls for further studies on combining EPO with thrombolysis but provides no data on thrombolytic responsiveness or severe stroke irreversibility.",
          "pmid": "19542052",
          "title": "The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses development of neuroprotective antioxidant compounds for ischemic stroke and mentions thrombolysis and thrombectomy only as existing treatments. It does not address differential responsiveness of severe versus mild strokes to thrombolysis, nor does it examine outcomes in relation to extent of irreversibly damaged tissue after reperfusion.",
          "key_findings": "The review summarizes preclinical development of antioxidant/neuroprotective compounds, including dose-response, therapeutic window, long-term neuroprotective effects, and in vivo antioxidant evaluations, and suggests these compounds may complement current treatments such as thrombolysis, but provides no data on how severe tissue damage affects response to thrombolytic therapy.",
          "pmid": "38136221",
          "title": "Development of Pharmacological Strategies with Therapeutic Potential in Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates safety and overall clinical efficacy of combination low-dose rt-PA plus eptifibatide versus standard-dose rt-PA in acute ischemic stroke, but it does not analyze treatment response specifically as a function of stroke severity, tissue extent, or irreversibility of damage. No data are presented on differential thrombolytic responsiveness in severe versus less severe strokes, nor on the role of extensive non-salvageable tissue despite recanalization.",
          "key_findings": "The CLEAR trial compared low-dose rt-PA plus eptifibatide to standard-dose rt-PA within 3 hours of stroke onset. Symptomatic intracranial hemorrhage was 1.4% in the combination group and 8.0% in the standard-dose group. There was a trend toward greater clinical efficacy with standard-dose rt-PA. Baseline NIHSS was higher in the combination group (median 14 vs 10), but the study does not examine how stroke severity or nonviable tissue burden affects responsiveness to thrombolysis, nor does it discuss lack of benefit in severe strokes due to irrecoverable tissue damage.",
          "pmid": "18772447",
          "title": "The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares low-dose versus standard-dose alteplase in acute ischemic stroke and reports improvements in neurological function and safety, but it does not analyze outcomes by stroke severity, infarct extent, or presence of irreversibly damaged tissue. There is no examination of differential responsiveness of severe versus mild strokes to thrombolysis, so it neither supports nor contradicts the proposed mechanism about extensive nonviable tissue limiting benefit.",
          "key_findings": "Both 0.6 mg/kg and 0.9 mg/kg alteplase intravenous thrombolysis improved neurological function and living ability in acute ischemic stroke patients, with reported safety and no persistent adverse reactions. The study does not stratify results by initial stroke severity, infarct size, or degree of tissue damage, and thus provides no direct evidence about reduced thrombolytic responsiveness in severe strokes with extensive irrecoverable tissue damage.",
          "pmid": "31894036",
          "title": "Efficacy of different doses of alteplase thrombolysis on acute ischemic stroke in patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates dosing, recanalization, and safety of intraarterial r-tPA in severe strokes (NIHSS 16\u201321), but it does not analyze outcomes specifically in relation to the extent of irreversible tissue damage or compare responsiveness of severe versus less severe strokes. It shows some neurological improvement and angiographic recanalization but does not link lack of response to extensive non-salvageable tissue, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Eight patients with acute ischemic stroke (NIHSS 16\u201321) received intraarterial r-tPA up to 40 mg; perfusion grade and thrombus burden improved dose-dependently; 4/8 patients had NIHSS improvement \u22652 points; asymptomatic intracerebral hemorrhage occurred in 2 patients; the study concludes intraarterial r-tPA up to 40 mg is relatively safe and facilitates recanalization, but does not assess impact of pre-existing irreversible tissue damage on treatment responsiveness.",
          "pmid": "10942026",
          "title": "Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses Panax notoginseng saponins as a treatment for ischemic stroke, focusing on mechanisms like anti-inflammatory and neuroprotective effects and general neurological recovery, but it does not address differential responsiveness of severe versus mild strokes to thrombolysis, nor the role of extensive irreversibly damaged tissue in limiting benefit from reperfusion therapies.",
          "key_findings": "PNS regulates oxidative stress, inflammation, apoptosis, ferroptosis, pyroptosis, angiogenesis, and neurogenesis; it lowers neurological deficit scores, improves hemorheology, and promotes neurological recovery in ischemic stroke; issues include low bioavailability and lack of high-quality clinical trials. No mention is made of thrombolysis, reperfusion, stroke severity stratification, or non-salvageable tissue burden.",
          "pmid": "41173082",
          "title": "Panax notoginseng saponins against ischemic stroke: From molecule to clinic.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how prior aspirin use and subsequent heparin dosing affect early intracranial hemorrhage risk after rt-PA thrombolysis and finds that hemorrhagic complications depend on baseline stroke severity (NIHSS). While this shows an association between stroke severity and bleeding risk, it does not address whether severe strokes are less responsive to thrombolysis due to irreversibly damaged tissue being non-salvageable even after reperfusion. No data on recanalization success, tissue viability, or clinical responsiveness to thrombolysis by severity are provided.",
          "key_findings": "In 300 rt-PA\u2013treated stroke patients, logistic regression showed no relationship of early hemorrhagic complications with aspirin pretreatment (p = 0.15) or heparin application (p = 0.38), but a dependence on baseline stroke severity (NIHSS; p = 0.01). The study concludes ASA pretreatment does not increase symptomatic bleeding risk after systemic thrombolysis, even when followed by anticoagulation.",
          "pmid": "12865603",
          "title": "Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a phase I dose-escalation safety trial of an intra-arterial neuroprotective agent (OTR4132) administered after successful endovascular reperfusion. It reports safety outcomes and only exploratory functional and imaging endpoints, without analyzing differential response to reperfusion or thrombolysis as a function of stroke severity or irreversibly damaged tissue. It does not examine whether severe strokes with extensive non-salvageable tissue are less responsive to thrombolysis or reperfusion, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "OTR4132, a heparan sulfate mimetic, was administered intra-arterially immediately after successful EVT (TICI 2b-3) in 19 anterior circulation stroke patients at escalating doses up to 2.5 mg. No treatment-related adverse events, vital sign changes, or lab abnormalities were observed through 3 months; four serious adverse events, including one fatal hemorrhagic transformation, were deemed unrelated or of unknown causality. The study focused on safety and dose tolerance, with efficacy endpoints exploratory and not analyzed in relation to baseline stroke severity or irreversibly damaged tissue volume.",
          "pmid": "41037228",
          "title": "Intra-arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares rates of ischemic and hemorrhagic stroke between edoxaban and warfarin in atrial fibrillation, focusing on prevention and subtype incidence. It does not address stroke severity, tissue viability, or differential responsiveness to thrombolysis, nor does it discuss outcomes after thrombolytic therapy. Therefore it neither supports nor conflicts with the proposed mechanism about reduced thrombolysis efficacy in severe strokes with extensive irreversible damage.",
          "key_findings": "High-dose edoxaban reduced overall stroke versus warfarin; low-dose edoxaban had similar or higher ischemic stroke rates. Both edoxaban regimens reduced hemorrhagic stroke and intracranial bleeding compared with warfarin. Ischemic stroke/TIA rates were similar for high-dose edoxaban and warfarin but higher for low-dose edoxaban. No data were presented on thrombolytic treatment response, infarct size, or tissue salvageability.",
          "pmid": "24947287",
          "title": "Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on thrombolysis decision-making in acute ischemic stroke patients taking NOACs, using drug-specific plasma level thresholds. It does not assess thrombolysis effectiveness as a function of stroke severity, tissue irreversibility, or extent of infarcted tissue, nor does it compare outcomes between severe and mild strokes after thrombolysis. Therefore, it neither supports nor contradicts the proposed mechanism that severe strokes are less responsive to thrombolysis due to extensive irreversible damage.",
          "key_findings": "The study prospectively evaluated AIS patients with and without NOAC therapy, measured NOAC plasma levels (dabigatran, rivaroxaban, apixaban), and applied predefined thresholds to determine eligibility for thrombolysis. It reports distribution of NOAC levels relative to these thresholds (e.g., some dabigatran and rivaroxaban patients below upper thresholds allowing thrombolysis; all apixaban patients above the threshold precluding thrombolysis) but does not report clinical outcomes or differential responsiveness to thrombolysis by stroke severity or tissue damage extent.",
          "pmid": "26001908",
          "title": "Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "statistical",
        "description": "NIHSS as a prognostic factor could create a ceiling effect, where those with very high scores have diminished likelihood of achieving 'alive and independent' outcomes.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"independent predictor\" OR \"confounding\" OR \"interaction effect\") AND (\"independent\" OR \"likelihood\" OR \"prognostic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 2,
      "conflict_count": 0,
      "neutral_count": 18,
      "support_percentage": 10.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.1,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke-associated pneumonia incidence, risk factors, and outcomes, including stroke severity as a risk factor, but does not mention NIHSS, its use as a prognostic scale, ceiling effects, or the specific outcome of being alive and independent. Therefore it neither supports nor contradicts the proposed statistical mechanism.",
          "key_findings": "SAP incidence is higher in ICU settings, partly attributed to higher stroke severity, mechanical ventilation, and stroke-induced immunodepression. SAP is associated with worse functional outcomes and increased short-term mortality in several study settings, but heterogeneity and confounding factors (larger neurological deficit, age, mechanical ventilation) complicate interpretation. No specific analysis of NIHSS-based prognostication or ceiling effects is provided.",
          "pmid": "23735757",
          "title": "Stroke-associated pneumonia: major advances and obstacles.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cell therapy, neurogenesis, and prognostic imaging markers in stroke but does not mention NIHSS, ceiling effects, or how baseline stroke severity scores influence probabilities of being alive and independent. There is no statistical or prognostic analysis related to NIHSS or any outcome scale that could inform the proposed ceiling effect mechanism.",
          "key_findings": "The abstract reviews: (1) mechanisms and promise of exogenous cell therapy in stroke (cell migration, survival, differentiation, angiogenesis, neurogenesis, immunomodulation, trophic factor secretion); (2) functional recovery and infarct volume reduction in animal models with MSCs and NSCs; (3) ethical and practical issues of different cell sources; (4) early clinical trial safety data; and (5) ongoing research into prognostic imaging markers and biomarkers of recovery. It does not address NIHSS, functional outcome scales, or statistical ceiling effects in prognostic modeling.",
          "pmid": "24627643",
          "title": "Brain repair: cell therapy in stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines infarct volume as a predictor of ICU/critical care needs after IV thrombolysis and reports that this relationship is independent of NIHSS. It does not analyze NIHSS specifically as a prognostic factor for \u2018alive and independent\u2019 outcomes, nor does it address ceiling effects in high NIHSS ranges. Therefore, it neither supports nor contradicts the proposed mechanism about NIHSS-related ceiling effects on functional outcomes.",
          "key_findings": "Infarct volume on early post-IVT MRI independently predicted ICU needs after adjusting for NIHSS and other covariates (OR 1.031 per cm\u00b3, p=0.024). ROC AUC for infarct volume alone was 0.766 and increased to 0.906 when combined with race, systolic blood pressure, and NIHSS. No analysis of NIHSS as a prognostic factor for \u2018alive and independent\u2019 outcomes or of any ceiling effect was presented.",
          "pmid": "25344632",
          "title": "Infarct volume predicts critical care needs in stroke patients treated with intravenous thrombolysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract identifies baseline NIHSS as an independent predictor of mortality, alongside age and mFPE. This directly supports the idea that NIHSS is a strong prognostic factor for poor outcome. While the abstract does not explicitly analyze a ceiling effect or stratify outcomes across very high NIHSS levels, demonstrating NIHSS as a powerful predictor of mortality is consistent with the proposed mechanism that higher NIHSS scores diminish the likelihood of achieving favorable outcomes such as being alive and independent.",
          "key_findings": "In multivariate analysis, predictors of mortality after thrombectomy for basilar artery occlusion were age (p<0.01), baseline NIHSS (p<0.01), and mFPE (p=0.01). FPE was a predictor of good functional outcome (mRS 0\u20132 at 90 days, p=0.04).",
          "pmid": "35724438",
          "title": "Predictors of first pass effect and effect on outcomes in mechanical thrombectomy for basilar artery occlusion.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that higher baseline NIHSS predicts worse mortality and poorer functional outcome after tPA, indicating it is treated as a prognostic factor. However, it does not examine or mention a ceiling effect at very high NIHSS values or specifically analyze the probability of achieving an 'alive and independent' outcome across the full NIHSS range to detect diminished likelihood at the upper end. Thus it neither supports nor contradicts the proposed ceiling-effect mechanism.",
          "key_findings": "Higher NIHSS at baseline was independently associated with increased risk of death (OR 1.12 per point increase) and with a reduced chance of good functional outcome (mRS 0\u20131; OR 0.80 per point increase). Age \u226580 years independently increased risk of symptomatic intracerebral hemorrhage and death, but not the chance of good functional outcome. No analysis of ceiling effects or specific behavior at very high NIHSS scores was reported.",
          "pmid": "22988960",
          "title": "TPA for ischemic stroke in patients \u226580\u00a0years.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions NIHSS as an adjusted covariate and confirms its role as a mortality predictor, but does not analyze prognostic ceiling effects, non-linearity, or differential outcomes at very high NIHSS levels. It focuses on biological age as an independent predictor, not on how NIHSS might create a ceiling effect for 'alive and independent' outcomes.",
          "key_findings": "Biological age estimated by DNA methylation predicts 3\u2011month mortality after ischemic stroke (OR\u22481.05 overall; stronger within large-artery atherosclerosis), independently of NIHSS score, chronological age, TOAST, vascular risk factors, previous mRS, and blood cell composition. NIHSS is included as a covariate but no analysis of ceiling effects or outcome stratification by NIHSS level is reported.",
          "pmid": "29515201",
          "title": "Biological Age is a predictor of mortality in Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that AF patients have higher baseline NIHSS scores and worse functional and mortality outcomes, but it does not analyze NIHSS as a prognostic factor in terms of a ceiling effect or examine whether very high NIHSS scores specifically limit the probability of achieving an 'alive and independent' outcome. No stratification by NIHSS level, non\u2011linearity, or ceiling behavior is presented, so the proposed statistical mechanism is neither supported nor refuted.",
          "key_findings": "AF patients had more severe neurological impairment at baseline (NIHSS 16 vs. 11), larger infarcts, more severe hypoperfusion, more parenchymal hematomas, greater disability (higher mRS), and higher mortality compared with non\u2011AF patients. AF was an independent predictor of parenchymal hematoma but not mortality. The abstract does not investigate or discuss a ceiling effect of NIHSS on the likelihood of achieving 'alive and independent' outcomes.",
          "pmid": "20693794",
          "title": "Pathophysiological determinants of worse stroke outcome in atrial fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines predictors of major neurologic improvement after rt-PA and the association between early NIHSS change and 3\u2011month outcome, but it does not analyze baseline NIHSS as a prognostic factor, nor does it evaluate ceiling effects or differential chances of achieving an \u2018alive and independent\u2019 outcome by NIHSS level. Therefore it neither supports nor contradicts the proposed statistical ceiling-effect mechanism.",
          "key_findings": "Major neurologic improvement was defined by \u22658\u2011point NIHSS improvement or NIHSS 0\u20131 at 24 hours; 28% of rt\u2011PA\u2013treated patients achieved this. Predictors of major neurologic improvement were glucose <8 mmol/L, lack of cortical involvement on 24\u2011hour CT, and female sex. Major neurologic improvement independently predicted good 3\u2011month outcome (mRS 0\u20131) with OR 12.8. Baseline NIHSS as a prognostic factor, or any ceiling effect related to high NIHSS and \u2018alive and independent\u2019 outcomes, was not analyzed.",
          "pmid": "16247041",
          "title": "Predictors of major neurologic improvement after thrombolysis in acute stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism is that baseline NIHSS, as a prognostic factor, creates a ceiling effect where very high scores are associated with a markedly reduced likelihood of achieving favorable outcomes (alive and independent). The abstract shows that patients who are SPAN-100-positive (age + NIHSS \u2265 100, thus combining high age and high NIHSS) have substantially lower odds of favorable outcome (mRS \u22642) despite similar reperfusion rates, and SPAN-100 positivity is an independent predictor of poor outcome. This directly supports the idea that high baseline NIHSS (especially when combined with age) strongly limits the chance of independent survival, consistent with a ceiling effect, although the abstract does not explicitly model the ceiling phenomenon itself.",
          "key_findings": "SPAN-100-positive patients (age + NIHSS \u2265 100) comprised 7.7% of the cohort and had a significantly lower rate of favorable clinical outcome (mRS \u22642 at 90 days) compared to SPAN-100-negative patients (26.7% vs 60.8%, P = .01), despite no difference in successful reperfusion rates. In multivariable analysis, SPAN-100-positive status was independently associated with lower odds of favorable outcome (OR 0.3, 95% CI 0.1\u20130.9, P = .04), indicating that high combined age and NIHSS substantially diminishes the likelihood of favorable outcome.",
          "pmid": "24557701",
          "title": "Impact of age and baseline NIHSS scores on clinical outcomes in the mechanical thrombectomy using solitaire FR in acute ischemic stroke study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies predictors of no early recanalization after IV t-PA (notably atrial fibrillation) and reports NIHSS changes as an outcome measure of neurological worsening. It does not analyze NIHSS as a prognostic factor for long-term functional status such as 'alive and independent,' nor does it discuss ceiling effects or differential prognostic impact at very high NIHSS scores. Therefore, it neither supports nor contradicts the proposed statistical mechanism.",
          "key_findings": "NIHSS was measured before and 24 hours after t-PA, and neurological worsening was defined as an NIHSS increase \u22654. No early recanalization occurred in 51.4% of patients with occluded arteries and was associated with neurological worsening. Atrial fibrillation was identified as an independent predictor of no early recanalization. The study does not evaluate NIHSS as a prognostic factor for 'alive and independent' outcomes or address ceiling effects related to high NIHSS values.",
          "pmid": "17964602",
          "title": "Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that baseline NIHSS is an independent predictor of outcome (mRS 0\u20132 at 90 days) with an odds ratio <1 per NIHSS point, indicating worse outcomes with higher scores. However, it does not examine or discuss a ceiling effect, does not stratify very high NIHSS ranges, and provides no analysis of whether extremely high NIHSS scores have a diminished likelihood of achieving independence relative to what would be expected. Thus, it neither supports nor refutes the specific proposed mechanism of a ceiling effect created by NIHSS as a prognostic factor.",
          "key_findings": "Baseline NIHSS independently predicted 90\u2011day independent outcome with OR 0.74 (95% CI 0.67\u20130.82, P<0.0001), indicating that higher NIHSS is associated with lower odds of mRS 0\u20132; the model does not evaluate nonlinearity or a ceiling effect at very high NIHSS values.",
          "pmid": "23549132",
          "title": "Favorable vascular profile is an independent predictor of outcome: a post hoc analysis of the safety and efficacy of NeuroFlo Technology in Ischemic Stroke trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how CT radiomic signatures correlate with baseline NIHSS, GCS, and 3\u2011month mRS compared with hematoma volume, but it does not analyze NIHSS as a prognostic factor for independence, does not examine outcome stratified by high NIHSS values, and does not address any ceiling effect of NIHSS on \u2018alive and independent\u2019 outcomes. Thus it neither supports nor contradicts the proposed ceiling-effect mechanism.",
          "key_findings": "Radiomic signatures from baseline CT hematoma features showed stronger correlations than hematoma volume with admission NIHSS (\u03c1\u22480.64\u20130.69 vs 0.56\u20130.57) and with 3\u2011month mRS (\u03c1\u22480.43\u20130.44 vs 0.32\u20130.33), and were independent predictors of 3\u2011month mRS after adjustment for known ICH outcome predictors. The study does not assess NIHSS as a limiting prognostic scale or investigate ceiling effects in relation to \u2018alive and independent\u2019 outcomes.",
          "pmid": "34189814",
          "title": "Admission computed tomography radiomic signatures outperform hematoma volume in predicting baseline clinical severity and functional outcome in the ATACH-2 trial intracerebral hemorrhage population.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract does not use NIHSS, does not examine prognostic ceiling effects, and does not analyze how baseline stroke severity scores constrain the probability of achieving an 'alive and independent' endpoint. It only notes that baseline mRS (a disability scale, not NIHSS) predicts HRQoL, without exploring distributional limits or ceiling phenomena.",
          "key_findings": "Baseline modified Rankin Scale (mRS) score was an independent predictor of long-term HRQoL; older age and female sex were associated with lower HRQoL and more mood symptoms; HRQoL and anxiety improved over 3\u201312 months post-stroke; atrial fibrillation had a small effect on EQ-5D-3L and HADS anxiety. No analysis of NIHSS or ceiling effects on an 'alive and independent' outcome was reported.",
          "pmid": "33421630",
          "title": "Health-related quality of life, anxiety and depression up to 12\u00a0months post-stroke: Influence of sex, age, stroke severity and atrial fibrillation - A longitudinal subanalysis of the Find-AF<sub>RANDOMISED</sub> trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports NIHSS values as outcomes and uses multivariate analysis for predictors of favorable outcome, but it does not analyze NIHSS as a prognostic factor in a way that addresses a ceiling effect on achieving 'alive and independent' outcomes. There is no examination of how very high NIHSS scores might limit functional independence, nor discussion of a ceiling phenomenon.",
          "key_findings": "NIHSS scores at 24 hours and 7 days post-mechanical thrombectomy are reported (lower in the Cerebrolysin group), and functional independence is defined as mRS 0\u20132 at 90 days. Multivariate analysis identifies Cerebrolysin as an independent predictor of favorable outcome, but the role of baseline NIHSS as a prognostic factor or any ceiling effect on independence is not specifically evaluated.",
          "pmid": "40325343",
          "title": "Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract uses baseline NIHSS as an adjustment variable in regression models to compare outcomes between intracerebral hemorrhage and ischemic stroke, but it does not analyze prognostic strata across the NIHSS range, does not examine non-linearity or ceiling effects, and does not link very high NIHSS scores to a diminished likelihood of achieving an 'alive and independent' outcome. Thus, it neither supports nor contradicts the specific proposed ceiling-effect mechanism.",
          "key_findings": "Baseline NIHSS was included as a covariate in multiple logistic and linear regressions evaluating 3\u2011month modified Rankin Scale outcomes and mortality; intracerebral hemorrhage remained an independent predictor of poor neurologic outcome and higher mRS scores, while not affecting mortality after adjustment. No analyses of NIHSS-specific prognostic thresholds or ceiling effects on functional independence were reported.",
          "pmid": "20434051",
          "title": "Comparison of outcomes after intracerebral hemorrhage and ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract uses NIHSS as an outcome measure and reports changes over time between treatment groups, but it does not analyze NIHSS as a prognostic factor, does not link baseline NIHSS to likelihood of achieving an 'alive and independent' outcome, and does not discuss or demonstrate any ceiling effect in functional outcomes.",
          "key_findings": "The study compares thrombectomy vs. thrombolysis beyond the standard time window and reports that both groups had decreased NIHSS and increased MoCA and G-CSF levels at 72 hours and 90 days, with better scores in the thrombectomy group. Multivariate analysis identifies treatment group as an independent predictor of improved outcomes. NIHSS is correlated with G-CSF, MoCA, and mTICI but is not evaluated as a prognostic factor for independence, nor is any ceiling effect described.",
          "pmid": "40001179",
          "title": "Clinical study on the effects of over time window thrombectomy and thrombolytic therapy on granulocyte colony-stimulating factor expression and postoperative brain function after acute cerebral infarction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract reports that baseline NIHSS score is an independent predictor of favorable 90\u2011day outcome (with an odds ratio <1 per unit), but it does not analyze or discuss a ceiling effect at very high NIHSS levels or examine nonlinearity or thresholds in the NIHSS\u2013outcome relationship. Thus, while it confirms prognostic value of NIHSS, it does not provide evidence specifically for or against a ceiling effect where very high NIHSS scores disproportionately limit the chance of being alive and independent.",
          "key_findings": "Baseline NIHSS score was an independent predictor of favourable outcome (OR 0.59, 95% CI 0.41\u20130.84) in logistic regression, whereas sex and age >80 years were not. Outcomes examined included favourable 90\u2011day modified Rankin Scale status, mortality, and symptomatic CNS bleeding, but no stratified or nonlinear analysis evaluating ceiling effects at very high NIHSS levels was reported.",
          "pmid": "18190509",
          "title": "The response to IV rt-PA in very old stroke patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses infection as an independent predictor of poor outcome after stroke and notes stroke severity as a risk factor for infection, but it does not address NIHSS specifically, its use as a prognostic factor, or any ceiling effect on achieving 'alive and independent' outcomes. Thus it neither supports nor contradicts the proposed statistical mechanism.",
          "key_findings": "Infection in the acute phase of stroke is identified as an independent predictor of poor short- and intermediate-term outcome; several risk factors for infection are listed, including increasing age and stroke severity; possible pathophysiological mechanisms and trials of prophylactic antibiotics and immunomodulating strategies are described. No mention is made of NIHSS scores or ceiling effects in outcome assessment.",
          "pmid": "22652018",
          "title": "[Advances in the pathophysiology and management of infections in the acute phase of stroke].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines blood pressure profiles as predictors of 90\u2011day functional outcome after ischemic stroke, using logistic regression that adjusts for initial stroke severity and other prognostic factors. It does not analyze NIHSS itself as a prognostic variable, nor does it evaluate ceiling effects or differential probabilities of achieving \u2018alive and independent\u2019 outcomes by NIHSS strata. Therefore it neither supports nor contradicts the specific proposed mechanism involving NIHSS-driven ceiling effects.",
          "key_findings": "Higher baseline systolic and diastolic blood pressure were associated with favorable 90\u2011day outcomes (mRS 0\u20131), whereas lower 0\u201372 h mean blood pressure and reduced diastolic variability were independent predictors of favorable outcome; analyses adjusted for initial stroke severity but did not investigate NIHSS-related ceiling effects.",
          "pmid": "16254220",
          "title": "Characteristics of blood pressure profiles as predictors of long-term outcome after acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract analyzes the effect of hemicraniectomy size on outcomes and identifies age and infarct volume as predictors, but it does not mention NIHSS, its use as a prognostic factor, or any ceiling effects related to NIHSS-based outcome prediction. Therefore it neither supports nor contradicts the proposed NIHSS-related statistical mechanism.",
          "key_findings": "In 130 patients with malignant MCA infarction, larger hemicraniectomy diameter (>14 cm) did not significantly change primary outcome (mRS \u22644 at 12 months), mortality, or complication rates compared with \u226414 cm. Multivariable analyses showed age and infarct volume, but not hemicraniectomy diameter, were associated with outcome.",
          "pmid": "37162579",
          "title": "Large diameter hemicraniectomy does not improve long-term outcome in malignant infarction.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "dbprand",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "High diastolic pressure may perpetuate cerebral edema, reducing alteplase efficacy during reperfusion efforts.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (\"diastolic blood pressure\" OR \"blood pressure\" OR \"hypertension\") AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"reperfusion\" OR \"perpetuate\" OR \"diastolic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions blood pressure management as part of general measures in acute ischemic stroke and reperfusion therapy but does not discuss diastolic pressure specifically, cerebral edema, or how high diastolic pressure might alter alteplase efficacy during reperfusion. No mechanistic or outcome data related to this specific pathway are provided.",
          "key_findings": "Acute ischemic stroke management includes ensuring hemodynamic stability, use of reperfusion therapies (intravenous thrombolytics and mechanical thrombectomy), and monitoring homeostasis of blood pressure, glycemia, temperature, and oxygenation, but without detailing the effects of high diastolic pressure on cerebral edema or thrombolytic efficacy.",
          "pmid": "37532617",
          "title": "Management of acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares higher vs lower blood pressure treatment targets in older adults and reports effects on stroke and cardiovascular outcomes, but it does not examine diastolic pressure in the context of acute ischemic stroke, cerebral edema, or alteplase efficacy. There is no discussion of reperfusion therapy, cerebral edema dynamics, or how diastolic pressure might influence alteplase outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Lower blood pressure targets (<140/90 mmHg or 110\u2013130 mmHg systolic) compared with higher targets (130\u2013150 or <150\u2013160/95\u2013105 mmHg) in hypertensive adults \u226565 years: (1) little to no difference in all-cause mortality over 2\u20134 years (RR 1.14, 95% CI 0.95\u20131.37); (2) reduced stroke with lower targets (RR 1.33, 95% CI 1.06\u20131.67); (3) likely reduced total serious cardiovascular adverse events with lower targets (RR 1.25, 95% CI 1.09\u20131.45); (4) no clear increase in withdrawals due to adverse effects. No data were presented on alteplase, reperfusion therapy, cerebral edema, or mechanistic links between diastolic pressure and thrombolytic efficacy.",
          "pmid": "39688187",
          "title": "Higher blood pressure targets for hypertension in older adults.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses lifestyle management of hypertension and general cardiovascular risk reduction. It does not address cerebral edema, alteplase use, reperfusion therapy, or how diastolic blood pressure might influence thrombolytic efficacy in stroke.",
          "key_findings": "The paper defines hypertension thresholds (SBP >140 mmHg and/or DBP \u226590 mmHg), notes its global prevalence and association with cardiovascular events including stroke, and recommends lifestyle interventions (weight control, physical activity, diet, smoking/alcohol cessation, stress and sleep management) as first-line management. No mechanistic data are presented regarding cerebral edema or alteplase efficacy.",
          "pmid": "37712135",
          "title": "Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ROS-induced endothelial cell death pathways (pyroptosis, parthanatos, ferroptosis) and their roles in various vascular-related diseases, including hypertension and ischemic stroke, but it does not address diastolic blood pressure levels, cerebral edema, alteplase, or reperfusion efficacy. There is no direct or indirect evidence linking high diastolic pressure to perpetuation of cerebral edema or to modulation of alteplase efficacy.",
          "key_findings": "Endothelial dysfunction and ROS-triggered endothelial cell death via pyroptosis, parthanatos, and ferroptosis contribute to vascular barrier disruption, vasoconstriction, diastolic dysfunction, inflammation, thrombosis, and diseases such as hypertension and ischemic stroke; sources and molecular mechanisms of ROS in endothelial cells are reviewed.",
          "pmid": "36389728",
          "title": "ROS-triggered endothelial cell death mechanisms: Focus on pyroptosis, parthanatos, and ferroptosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses non-pharmacological management of hypertension and the cardiovascular risks of air pollution, but it does not address diastolic pressure in the context of acute stroke, cerebral edema, alteplase use, or reperfusion efficacy. There is no mention of cerebral edema dynamics or thrombolytic response, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Lifestyle modifications (dietary changes, physical activity, weight loss, limited alcohol, relaxation techniques) can lower blood pressure; air pollution, particularly PM2.5, is associated with increased cardiovascular morbidity and mortality including stroke. No data are presented on diastolic pressure effects on cerebral edema or alteplase efficacy.",
          "pmid": "33738923",
          "title": "Non-pharmacological management of hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the blood-pressure\u2013lowering efficacy and safety of renal denervation in hypertension but does not address acute stroke treatment, alteplase use, cerebral edema, or how diastolic pressure might influence reperfusion efficacy. It reports reductions in diastolic blood pressure but provides no data linking diastolic pressure levels to cerebral edema or alteplase outcomes.",
          "key_findings": "Catheter-based renal denervation, compared with sham, produced modest reductions in 24-hour and office systolic and diastolic blood pressure and showed no major safety signal (no significant differences in vascular complications, renal artery stenosis, hypertensive crisis, all-cause death, or change in renal function). These findings are not connected to cerebral edema or thrombolysis efficacy.",
          "pmid": "39355923",
          "title": "Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns high diastolic pressure perpetuating cerebral edema and thereby reducing alteplase efficacy during reperfusion. The trial studies post-thrombectomy systolic blood pressure targets (intensive <120 vs 140\u2013180 mm Hg) after successful endovascular reperfusion, does not measure or manipulate diastolic pressure, does not assess cerebral edema as a mediator, and does not involve alteplase efficacy as an outcome. Therefore, while it is about blood pressure and post-reperfusion outcomes, it does not directly address the specific mechanistic pathway proposed.",
          "key_findings": "In patients with elevated systolic blood pressure after successful endovascular thrombectomy, targeting intensive SBP <120 mm Hg (vs 140\u2013180 mm Hg) was associated with worse functional outcomes (common OR for poorer mRS 1.37, 95% CI 1.07\u20131.76), more early neurological deterioration (OR 1.53, 95% CI 1.18\u20131.97), and more major disability at 90 days (OR 2.07, 95% CI 1.47\u20132.93), without significant differences in symptomatic intracerebral hemorrhage, serious adverse events, or mortality. Diastolic pressure, cerebral edema, and alteplase efficacy were not specifically examined.",
          "pmid": "36341753",
          "title": "Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses collateral flow variability, pericytes, and cerebral microcirculation in stroke, but does not mention diastolic blood pressure, cerebral edema, or alteplase efficacy. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Summarizes studies on mechanisms of collateral flow variability in stroke and the role of pericytes in cerebral microcirculation and stroke, without reference to blood pressure, edema, or thrombolytic treatment effects.",
          "pmid": "34078110",
          "title": "Vascular Biology.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of dietary patterns and sodium reduction on systolic and diastolic blood pressure in adults with type 2 diabetes, but it does not involve stroke, reperfusion therapy, alteplase use, cerebral edema, or any cerebrovascular outcomes. It reports modest decreases in diastolic pressure but provides no data on whether high diastolic pressure perpetuates cerebral edema or alters alteplase efficacy during reperfusion.",
          "key_findings": "In a randomized 4-period crossover trial (DASH4D), adults with type 2 diabetes experienced reductions in blood pressure when consuming a DASH-style, lower-sodium diet versus a higher-sodium comparison diet: systolic blood pressure decreased by 4.6 mm Hg and diastolic blood pressure by 2.3 mm Hg. Effects were largely attributable to sodium reduction and occurred mostly within the first 3 weeks, with infrequent adverse events. No information was provided on cerebral edema, stroke, or alteplase treatment.",
          "pmid": "40489102",
          "title": "Dietary Patterns, Sodium Reduction, and Blood Pressure in Type 2 Diabetes: The DASH4D Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension, arterial stiffness, blood pressure variability, and cerebrovascular pathophysiology in general terms, but does not address diastolic pressure levels at the time of reperfusion, cerebral edema dynamics, or alteplase efficacy. No data or claims link high diastolic pressure to perpetuation of cerebral edema or to reduced effectiveness of thrombolysis.",
          "key_findings": "The article describes: (1) evolution of hypertension from sympathetically driven elevated mean BP to a phenotype with rising systolic and falling diastolic pressures; (2) associations of hypertension and BP variability with risk of ischemic and hemorrhagic stroke; (3) increased arterial stiffness and cerebral arterial pulsatility, reduced CO2 reactivity, and uncertain modifiability of cerebral autoregulation as risk factors. It does not discuss reperfusion therapy, alteplase, or cerebral edema effects of diastolic pressure.",
          "pmid": "35255709",
          "title": "New Insights Into Cerebrovascular Pathophysiology and Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses orthostatic hypotension, defined by a drop in blood pressure on standing, and its epidemiology, prognosis, and treatment. It does not address high diastolic pressure, cerebral edema, alteplase, or reperfusion in stroke, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Orthostatic hypotension is defined as a \u226520/10 mm Hg fall in systolic/diastolic blood pressure upon standing; it is common in older adults and is associated with increased mortality and cardiovascular events (myocardial infarction, stroke, heart failure, atrial fibrillation). The review outlines etiology, prevalence, diagnostic and therapeutic approaches, and clinical consequences of low standing blood pressure.",
          "pmid": "26271068",
          "title": "Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses nervous system\u2013kidney crosstalk, hypertension, and cerebrovascular risks in CKD/AKI, but it does not address diastolic blood pressure effects on cerebral edema, alteplase efficacy, or reperfusion mechanisms in stroke.",
          "key_findings": "CKD and AKI are linked to increased risk of stroke and cognitive impairment; kidney damage affects the central nervous system via factors such as uremic toxins and phosphate; renal nerves and cholinergic anti-inflammatory pathways modulate kidney inflammation and fibrosis. No data are presented on diastolic pressure, cerebral edema, or thrombolytic treatment outcomes.",
          "pmid": "32001065",
          "title": "Crosstalk between the nervous system and the kidney.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cardiovascular complications, hemodynamic monitoring, and hypertension management after acute ischemic stroke, but it does not address diastolic blood pressure effects on cerebral edema, nor any impact of diastolic pressure on alteplase efficacy or reperfusion outcomes.",
          "key_findings": "The review highlights brain\u2013heart axis dysfunction after AIS, lists cardiac complications (e.g., heart failure, diastolic dysfunction, arrhythmias), and mentions antihypertensive agents (labetalol, nicardipine, nitroprusside) for blood pressure control. It does not analyze diastolic pressure in relation to cerebral edema, nor discuss alteplase or thrombolysis efficacy.",
          "pmid": "32317013",
          "title": "Brain-heart interaction after acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates a long-term, primary care\u2013based digital health intervention for stroke survivors, focusing mainly on systolic blood pressure reduction and stroke recurrence. It does not address acute reperfusion therapy, alteplase use, cerebral edema, or the specific role of diastolic blood pressure in modulating edema or thrombolysis efficacy. Therefore, it neither supports nor contradicts the proposed physiological mechanism.",
          "key_findings": "The intervention led to a modest net reduction in systolic blood pressure (\u22122.8 mm Hg) and a reduction in stroke recurrence risk (RR 0.77) over 5.5 years, with tendencies toward lasting benefits in several secondary outcomes. Diastolic blood pressure was listed as a secondary outcome but no specific diastolic BP data or mechanistic analysis related to edema or alteplase was reported.",
          "pmid": "39671199",
          "title": "Primary Care-Based Digital Health-Enabled Stroke Management Intervention: Long-Term Follow-Up of a Cluster Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates associations between ambulatory blood pressure time-in-target ranges and long-term cardiovascular outcomes in a general population cohort. It does not address acute stroke treatment, alteplase efficacy, cerebral edema, or the specific impact of high diastolic pressure on cerebral edema during reperfusion. Therefore, it neither supports nor contradicts the proposed physiological mechanism.",
          "key_findings": "Higher percentage of time that ambulatory blood pressure is within ESC 2024 target ranges is associated with lower all-cause mortality and cardiovascular events over a median 10.9-year follow-up; office blood pressure misclassified many individuals compared with ambulatory PTTR-based assessment.",
          "pmid": "40249369",
          "title": "Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews coagulation abnormalities in hypertension but does not address cerebral edema, alteplase efficacy, or how diastolic pressure affects reperfusion outcomes in stroke. It links blood pressure to coagulation markers and thromboembolic risk, not to edema dynamics or thrombolytic response.",
          "key_findings": "Elevated D-dimer and fibrinogen in hypertensive individuals, increasing with severity and duration of hypertension; associations of systolic and diastolic blood pressure with prothrombin time and aPTT; roles of P-selectin, suPAR, thrombomodulin, tissue factor, vWF, and other coagulation-related markers in hypertension and related vascular conditions. No mention of cerebral edema or alteplase-mediated reperfusion.",
          "pmid": "37561240",
          "title": "Irregularities of Coagulation in Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses vascular stiffness, pulse pressure, altered cerebral autoregulation, and risk of perioperative ischemic stroke, but it does not address diastolic pressure levels, cerebral edema, alteplase use, or reperfusion efficacy. Therefore it neither supports nor contradicts the specific mechanism that high diastolic pressure perpetuates cerebral edema and reduces alteplase efficacy.",
          "key_findings": "Central pulse pressure and vascular stiffness are associated with increased perioperative morbidity including ischemic stroke; vascular stiffness causes altered cerebral autoregulation, a higher lower limit of autoregulation (>65 mmHg), and may predispose to cerebral hypoperfusion and neurologic, cardiac, and renal injury.",
          "pmid": "30543556",
          "title": "Pulse pressure and perioperative stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on LOX-1, its ligands, and their associations with atherosclerotic disease and risk factors (including diastolic hypertension) as biomarkers. It does not address cerebral edema, alteplase efficacy, reperfusion, or the impact of diastolic blood pressure on cerebral edema or thrombolysis outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "LOX-1 and its ligand-containing apoB (LAB) are associated with carotid intima-media thickness and incidence of coronary artery disease and ischemic stroke, independent of conventional lipid measures. LAB correlates with atherosclerotic risk factors such as smoking, obesity, diabetes, diastolic hypertension, hypertriglyceridemia, and metabolic syndrome, and sLOX-1/LAB may serve as biomarkers for atherosclerosis and related diseases.",
          "pmid": "25463747",
          "title": "LOX-1 in atherosclerotic disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses patterns of blood pressure with aging, cardiovascular risk, and treatment effects in elderly hypertensive patients but does not address diastolic pressure in the context of acute stroke, cerebral edema, alteplase use, or reperfusion efficacy. No mechanism linking high diastolic pressure to perpetuation of cerebral edema or modification of thrombolytic effectiveness is examined.",
          "key_findings": "Isolated systolic hypertension is common in those aged 50+; age-related blood pressure increase is linked to arterial stiffness; increased pulse pressure (higher systolic, lower diastolic) is a strong cardiovascular risk predictor in the elderly; treating hypertension in the elderly reduces cardiovascular events, though evidence is lacking for the very elderly and overtreatment may increase mortality.",
          "pmid": "17308214",
          "title": "Blood pressure and ageing.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract evaluates intensive versus conventional post-thrombectomy blood pressure control and reports worse functional outcomes with intensive systolic BP lowering, but it does not measure diastolic pressure specifically, cerebral edema, or alteplase efficacy during reperfusion. Thus it does not directly address whether high diastolic pressure perpetuates cerebral edema and reduces alteplase efficacy.",
          "key_findings": "In patients with successful reperfusion after EVT for acute ischemic stroke, intensive BP control (target systolic <140 mmHg) was associated with higher rates of functional disability or death at 90 days (54.9% vs 44.1%, OR 1.51) and higher severe disability (mRS 3-5; OR 1.75), with no significant differences in symptomatic intracranial hemorrhage or mortality. Diastolic pressure, cerebral edema, and alteplase-related mechanisms were not assessed.",
          "pmid": "38494461",
          "title": "Blood pressure targets after successful reperfusion in mechanical thrombectomy for acute ischemic stroke: an updated systematic review and meta-analysis of randomized clinical trials.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "dbprand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Hypertension is linked to blood-brain barrier dysfunction, heightening the risk of hemorrhagic transformation after thrombolysis.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (\"diastolic blood pressure\" OR \"blood pressure\" OR \"hypertension\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"transformation\" OR \"hypertension\" OR \"thrombolysis\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke epidemiology, imaging, treatment options (including thrombolysis and thrombectomy), and management of intracerebral haemorrhage, but it does not address hypertension-related blood\u2013brain barrier dysfunction or its role in hemorrhagic transformation after thrombolysis.",
          "key_findings": "Mentions that small vessel disease is the most frequent cause of intracerebral haemorrhage; describes use of intravenous thrombolysis (alteplase/tenecteplase) and extended windows for thrombectomy; notes bundled care for intracerebral haemorrhage including blood pressure lowering. No data are presented on blood\u2013brain barrier integrity, hypertension as a mechanistic factor, or hemorrhagic transformation after thrombolysis.",
          "pmid": "38759664",
          "title": "Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension as a major modifiable risk factor for stroke and mentions blood pressure variability and stroke risk, but it does not address blood-brain barrier function, thrombolysis, or hemorrhagic transformation. Therefore, it neither supports nor contradicts the specific mechanism linking hypertension-induced blood\u2013brain barrier dysfunction to increased hemorrhagic transformation after thrombolysis.",
          "key_findings": "Hypertension is identified as a major modifiable risk factor for stroke; some blood pressure medications may increase blood pressure variability and stroke risk. The article focuses on epidemiology and risk factor management, not on blood\u2013brain barrier dysfunction or outcomes after thrombolytic therapy.",
          "pmid": "28157742",
          "title": "Stroke Epidemiology and Risk Factor Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ischemic stroke management, reperfusion therapies, treatment time windows, and general secondary prevention including blood pressure control, but it does not address blood-brain barrier function, hemorrhagic transformation, or how hypertension might mechanistically increase the risk of hemorrhagic transformation after thrombolysis.",
          "key_findings": "The abstract states that intravenous thrombolysis and endovascular thrombectomy reduce disability when given within specific time windows, and that secondary prevention includes blood pressure control among other cardiovascular risk management strategies. No data or discussion is provided on BBB dysfunction, hypertension-related BBB changes, or hemorrhagic transformation risk after thrombolysis.",
          "pmid": "31601801",
          "title": "Ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares ischemic stroke patients to stroke mimics in terms of risk factors, thrombolysis rates, hemorrhage, and outcomes, but it does not assess blood-brain barrier function, nor does it analyze how hypertension might cause BBB dysfunction or influence hemorrhagic transformation specifically after thrombolysis.",
          "key_findings": "Stroke patients had higher blood pressure and higher intracranial hemorrhage rates than stroke mimics, but no mechanistic or direct link to blood-brain barrier dysfunction is examined, and the role of hypertension in BBB-related hemorrhagic transformation after thrombolysis is not investigated.",
          "pmid": "34656244",
          "title": "Ischemic stroke mimics: A comprehensive review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes hypertension as a risk factor for stroke and a target for prevention, but does not discuss blood-brain barrier dysfunction, thrombolysis, or hemorrhagic transformation. It addresses stroke prevention broadly, not the specific mechanistic link between hypertension, BBB disruption, and post-thrombolysis hemorrhage.",
          "key_findings": "Hypertension is identified as a key modifiable risk factor in the primary and secondary prevention of ischemic stroke and cerebral hemorrhage; treatment of hypertension is emphasized as an important preventive strategy. No mention is made of blood-brain barrier function or hemorrhagic transformation after thrombolysis.",
          "pmid": "32299593",
          "title": "Primary and Secondary Prevention of\u00a0Ischemic Stroke and Cerebral\u00a0Hemorrhage: JACC Focus Seminar.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses secondary stroke prevention, vascular risk factor control (including hypertension), and various treatment strategies, but it does not mention blood-brain barrier function, thrombolysis, or hemorrhagic transformation. Therefore, it neither supports nor contradicts the specific mechanistic link between hypertension-induced blood-brain barrier dysfunction and increased risk of hemorrhagic transformation after thrombolysis.",
          "key_findings": "Hypertension is identified as a vascular risk factor to control for stroke prevention, but no mechanistic details are provided regarding its effect on the blood-brain barrier or outcomes after thrombolytic therapy.",
          "pmid": "26300647",
          "title": "Secondary stroke prevention: challenges and solutions.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on patent foramen ovale, paradoxical embolism, and stroke risk/reduction with PFO closure. It does not address hypertension, blood-brain barrier integrity, thrombolysis, or hemorrhagic transformation, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "PFO is present in ~25% of adults and is a common cause of stroke in younger patients; the RoPE score and PASCAL classification help estimate causal likelihood of PFO-related stroke; pooled trials show PFO closure reduces recurrent ischemic stroke in selected patients \u226460 years, particularly those classified as PASCAL 'probable'; PASCAL 'unlikely' patients gain little benefit and have higher procedural risks such as atrial fibrillation.",
          "pmid": "40720119",
          "title": "Patent Foramen Ovale and Stroke: A Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension as a major modifiable risk factor for stroke and addresses blood pressure management before, during, and after stroke, but it does not mention blood-brain barrier dysfunction, thrombolysis, or hemorrhagic transformation. Therefore, it neither supports nor contradicts the specific mechanistic link between hypertension, BBB dysfunction, and increased risk of hemorrhagic transformation after thrombolysis.",
          "key_findings": "Hypertension is described as the leading modifiable contributor to stroke; blood pressure control is important for long-term outcomes; controversies remain about optimal timing, targets, and management of blood pressure in acute and specific stroke settings. No reference is made to blood-brain barrier integrity, thrombolytic therapy, or hemorrhagic transformation.",
          "pmid": "29149815",
          "title": "Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses blood pressure management after ischemic stroke and around thrombolysis but does not address blood-brain barrier integrity, hemorrhagic transformation risk, or a mechanistic link between hypertension and BBB dysfunction. It focuses on clinical BP-lowering trials and management strategies, not on BBB-related mechanisms or hemorrhagic complications.",
          "key_findings": "High BP after ischemic stroke is common and associated with poor outcome and mortality; large BP-lowering trials have not changed overall outcomes; optimal BP management may vary by timing and clinical scenario, including before, during, and after thrombolysis and thrombectomy. No mention is made of BBB dysfunction or hemorrhagic transformation mechanisms.",
          "pmid": "35291822",
          "title": "Blood Pressure Management for Ischemic Stroke in the First 24 Hours.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension-related cerebrovascular pathophysiology (arterial stiffness, pulsatility, endothelial dysfunction, small vessel disease, autoregulation) but does not mention blood-brain barrier integrity or hemorrhagic transformation after thrombolysis, nor their relationship to hypertension. Thus it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Hypertension is associated with a high proportion of ischemic and hemorrhagic strokes; arterial stiffness and increased aortic/cerebral pulsatility, endothelial dysfunction, and impaired cerebrovascular reactivity are highlighted as mechanisms; blood pressure variability is an independent predictor of ischemic and intracerebral hemorrhage. No data are provided on blood-brain barrier dysfunction or hemorrhagic transformation after thrombolytic therapy.",
          "pmid": "35255709",
          "title": "New Insights Into Cerebrovascular Pathophysiology and Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the prevalence and clinical features of hypertensive emergencies and urgencies and the distribution of acute hypertension-mediated organ damage subtypes, including ischemic and hemorrhagic stroke. It does not assess blood-brain barrier function, thrombolysis, or hemorrhagic transformation after thrombolysis, nor does it link hypertension-induced BBB dysfunction to outcomes of thrombolytic therapy.",
          "key_findings": "Among hypertensive emergencies, pulmonary edema/heart failure was most frequent (32%), followed by ischemic stroke (29%) and hemorrhagic stroke (11%). Blood pressure levels at presentation did not differ meaningfully between hypertensive emergencies and urgencies, and clinical symptoms were more predictive of acute hypertension-mediated organ damage. No data were presented on blood-brain barrier integrity, thrombolytic treatment, or hemorrhagic transformation risk after thrombolysis.",
          "pmid": "32510905",
          "title": "Hypertensive emergencies and urgencies in emergency departments: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses perioperative stroke risk, blood pressure control, and the use of intravenous thrombolysis, but does not address blood-brain barrier function, hypertension-induced BBB dysfunction, or hemorrhagic transformation after thrombolysis.",
          "key_findings": "The statement reviews perioperative stroke risk factors and management, including blood pressure control and early use of intravenous thrombolysis and mechanical embolectomy in postoperative strokes, but provides no data or claims about BBB dysfunction or hemorrhagic transformation risk related to hypertension.",
          "pmid": "33827230",
          "title": "Perioperative Neurological Evaluation and Management to Lower the Risk of Acute Stroke in Patients Undergoing Noncardiac, Nonneurological Surgery: A Scientific Statement From the American Heart Association/American Stroke Association.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links hypertension to increased blood-brain barrier permeability and altered response to acute ischemia, but does not mention thrombolysis, hemorrhagic transformation, or outcomes specifically after thrombolytic therapy. Thus it is related to part of the proposed pathway (hypertension \u2192 BBB dysfunction) but does not address the key outcome (risk of hemorrhagic transformation after thrombolysis).",
          "key_findings": "Hypertension promotes cerebral small vessel disease through mechanisms including diminished autoregulatory capacity and localized increase in blood-brain barrier permeability; comorbidities like hypertension alter the response to acute ischemia and the pathophysiology of ischemic stroke.",
          "pmid": "30198826",
          "title": "The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses intracerebral hemorrhage, its etiologies (including hypertensive arteriopathy), and imaging for detecting hemorrhagic transformation or hematoma expansion, but it does not address blood-brain barrier dysfunction, nor does it link hypertension-mediated BBB changes to risk of hemorrhagic transformation after thrombolysis.",
          "key_findings": "Hypertension (deep perforator arteriopathy) is noted as a common cause of spontaneous ICH; imaging (CT and MRI) is useful for detecting hemorrhagic transformation and hematoma expansion; the AHA 2022 guidelines review ICH mechanisms including edema, inflammation, and blood product toxicity. No mention is made of BBB dysfunction or thrombolytic therapy as mediators of hemorrhagic transformation risk in hypertensive patients.",
          "pmid": "35870549",
          "title": "Essential Topics About the Imaging Diagnosis and Treatment of Hemorrhagic Stroke: A Comprehensive Review of the 2022 AHA Guidelines.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines safety and efficacy of catheter-directed low-dose fibrinolysis for pulmonary embolism and reports bleeding outcomes, including absence of intracranial hemorrhage. It does not address hypertension, blood-brain barrier integrity, or mechanisms of hemorrhagic transformation after thrombolysis in the brain, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In 150 patients with massive or submassive pulmonary embolism treated with ultrasound-facilitated, catheter-directed low-dose tPA, there was improvement in RV/LV ratio, pulmonary artery systolic pressure, and thrombus burden. Major bleeding events were uncommon, and no intracranial hemorrhages occurred. Hypertension or blood-brain barrier dysfunction were not evaluated.",
          "pmid": "26315743",
          "title": "A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that hypertension is a risk factor for post\u2011stroke dysphagia, but it does not mention blood-brain barrier dysfunction, thrombolysis, or hemorrhagic transformation. Thus, it neither supports nor contradicts the specific mechanism linking hypertension to BBB dysfunction and increased hemorrhagic transformation after thrombolysis.",
          "key_findings": "Meta-analysis of 10 studies (4637 ischemic stroke patients) found that hypertension (OR = 1.96, 95% CI: 1.48\u20132.61) is associated with dysphagia after ischemic stroke, along with elder age, diabetes, and brainstem stroke. No data on blood-brain barrier status, thrombolytic therapy, or hemorrhagic transformation are provided.",
          "pmid": "35709228",
          "title": "Risk factors of dysphagia in patients with ischemic stroke: A meta-analysis and systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses diabetes, hyperglycemia, and their impact on cerebrovascular structure and function, stroke risk, and outcomes after thrombolysis, but it does not mention hypertension or blood-brain barrier dysfunction as mediators of hemorrhagic transformation after thrombolysis. Therefore it neither supports nor contradicts the specific mechanism linking hypertension, BBB dysfunction, and hemorrhagic transformation.",
          "key_findings": "1) Diabetes and hyperglycemia increase the risk of stroke and worsen outcomes after acute ischemic stroke, including reduced benefit from IV tPA. 2) Experimental models show chronic hyperglycemia causes deficits in cerebrovascular structure and function, with increased edema, neovascularization, protease expression, and altered vascular reactivity and tone. 3) Stroke risk is higher in diabetic patients with hypertension, but no mechanistic link via blood-brain barrier dysfunction or hemorrhagic transformation after thrombolysis is described.",
          "pmid": "35216512",
          "title": "Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract identifies hypertension as a risk factor for different ischemic stroke subtypes but does not examine blood-brain barrier function, thrombolysis, or hemorrhagic transformation. It addresses vascular risk association with stroke type, not the mechanistic link between hypertension, BBB dysfunction, and hemorrhagic transformation after thrombolysis.",
          "key_findings": "Hypertension, diabetes mellitus, high total cholesterol, hypertriglyceridemia, and smoking are reported as independent risk factors for cerebral small vessel disease (SVD) stroke; hypertension, diabetes, high LDL, hypertriglyceridemia, and smoking are risk factors for large artery atherosclerosis (LAA) stroke; cerebral SVD patients are more likely than LAA patients to have high total cholesterol.",
          "pmid": "35114778",
          "title": "Risk factors for ischemic stroke: differences between cerebral small vessel and large artery atherosclerosis aetiologies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a guideline summary that mentions blood pressure thresholds for treatment before thrombolysis, but it does not discuss blood-brain barrier dysfunction, nor does it analyze the relationship between hypertension, BBB integrity, and risk of hemorrhagic transformation after thrombolysis.",
          "key_findings": "Guidelines recommend treating blood pressure only if it exceeds 185/105 mmHg in acute ischemic stroke and discuss indications and time windows for thrombolysis and thrombectomy, but they provide no mechanistic or empirical data on BBB dysfunction or its link to hemorrhagic transformation in hypertensive patients.",
          "pmid": "22152803",
          "title": "Guidelines for the treatment of acute ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses prevalence of hypertension and other risk factors in young ischemic stroke patients across regions and ethnicities, and differences in short-term mortality, but it does not examine blood-brain barrier function, thrombolysis, or hemorrhagic transformation. Therefore it neither supports nor contradicts the proposed mechanistic link between hypertension, BBB dysfunction, and hemorrhagic transformation after thrombolysis.",
          "key_findings": "Hypertension is common among young ischemic stroke patients, particularly in Black and Asian groups (around 46\u201352% prevalence). The study describes variations in stroke etiology and higher 3\u2011month mortality in low- and middle-income countries, but provides no data on blood-brain barrier integrity, use of thrombolytic therapy, or rates of hemorrhagic transformation.",
          "pmid": "34906974",
          "title": "Global Differences in Risk Factors, Etiology, and Outcome of Ischemic Stroke in Young Adults-A Worldwide Meta-analysis: The GOAL Initiative.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "dbprand",
      "mechanism": {
        "mechanism_type": "statistical",
        "description": "Confounding with hypertension-related end-organ damage where higher DBP reflects advanced vascular disease.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (\"diastolic blood pressure\" OR \"blood pressure\" OR \"hypertension\") AND (\"independent predictor\" OR \"confounding\" OR \"interaction effect\") AND (\"hypertension\" OR \"confounding\" OR \"reflects\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 1,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a broad narrative review of alcohol\u2019s associations with various cardiovascular diseases and general methodological issues like confounding, but it does not mention diastolic blood pressure, hypertension-related end-organ damage, or vascular disease severity as a specific confounder or mechanism. There is no direct evidence addressing whether higher DBP reflects advanced vascular disease and confounds observed associations.",
          "key_findings": "The abstract states that alcohol has complex, often non-linear associations with multiple cardiovascular diseases and highlights general concerns about exposure measurement and confounding variables. It calls for large longitudinal studies with extensive assessment of genetic and confounding variables, but does not specify DBP levels or hypertension-related end-organ damage as a confounding pathway.",
          "pmid": "34684419",
          "title": "Alcohol's Impact on the Cardiovascular System.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates associations between blood pressure variability and cardiovascular outcomes independent of mean blood pressure, focusing on variability itself as a risk factor. It does not analyze diastolic blood pressure specifically, nor does it examine confounding by hypertension-related end-organ damage or advanced vascular disease as an explanation for the observed associations. The mention of avoiding confounding is generic and not specific to end-organ damage or diastolic BP, so the proposed confounding mechanism is neither supported nor refuted.",
          "key_findings": "The meta-analysis found that increased long-term systolic blood pressure variability is associated with higher risk of all-cause mortality, cardiovascular mortality, cardiovascular events, coronary heart disease, and stroke, over and above mean blood pressure. Mid-term and short-term daytime systolic blood pressure variability also showed positive associations with all-cause mortality. Studies with high risk of confounding were excluded from main analyses, but specific confounders such as hypertension-related end-organ damage or advanced vascular disease were not detailed.",
          "pmid": "27511067",
          "title": "Blood pressure variability and cardiovascular disease: systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract reports that hypertension and cardiovascular events are more prevalent in peri- and postmenopausal women with PCOS and acknowledges multiple confounders (e.g., obesity), but it does not analyze diastolic blood pressure levels, end-organ damage, or explicitly evaluate confounding of associations by hypertension-related vascular disease. Therefore it neither supports nor contradicts the specific mechanism that higher DBP reflects advanced vascular disease leading to confounding.",
          "key_findings": "Women \u226545 years with PCOS had higher odds of hypertension (OR 1.79) and higher odds of myocardial infarction and stroke than controls; most cardiometabolic comorbidities appeared driven by coexistent weight excess. The meta-analysis used random-effects models and performed sensitivity analyses for BMI and diagnostic criteria but did not assess diastolic blood pressure as a marker of end-organ damage or its role as a confounder.",
          "pmid": "37353908",
          "title": "PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses developmental origins of adult disease, including hypertension, but does not address statistical confounding with hypertension-related end-organ damage, does not mention diastolic blood pressure specifically, and does not analyze whether higher DBP reflects advanced vascular disease. It instead focuses on birthweight and early growth as causal factors, not on confounding structures in adult BP\u2013outcome relationships.",
          "key_findings": "Low birthweight is associated with higher rates of coronary heart disease, stroke, hypertension, and type 2 diabetes, across the normal birthweight range and after accounting for confounding variables; these associations are attributed to developmental plasticity and are exacerbated by impaired infant growth and rapid childhood weight gain.",
          "pmid": "15640511",
          "title": "The developmental origins of adult disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses heterogeneous pathophysiological mechanisms and risk factors (including hypertension) in HFpEF but does not analyze diastolic blood pressure levels, end-organ damage, or statistical confounding between DBP and hypertension-related vascular damage. There is no direct evidence presented for or against the proposed confounding mechanism.",
          "key_findings": "HFpEF is common and heterogeneous; mechanisms include diastolic dysfunction, impaired systolic reserve, vascular dysfunction, nitric oxide issues, autonomic tone, and peripheral impairments. Hypertension is noted as a typical risk factor for HFpEF, but no specific analysis of DBP, end-organ damage, or confounding is provided.",
          "pmid": "24958077",
          "title": "The pathophysiology of heart failure with preserved ejection fraction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates comparative effectiveness and safety of first-line antihypertensive drug classes using large-scale propensity score methods, but it does not analyze diastolic blood pressure levels, hypertension-related end-organ damage, or confounding by advanced vascular disease as an explanation for observed outcomes. The focus is on drug class comparisons, not on statistical confounding by DBP or vascular damage.",
          "key_findings": "Thiazide or thiazide-like diuretics showed better primary effectiveness and safety than ACE inhibitors; non-dihydropyridine calcium channel blockers were inferior to other classes. The study used large-scale propensity adjustment to minimize residual confounding but did not specifically examine or attribute effects to confounding with hypertension-related end-organ damage or higher DBP as a marker of advanced vascular disease.",
          "pmid": "31668726",
          "title": "Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses alcohol consumption and general cardiovascular disease risk, along with concerns about bias and confounding in observational research, but it does not mention diastolic blood pressure, hypertension-related end-organ damage, or any analysis of confounding by vascular disease severity. Therefore, it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Observational evidence suggests low alcohol intake (1\u20132 drinks/day) may be associated with no risk to possible risk reduction for several cardiovascular outcomes, while heavy alcohol intake (\u22653 drinks/day or binge drinking) is associated with worse outcomes. The statement emphasizes that most data are observational and subject to bias and confounding but does not specify confounding with hypertension-related end-organ damage or higher diastolic blood pressure.",
          "pmid": "40485439",
          "title": "Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines LOX-1\u2013related biomarkers (LAB, sLOX-1, LOX index) and their associations with atherosclerotic disease and various risk factors, including diastolic hypertension. It does not analyze diastolic blood pressure as a marker of hypertension-related end-organ damage, nor does it address confounding by advanced vascular disease in statistical associations. Thus, it neither supports nor contradicts the specific mechanism of confounding with hypertension-related end-organ damage where higher DBP reflects advanced vascular disease.",
          "key_findings": "LAB and LOX index are associated with carotid intima-media thickness, coronary artery disease, and ischemic stroke, independent of LDL or non-HDL cholesterol; LAB is associated with several risk factors, including diastolic hypertension, but the role of DBP as a confounder via end-organ damage is not evaluated.",
          "pmid": "25463747",
          "title": "LOX-1 in atherosclerotic disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses goals and outcomes of antihypertensive therapy, including the role of absolute cardiovascular risk and measures of cardiac/vascular damage (e.g., LVH), but it does not analyze diastolic blood pressure levels as markers of pre\u2011existing hypertension-related end-organ damage or as confounders in observed associations. There is no explicit examination of how higher DBP might reflect advanced vascular disease and thereby confound outcome relationships.",
          "key_findings": "The abstract notes that: (1) cardiovascular risk is influenced by age, sex, race, and other risk factors in addition to blood pressure; (2) drug therapy reduces stroke, heart failure, and renal failure but has less clear benefit on coronary events; (3) LVH is an independent predictor of coronary disease and can regress with several antihypertensive classes; and (4) it may be appropriate in low-risk younger patients to monitor measures of cardiac and vascular damage. None of these findings directly address confounding by hypertension-related end-organ damage tied to diastolic blood pressure levels.",
          "pmid": "7729325",
          "title": "Goals of antihypertensive therapy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that both systolic and diastolic blood pressure predict stroke risk, but it does not assess or discuss confounding by hypertension-related end-organ damage nor whether higher DBP is specifically a marker of advanced vascular disease. It treats BP components as risk predictors without exploring underlying vascular damage or confounding structures, so it neither supports nor refutes the proposed confounding mechanism.",
          "key_findings": "In meta-analysis of 11 studies, a 10 mmHg increase in pulse pressure was associated with higher stroke risk (HR 1.046, 95% CI 1.025\u20131.068). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were also significant predictors of stroke (SBP HR 1.053, 95% CI 1.033\u20131.073; DBP HR 1.056, 95% CI 1.038\u20131.074). For all-cause mortality, pulse pressure and DBP were not significant, while SBP was (HR 1.008, 95% CI 1.002\u20131.014). No data are provided on hypertension-related end-organ damage or confounding by such damage.",
          "pmid": "26902972",
          "title": "Pulse pressure as an independent predictor of stroke: a systematic review and a meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses intraoperative hypotension, cerebral autoregulation, and general confounding factors affecting neurological outcomes, but does not address diastolic blood pressure levels, hypertension-related end-organ damage, or the idea that higher DBP reflects advanced vascular disease as a statistical confounder. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The review notes: (1) no definitive blood pressure threshold for neurological complications from intraoperative hypotension; (2) cerebral blood flow is influenced by cerebral autoregulation and various patient, surgical, and anesthesia-related confounders; (3) most evidence comes from cohort studies with limited causal inference; (4) targeting blood pressure guided by regional cerebral oxygen saturation or cerebral autoregulation may reduce postoperative neurological complications.",
          "pmid": "32769747",
          "title": "Intraoperative hypotension and neurological outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns statistical confounding by hypertension-related end-organ vascular damage reflected in higher diastolic blood pressure. The abstract discusses homocysteine, hypertension, and stroke in general terms, highlighting confounding by renal impairment, diet, and smoking, and calling for better control of confounders. It does not analyze blood pressure levels as a marker of end-organ damage, nor does it evaluate or even mention confounding specifically via hypertension-related vascular disease or diastolic blood pressure patterns. Thus it neither supports nor contradicts this specific confounding mechanism.",
          "key_findings": "The abstract notes: (1) observational evidence that elevated homocysteine is associated with carotid artery disease and stroke; (2) concern about confounding from renal impairment, atherogenic diet, and smoking; (3) inconsistent links between MTHFR polymorphism and stroke; (4) limited and inconsistent evidence linking homocysteine with hypertension; and (5) a need for prospective and randomized studies with good measurement of homocysteine, blood pressure, and other confounders. It does not address hypertension-related end-organ damage or higher diastolic blood pressure as a confounder.",
          "pmid": "10376845",
          "title": "Homocysteine, hypertension and stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a methodological overview of individual participant data meta-analysis and does not analyze or report any specific relationship between diastolic blood pressure, hypertension-related end-organ damage, or vascular disease. It mentions blood pressure after endovascular thrombectomy only as part of an example dataset, without mechanistic or confounding analyses relevant to the proposed mechanism.",
          "key_findings": "Describes the advantages and methods of IPD meta-analysis (e.g., handling covariates, exploring interaction terms) and illustrates with examples including studies of blood pressure levels after endovascular thrombectomy and functional outcomes in stroke, but provides no specific results or discussion about confounding with hypertension-related end-organ damage or advanced vascular disease reflected by higher diastolic blood pressure.",
          "pmid": "36797070",
          "title": "An Introduction to Individual Participant Data Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The proposed mechanism suggests that the association (here, between proteinuria and stroke) is largely or substantially due to confounding by hypertension-related end-organ damage, implying the effect should attenuate with more thorough adjustment for blood pressure. This meta-analysis explicitly examined that possibility and found that the association between proteinuria and stroke risk persisted with little attenuation even after increasingly extensive adjustment for hypertension, arguing against confounding by hypertension-related vascular damage as the main explanation.",
          "key_findings": "In 38 studies (1,735,390 participants; 26,405 strokes), proteinuria was associated with higher stroke risk: crude RR 2.00 (95% CI 1.63\u20132.46) and adjusted RR 1.72 (1.51\u20131.95). Importantly, the association did not substantially attenuate with more complete BP adjustment: single baseline BP measure (10 studies; adjusted RR 1.92, 1.39\u20132.66), history/treated hypertension (4 studies; adjusted RR 1.76, 1.13\u20132.75), and multiple BP measurements over months to years (4 studies; RR 1.68, 1.33\u20132.14). Authors conclude that proteinuria is strongly and independently associated with incident stroke risk even after extensive adjustment for hypertension.",
          "pmid": "31935154",
          "title": "Proteinuria as an independent predictor of stroke: Systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on resting heart rate as an independent predictor of cardiovascular and cerebrovascular morbidity and mortality, including its relationship with blood pressure and metabolic factors. It does not analyze diastolic blood pressure, hypertension-related end-organ damage, or confounding by advanced vascular disease as an explanation for observed associations. Thus, it neither supports nor contradicts the specific proposed mechanism about confounding with hypertension-related end-organ damage where higher DBP reflects advanced vascular disease.",
          "key_findings": "Increased heart rate is consistently associated with higher cardio- and cerebrovascular morbidity and mortality; this association remains significant even after adjustment for major cardiovascular risk factors such as blood pressure and metabolic disturbances, and is generally stronger in men. The abstract does not address diastolic blood pressure, end-organ damage, or confounding mechanisms related to advanced vascular disease.",
          "pmid": "29355923",
          "title": "Heart rate as a predictor of cardiovascular risk.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses management of symptomatic intracranial stenosis, compares warfarin vs aspirin, and stenting vs aggressive medical management, and mentions systolic blood pressure targets as part of risk factor control. It does not analyze diastolic blood pressure, hypertension-related end-organ damage, or any confounding effects of higher DBP reflecting advanced vascular disease on outcomes. Thus it neither supports nor contradicts the proposed confounding mechanism.",
          "key_findings": "Aggressive medical management with risk factor control (including target systolic BP <140 mmHg, LDL <70 mg/dL, HbA1c <7%) and lifestyle modification reduces stroke risk compared to prior trials; warfarin is not superior to aspirin and has higher hemorrhage risk; stenting adds risk without benefit. No data on diastolic BP, hypertension-related end-organ damage, or confounding by such damage.",
          "pmid": "27443379",
          "title": "Management of Symptomatic Intracranial Stenosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines pulse pressure and mean pressure as predictors of mortality in hypertensive patients, but does not address whether diastolic blood pressure specifically serves as a proxy for hypertension-related end-organ damage or advanced vascular disease, nor does it analyze confounding by such damage. The mechanism is about confounding with DBP as an indicator of vascular damage, whereas the study focuses on the independent prognostic value of pulse pressure and mean pressure after statistical adjustment for basic covariates.",
          "key_findings": "In hypertensive patients, a 10 mmHg higher pulse pressure was independently associated with ~6\u20137% increased risk of total, cardiovascular, and coronary mortality, while mean pressure was not an independent predictor. The prognostic value of pulse pressure for fatal stroke increased with age, and mean pressure had greater prognostic power for coronary mortality in younger patients. No analysis of diastolic pressure as a confounder via hypertension-related end-organ damage or advanced vascular disease is presented.",
          "pmid": "11791038",
          "title": "Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates associations between occupational noise exposure and cardiovascular outcomes (IHD, stroke, hypertension) but does not discuss diastolic blood pressure levels, end-organ damage, vascular disease severity, or confounding structures involving hypertension-related end-organ damage. It focuses on exposure-outcome risk estimates and evidence quality, not on whether higher DBP reflects advanced vascular disease or acts as a confounder.",
          "key_findings": "The review and meta-analysis found low-certainty evidence that occupational noise exposure (\u226585 dBA) may increase incidence of IHD (RR 1.29, 95% CI 1.15\u20131.43), and no clear evidence of harmfulness for stroke or hypertension incidence or mortality. Confounding by hypertension-related end-organ damage or diastolic blood pressure is not assessed or mentioned.",
          "pmid": "33612311",
          "title": "The effect of occupational exposure to noise on ischaemic heart disease, stroke and hypertension: A systematic review and meta-analysis from the WHO/ILO Joint Estimates of the Work-Related Burden of Disease and Injury.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses alcohol consumption, cardiovascular disease, and intermediate endpoints such as hypertension and diabetes in broad terms, but it does not address diastolic blood pressure specifically, nor confounding by hypertension-related end-organ damage or advanced vascular disease as an explanation for any observed associations. No statistical or mechanistic analysis related to higher DBP reflecting more advanced vascular damage is presented.",
          "key_findings": "Observational evidence suggests light to moderate alcohol intake is associated with lower cardiovascular disease risk, with higher intake increasing risks such as cardiomyopathy, sudden death, and hemorrhagic stroke. The abstract notes interest in alcohol\u2019s role in intermediate endpoints like hypertension and diabetes, but provides no detailed data or mechanisms on diastolic blood pressure or end-organ damage\u2013related confounding.",
          "pmid": "24667667",
          "title": "An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on medicolegal issues surrounding tPA use in acute stroke, including case descriptions of failure to treat, misdiagnosis, bleeding complications, and expert testimony. It does not analyze or even mention diastolic blood pressure, hypertension-related end-organ damage, or any statistical confounding mechanisms involving advanced vascular disease.",
          "key_findings": "Discusses malpractice cases related to use or non-use of tPA in stroke, misdiagnosis, bleeding after tPA in a hypertensive patient, and legal consequences for expert testimony; no data or analysis on blood pressure levels, end-organ damage, or their role as confounders.",
          "pmid": "16728683",
          "title": "Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "weight",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Alteplase dosing is weight-adjusted, impacting concentration and treatment efficacy, as incorrect dosing can lead to inefficacy.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (weight OR BMI OR obesity OR \"body mass\" OR \"pharmacokinetics\") AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"concentration\" OR \"inefficacy\" OR \"treatment\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 0,
      "neutral_count": 19,
      "support_percentage": 5.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses dose adjustment of direct oral anticoagulants in chronic kidney disease but does not mention alteplase, weight-based dosing, or how incorrect alteplase dosing affects drug concentration or efficacy. Thus it does not provide direct evidence for or against the proposed alteplase-specific, weight-adjusted dosing mechanism.",
          "key_findings": "The review describes that DOACs are noninferior to warfarin with lower bleeding in general populations; in CKD, certain DOACs show lower stroke, embolism, bleeding, or mortality versus warfarin; all DOACs warrant dose adjustment in moderate-to-severe CKD; and current evidence questions anticoagulation in dialysis patients due to high bleeding rates. No data concern alteplase or weight-adjusted thrombolytic dosing.",
          "pmid": "38035566",
          "title": "Anticoagulation in Patients with Chronic Kidney Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares alteplase with tenecteplase in terms of efficacy, pharmacokinetics, pharmacodynamics, ease of administration, and time/cost benefits, but it does not mention weight-adjusted dosing of alteplase, its impact on drug concentration, or consequences of incorrect weight-based dosing on efficacy. Therefore it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Tenecteplase has favorable pharmacokinetics/pharmacodynamics, is easier to administer than alteplase, and in clinical trials is non-inferior or possibly superior to alteplase in acute ischemic stroke, especially with large vessel occlusion; current evidence suggests tenecteplase could replace alteplase due to time and cost benefits.",
          "pmid": "38686848",
          "title": "Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies apixaban versus warfarin in hemodialysis patients, including some weight-based dose adjustments for apixaban and associated pharmacokinetics, but it does not investigate alteplase, alteplase dosing strategies, or how weight-adjusted alteplase dosing affects concentration or treatment efficacy. Therefore it neither supports nor contradicts the proposed alteplase-specific mechanism.",
          "key_findings": "Apixaban 5 mg BID (or 2.5 mg BID for age \u226580 years or weight \u226460 kg) was compared with dose-adjusted warfarin in hemodialysis patients with AF. The trial reported bleeding and stroke rates, overall mortality, and apixaban pharmacokinetic parameters (AUC and blood concentrations) for different apixaban doses, noting overlap of exposure between those with and without bleeding events. No data were presented on alteplase, thrombolysis, or weight-based alteplase dosing.",
          "pmid": "36335914",
          "title": "Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on post-stroke depression mechanisms and pharmacological treatment, mainly SSRIs, their pleiotropic actions, and safety (including bleeding risk). It does not discuss alteplase, thrombolytic therapy, weight-adjusted dosing, concentration\u2013response relationships, or efficacy changes due to incorrect dosing.",
          "key_findings": "Describes multifactorial mechanisms of post-stroke depression (monoaminergic dysfunction, neuroinflammation, HPA-axis activation, impaired neurogenesis, mitochondrial dysfunction) and reviews SSRIs as preventive/curative treatments, including their anti-inflammatory and neurotrophic effects and bleeding risk. No mention of alteplase, its dosing, or its pharmacodynamic consequences.",
          "pmid": "29128343",
          "title": "Post-stroke depression: Mechanisms and pharmacological treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions that alteplase is dosed at 0.9 mg/kg and compares it with two weight-based doses of tenecteplase, but it does not investigate how incorrect or non\u2013weight-adjusted alteplase dosing affects plasma concentration or treatment efficacy. The trial assumes standard weight-adjusted dosing for alteplase and does not analyze dose\u2013response or misdosing effects for alteplase specifically, so it neither supports nor contradicts the proposed mechanism about the impact of incorrect alteplase dosing.",
          "key_findings": "Alteplase was administered at a standard weight-adjusted dose of 0.9 mg/kg; tenecteplase was given at 0.1 or 0.25 mg/kg. Higher-dose tenecteplase (0.25 mg/kg) showed better reperfusion and clinical outcomes than lower-dose tenecteplase and alteplase, with no significant difference in serious adverse events between groups. No data are presented on variations or errors in alteplase dosing, nor on how non\u2013weight-adjusted or incorrect dosing of alteplase influences efficacy.",
          "pmid": "22435369",
          "title": "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses weight-based dosing and pharmacokinetics/pharmacodynamics of ravulizumab, not alteplase. Although it notes that weight-based dosing achieves target concentrations irrespective of body weight, it does not examine alteplase, nor does it address how incorrect alteplase dosing affects concentration or efficacy.",
          "key_findings": "Ravulizumab was administered using weight-based loading and maintenance doses; target serum concentrations (>175 \u00b5g/mL) and complete, sustained inhibition of free C5 were achieved and maintained across body-weight categories, with no meaningful PK differences between weight categories.",
          "pmid": "36890354",
          "title": "Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on the pharmacokinetics, metabolism, dosing regimen, and drug\u2013drug interactions of losartan, an angiotensin-receptor antagonist. It does not discuss alteplase, weight-adjusted dosing, or any relationship between body weight, drug concentration, and efficacy for alteplase or similar thrombolytics. Therefore, it neither supports nor conflicts with the proposed alteplase dosing mechanism.",
          "key_findings": "Losartan shows linear, dose-proportional pharmacokinetics; has an active metabolite (E 3174) with longer half-life; standard fixed doses (50\u2013100 mg/day) are recommended without adjustment for age, sex, race, mild hepatic impairment, or renal insufficiency; and pharmacokinetics are not substantially altered by food or many CYP450 modulators. None of these findings address weight-adjusted alteplase dosing or its impact on efficacy.",
          "pmid": "16029066",
          "title": "Clinical pharmacokinetics of losartan.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses resveratrol\u2019s clinical benefits, safety, pharmacokinetics, and issues of bioavailability, but does not mention alteplase, weight-adjusted dosing, or how dosing errors affect efficacy. It is focused on a different compound and does not address the proposed alteplase dosing mechanism.",
          "key_findings": "Resveratrol is evaluated in numerous clinical trials for various diseases; it is safe up to 5 g/day, has pleiotropic molecular targets, and its use is limited by rapid metabolism and poor bioavailability. No information on alteplase, weight-based dosing, or dose\u2013efficacy relationships is provided.",
          "pmid": "30741437",
          "title": "Health benefits of resveratrol: Evidence from clinical studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract directly tests different fixed rt-PA doses and shows that dose (and effectively drug exposure relative to body weight) affects safety while maintaining efficacy. Lower dose (thus lower concentration, especially in lower-weight patients) preserved thrombolytic efficacy but reduced bleeding, particularly in patients <65 kg, demonstrating that dosing relative to body weight impacts clinical outcomes and that non-optimized dosing can increase harm without efficacy gain.",
          "key_findings": "In a randomized multicenter trial of 118 acute PTE patients, a 50 mg/2 h rt-PA regimen had similar efficacy to 100 mg/2 h for improving right ventricular dysfunction, lung perfusion defects, and pulmonary artery obstruction. Overall bleeding was lower in the 50 mg group (3%) than the 100 mg group (10%). Among patients with body weight <65 kg, bleeding was 14.8% with 50 mg vs 41.2% with 100 mg (P = .049). Mortality was similar (2% vs 6%), and no fatal recurrent PTE occurred in either group. Authors conclude optimizing rt-PA dosing is worthwhile, and lower dosing may offer better safety with maintained efficacy, especially in lower-weight patients.",
          "pmid": "19741062",
          "title": "Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies HU6, a metabolic accelerator for obesity-related HFpEF, not alteplase. It does not discuss alteplase, weight-adjusted thrombolytic dosing, drug concentration, or treatment efficacy related to dosing errors, so it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "HU6 treatment in obese HFpEF patients led to modest but statistically significant reductions in body weight, total fat mass, and visceral fat percentage over 19 weeks, without significant changes in exercise capacity or cardiac biomarkers; safety events were similar between HU6 and placebo.",
          "pmid": "40072462",
          "title": "Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns network pharmacology and mechanisms of heat-clearing Chinese herbs in ischemic encephalopathy. It does not mention alteplase, thrombolytics, weight-based dosing, drug concentration, or dose\u2013response efficacy relationships, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The study identifies common heat-clearing herbs and their bioactive components (e.g., beta-sitosterol, quercetin, stigmasterol), maps them to molecular targets (RELA, AKT1, JUN, etc.), and implicates multiple signaling pathways (Calcium, PI3K-Akt, MAPK, cAMP, IL-17, HIF-1, TNF, T-cell receptor, NF-\u03baB, JAK-STAT) in cerebroprotection against ischemic encephalopathy. No data on alteplase or weight-adjusted pharmacologic dosing are provided.",
          "pmid": "38285889",
          "title": "Substance basis and pharmacological mechanism of heat-clearing herbs in the treatment of ischaemic encephalopathy: a systematic review and network pharmacology.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates fixed-dose simvastatin plus ezetimibe in chronic kidney disease and reports clinical outcomes, but it does not involve alteplase, weight-based dosing, drug concentrations, or dosing accuracy effects on efficacy. Therefore it neither supports nor contradicts the proposed mechanism about weight-adjusted alteplase dosing.",
          "key_findings": "In the SHARP trial, patients with chronic kidney disease were randomized to simvastatin 20 mg plus ezetimibe 10 mg daily versus placebo. The treatment reduced LDL cholesterol by an average of 0.85 mmol/L and yielded a 17% proportional reduction in major atherosclerotic events over 4.9 years, with acceptable safety. No information is provided about alteplase, weight-based dosing, or dose\u2013response related to body weight.",
          "pmid": "21663949",
          "title": "The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies methylene blue infusion in septic shock, not alteplase. Although methylene blue is dosed per kg, the paper does not investigate weight-adjusted dosing effects on drug concentration, nor the consequences of incorrect dosing on efficacy. It therefore does not address the proposed alteplase dosing mechanism.",
          "key_findings": "In septic shock patients, methylene blue given as a 2 mg/kg bolus followed by stepwise weight-based infusion improved mean arterial pressure, reduced vasopressor requirements, maintained oxygen delivery, lowered body temperature and nitrate/nitrite levels, and had no major adverse effects on measured organ function variables. These results are unrelated to alteplase dosing or its weight-adjusted efficacy.",
          "pmid": "11588440",
          "title": "Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the pharmacokinetics, pharmacodynamics, safety, and clinical outcomes of desmoteplase, including that fibrinolytic activity is linearly related to blood concentration and doses are expressed in \u03bcg/kg. However, it does not examine alteplase dosing, weight-adjustment of alteplase, or how incorrect alteplase dosing affects efficacy. Any mention of desmoteplase versus alteplase is comparative at the clinical outcome level, not about alteplase\u2019s weight-adjusted dosing mechanism.",
          "key_findings": "Desmoteplase shows linear plasma fibrinolytic activity with blood concentration, has a terminal half-life of 3.8\u20134.92 hours (at 50 vs. 90 \u03bcg/kg), and is generally well tolerated. It has been compared to alteplase in myocardial infarction and pulmonary embolism with promising results, and in ischemic stroke it showed variable safety and efficacy across DIAS trials. No data are provided on how weight-adjusted alteplase dosing affects drug concentration or treatment efficacy.",
          "pmid": "34893967",
          "title": "Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses edoxaban, an oral factor Xa inhibitor, its clinical trials, and comparison with warfarin, but does not mention alteplase, weight-based dosing, drug concentrations, or dose\u2013efficacy relationships. Therefore it neither supports nor contradicts the proposed mechanism about weight-adjusted alteplase dosing and its impact on efficacy.",
          "key_findings": "Edoxaban tosylate is being developed as an orally active direct factor Xa inhibitor; large phase III trials (ENGAGE AF TIMI 48 and HOKUSAI VTE) compare fixed dosing regimens of edoxaban with warfarin for prevention and treatment of thromboembolic events. No information is provided about alteplase or weight-based dosing effects.",
          "pmid": "21446778",
          "title": "Edoxaban tosylate.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke pharmacogenomics and mentions rtPA (alteplase) among principal drugs but does not address weight-adjusted dosing, its impact on drug concentration, or treatment efficacy. No data or statements are provided about dosing accuracy, under/over-dosing by weight, or related clinical outcomes.",
          "key_findings": "The paper aims to review commonly used stroke drugs, including rtPA in the acute phase, focusing on pharmacogenetics and genetic determinants of stroke and drug response, without specific discussion of alteplase weight-based dosing or its consequences.",
          "pmid": "19925046",
          "title": "Stroke pharmacogenomics.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antiplatelet therapy, pharmacokinetics/pharmacodynamics, and platelet function testing in neurointerventional procedures, but it does not mention alteplase, thrombolytic dosing, weight-based dosing, or treatment efficacy as a function of alteplase concentration. Therefore it neither supports nor contradicts the proposed mechanism about weight-adjusted alteplase dosing and efficacy.",
          "key_findings": "The review covers indications and regimens for antiplatelet medications in neurointervention, including dual antiplatelet therapy, clopidogrel function testing, and use of glycoprotein IIb/IIIa inhibitors. It notes limited randomized trial evidence for antiplatelet use in acute large vessel occlusion stroke and emphasizes the need for comparative trials and standardized protocols. No data on alteplase or its dosing strategy are provided.",
          "pmid": "37562452",
          "title": "Antiplatelet Therapy in Neurointervention.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses apixaban, a fixed-dose direct oral anticoagulant, and does not mention alteplase, weight-adjusted dosing, or any relationship between dosing accuracy, plasma concentration, and efficacy. It therefore neither supports nor contradicts the proposed mechanism about weight-based alteplase dosing and treatment efficacy.",
          "key_findings": "Apixaban is described as a DOAC with a fixed anticoagulation profile and specified doses that does not require routine monitoring, and randomized trials (ARISTOTLE, AMPLIFY) showed it to be noninferior to vitamin K antagonists for preventing stroke and VTE with a good safety profile. No data on alteplase or weight-based dosing are provided.",
          "pmid": "28744136",
          "title": "Quick reference guide to apixaban.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical efficacy and safety of tenecteplase versus alteplase and mentions pharmacokinetic advantages of tenecteplase, but it does not address alteplase\u2019s weight-based dosing, its impact on drug concentration, or the consequences of incorrect weight-adjusted dosing on efficacy.",
          "key_findings": "Tenecteplase, a genetically modified form of alteplase, showed higher rates of recanalization and early neurological improvement than alteplase, with no differences in functional outcome at 3 months, intracranial hemorrhage, symptomatic ICH, or mortality. The study notes tenecteplase\u2019s more favorable pharmacokinetic profile and bolus administration but does not discuss weight-adjusted dosing or dosing errors for alteplase.",
          "pmid": "33440328",
          "title": "Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses edoxaban, a direct oral anticoagulant, including its pharmacology, clinical efficacy, and adverse-effect profile. It does not mention alteplase, weight-adjusted dosing, dose\u2013concentration relationships, or how incorrect weight-based dosing might affect alteplase efficacy. Therefore, it neither supports nor contradicts the proposed alteplase-specific pharmacological mechanism.",
          "key_findings": "Edoxaban is a direct factor Xa inhibitor DOAC, noninferior to warfarin for stroke prevention in nonvalvular atrial fibrillation and for treatment of venous thromboembolism, with some limitations related to renal function (higher stroke rate in AF patients with creatinine clearance \u226595 mL/min). No discussion of alteplase, weight-based dosing, or dosing-related efficacy mechanisms.",
          "pmid": "28122753",
          "title": "Edoxaban: A direct oral anticoagulant.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "weight",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Obesity is associated with hypercoagulability, impacting stroke severity and response to thrombolytics.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (weight OR BMI OR obesity OR \"body mass\" OR \"pharmacokinetics\") AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"hypercoagulability\" OR \"thrombolytics\" OR \"associated\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity\u2019s epidemiology and its association with multiple diseases, including stroke, but does not mention hypercoagulability, coagulation pathways, stroke severity, or response to thrombolytic therapy. Therefore, it does not provide mechanism-specific evidence for or against the proposed pathway.",
          "key_findings": "Obesity prevalence has risen globally; obesity increases risk of several diseases including stroke; current prevention and treatment strategies have limited long-term success; calls for better understanding of societal causes and interventions. No discussion of coagulation status, hypercoagulability, or thrombolytic response.",
          "pmid": "30814686",
          "title": "Obesity: global epidemiology and pathogenesis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity in the context of the gut-microbiota-brain axis, metabolism, appetite regulation, and potential microbiome-based therapies, but it does not address coagulation, hypercoagulability, stroke severity, or response to thrombolytic therapy. Therefore it neither supports nor contradicts the specific proposed mechanism about obesity-related hypercoagulability and stroke outcomes.",
          "key_findings": "Obesity is linked to various physiological and mental disorders; the gut microbiota influences obesity via neural, endocrine, and immune pathways within the gut-brain axis, affecting metabolism, adiposity, energy balance, and appetite; altering the gut microbiome (e.g., via fecal microbiota transplant, probiotics, prebiotics) is proposed as an anti-obesity strategy.",
          "pmid": "35421277",
          "title": "Obesity and gut-microbiota-brain axis: A narrative review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes obesity as a modifiable risk factor for atrial fibrillation and mentions structural and electrical atrial remodeling, but it does not discuss hypercoagulability, stroke severity, or response to thrombolytics. Thus, it neither supports nor contradicts the specific proposed mechanism about obesity-related hypercoagulability affecting stroke outcomes.",
          "key_findings": "Obesity is identified as a modifiable risk factor for atrial fibrillation and is said to induce structural and electrical atrial remodeling; no mention is made of coagulation status, stroke severity, or thrombolytic response.",
          "pmid": "36434795",
          "title": "Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses effects of intermittent and periodic fasting on metabolic health, cardiovascular risk factors, neurological disorders including stroke, and underlying cellular mechanisms. It does not address obesity-related hypercoagulability, stroke severity, or response to thrombolytics, nor coagulation parameters in general.",
          "key_findings": "Intermittent and periodic fasting improve weight, insulin resistance, and cardiovascular risk factors, and benefit experimental models of age-related diseases including stroke via stress-response pathways, mitochondrial health, DNA repair, autophagy, and stem cell\u2013based regeneration. No measurements or discussion of coagulation status, hypercoagulability, or thrombolytic response are provided.",
          "pmid": "27810402",
          "title": "Impact of intermittent fasting on health and disease processes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how excessive fructose consumption contributes to obesity and cardiometabolic disease via metabolic and physiological pathways, but it does not mention coagulation, hypercoagulability, stroke severity, or response to thrombolytics. Thus it is related to obesity and cardiometabolic risk in general, but does not address the specific coagulation- and stroke-related mechanism.",
          "key_findings": "Excess sugar (especially fructose) intake is implicated in the epidemics of obesity and cardiometabolic disease; fructose has unique metabolic properties that can signal normal sugar intake but in excess may drive metabolic disease; the review covers biochemistry, genetics, and physiology of fructose metabolism and potential therapeutic targets.",
          "pmid": "34619074",
          "title": "Molecular aspects of fructose metabolism and metabolic disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses metabolic syndrome, obesity, and their links to conditions including stroke, focusing on mitochondrial dysfunction, oxidative stress, and systemic inflammation. It does not address coagulation status, hypercoagulability, stroke severity, or response to thrombolytic therapy, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Metabolic syndrome, which includes obesity, is associated with increased risk of stroke and other cardiometabolic diseases, and mitochondrial dysfunction is implicated via oxidative stress and systemic inflammation; no mention is made of coagulation, clotting tendencies, or thrombolytic response.",
          "pmid": "32428560",
          "title": "Mitochondrial dysfunction in metabolic syndrome.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on non-pharmacological management of hypertension (lifestyle, diet, physical activity, pollution) and cardiovascular risk in general. It does not discuss obesity-related hypercoagulability, stroke severity, or response to thrombolytic therapy, nor coagulation parameters in obese individuals.",
          "key_findings": "Lifestyle modifications such as weight loss, increased physical activity, dietary changes, and various relaxation techniques can lower blood pressure; air pollution (PM2.5) is associated with increased cardiovascular events including stroke. No data are presented on obesity, hypercoagulability, or thrombolytic response.",
          "pmid": "33738923",
          "title": "Non-pharmacological management of hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses salt intake, hypertension, and obesity as a risk factor for salt sensitivity and blood pressure, but it does not mention hypercoagulability, stroke severity, or response to thrombolytic therapy. Therefore it neither supports nor contradicts the specific mechanism that obesity-related hypercoagulability impacts stroke severity and thrombolytic response.",
          "key_findings": "High salt intake is linked to hypertension and increased cardiovascular and kidney risk; salt reduction lowers blood pressure, particularly in hypertensive and salt-sensitive individuals. Salt sensitivity is more common in people with metabolic syndrome or obesity. No data are presented regarding coagulation status, stroke severity, or thrombolytic treatment response.",
          "pmid": "27757935",
          "title": "Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity, diabetes, and stroke risk/outcomes in general but does not mention hypercoagulability, coagulation status, or response to thrombolytic therapy, nor does it link obesity to these factors. Therefore it neither supports nor contradicts the specific mechanism that obesity-related hypercoagulability impacts stroke severity and thrombolytic response.",
          "key_findings": "The abstract notes rising obesity and diabetes rates, increased stroke risk and poorer outcomes in individuals with diabetes (especially following ischemic stroke), and susceptibility to cerebral small vessel disease. It does not address coagulation parameters, hypercoagulability, or pharmacologic response to thrombolytics.",
          "pmid": "27079344",
          "title": "Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on the effects of unilateral lower-limb exoskeleton robot-assisted gait training on balance, gait recovery, and neuroplasticity in subacute stroke patients. It does not assess obesity, coagulation status, hypercoagulability, stroke severity related to obesity, or response to thrombolytic therapy, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Robot-assisted overground gait training led to greater improvements in balance (BBS), lower limb motor function (FMA-LE), functional ambulation (FAC), activities of daily living (mBI), and certain gait parameters, along with increased cortical activity in motor and prefrontal areas, compared with conventional training in subacute stroke patients.",
          "pmid": "39639336",
          "title": "Effectiveness of unilateral lower-limb exoskeleton robot on balance and gait recovery and neuroplasticity in patients with subacute stroke: a randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines effects of sleep restriction during caloric restriction on body weight, body composition, respiratory quotient, and leptin. It does not assess coagulation parameters, stroke outcomes, or response to thrombolytic therapy, nor does it discuss hypercoagulability in obesity. Therefore it neither supports nor contradicts the proposed mechanism about obesity-related hypercoagulability affecting stroke severity and thrombolytic response.",
          "key_findings": "Moderate sleep restriction during an 8-week hypocaloric diet led to a similar amount of total weight, lean mass, and fat mass loss compared with caloric restriction alone, but a smaller proportion of weight lost as fat in the sleep-restricted group. Resting respiratory quotient decreased only in the caloric restriction alone group, and fasting leptin decreased only in the caloric restriction plus sleep restriction group.",
          "pmid": "29438540",
          "title": "Influence of sleep restriction on weight loss outcomes associated with caloric restriction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity as a comorbidity in heart failure and reviews weight loss strategies and their safety/efficacy, but it does not address hypercoagulability, stroke severity, or response to thrombolytic therapy. Therefore, it neither supports nor contradicts the proposed coagulation- and stroke-related mechanism.",
          "key_findings": "Obesity is common in HFrEF and HFpEF, with a strong pathophysiologic link to HFpEF. Lifestyle measures, bariatric surgery, and antiobesity medications, particularly GLP-1 and GIP/GLP-1 agonists such as semaglutide, are discussed in terms of weight loss efficacy and cardiovascular safety in heart failure patients, including reductions in HF hospitalizations and medium-term mortality. No data are presented on coagulation parameters, stroke outcomes, or thrombolytic response.",
          "pmid": "39093256",
          "title": "Obesity and Weight Loss Strategies for Patients With Heart\u00a0Failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epigenetic and epitranscriptomic mechanisms, gut microbiota, and post-stroke depression, with mention of fat mass and obesity-associated protein (FTO) as a molecular candidate. However, it does not address obesity as a clinical condition, hypercoagulability, stroke severity, or response to thrombolytic therapy. Thus it provides no direct evidence for or against the proposed mechanism linking obesity-associated hypercoagulability to stroke outcomes.",
          "key_findings": "The review highlights interactions between gut microbiota and epigenetic/epitranscriptomic pathways (including N6-methyladenosine and FTO) in modulating genes implicated in post-stroke depression, such as brain-derived neurotrophic factor and ten-eleven translocation proteins. It does not report data on obesity, coagulation status, stroke severity, or thrombolytic responsiveness.",
          "pmid": "37188778",
          "title": "Post-stroke depression: epigenetic and epitranscriptomic modifications and their interplay with gut microbiota.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity, heart failure, myocardial remodeling, and the obesity paradox, but does not mention hypercoagulability, stroke, thrombolytics, or any coagulation-related outcomes. Therefore it neither supports nor contradicts the proposed mechanism about obesity-driven hypercoagulability affecting stroke severity and thrombolytic response.",
          "key_findings": "Obesity increases risk of heart failure through hemodynamic changes, neurohormonal activation, endocrine/paracrine adipose effects, ectopic fat, and lipotoxicity, leading mainly to concentric LV remodeling and HFpEF. An obesity paradox is observed in heart failure survival, and intentional weight loss or bariatric surgery improves metabolic risk factors, myocardial dysfunction, quality of life, and HF/CVD outcomes. No data are presented regarding coagulation, hypercoagulability, stroke, or thrombolytic therapy.",
          "pmid": "37236574",
          "title": "Heart Failure and Obesity: The Latest Pandemic.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines obesity (via BMI and waist-height ratio) in HFpEF patients and how it modifies clinical characteristics and response to tirzepatide, but it does not assess coagulation status, hypercoagulability, stroke occurrence, stroke severity, or response to thrombolytic therapy. Therefore it neither supports nor contradicts the proposed mechanism linking obesity-associated hypercoagulability to stroke severity and thrombolytic response.",
          "key_findings": "In obese patients with HFpEF, higher BMI and central adiposity were associated with younger age, female sex, more severe HF symptoms, greater volume overload, higher inflammation, worse kidney function, and lower exercise capacity. Tirzepatide reduced risk of cardiovascular death or worsening HF across BMI and WHR tertiles and produced greater improvements in 6-minute walk distance, weight loss, blood pressure, and quality-of-life measures with higher baseline BMI and greater weight loss. No data were presented on coagulation parameters, stroke outcomes, or response to thrombolytics.",
          "pmid": "40701669",
          "title": "Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions obesity as a shared risk factor for migraine and stroke but does not discuss hypercoagulability, stroke severity, or response to thrombolytics in relation to obesity. No coagulation parameters or treatment responses are described, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Obesity is listed among several conditions (including dyslipidemia and platelet dysfunction) that are linked to both migraine and stroke, but no mechanistic detail regarding coagulation status, hypercoagulability, or thrombolytic response is provided.",
          "pmid": "39979846",
          "title": "Migraine and stroke: correlation, coexistence, dependence - a modern perspective.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates relationships between physical activity and mortality/CVD outcomes, including ischemic stroke, but does not address obesity, hypercoagulability, stroke severity, or response to thrombolytic therapy. It is outcome/epidemiology focused and does not investigate coagulation status or treatment response mechanisms in obese individuals.",
          "key_findings": "Higher moderate-to-vigorous physical activity is associated with reduced all-cause mortality, cardiovascular mortality, and incident atherosclerotic CVD (including ischemic stroke and heart failure); benefits begin at low activity levels, increase with dose, and there is no evidence of excess risk at high activity up to 3\u20135 times guideline levels.",
          "pmid": "31095084",
          "title": "Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses irisin, an exercise-induced myokine, and its broad roles in metabolic, cardiovascular, and nervous system diseases including obesity and stroke, but it does not address coagulation status, hypercoagulability, stroke severity, or response to thrombolytic therapy in obesity. Therefore it neither supports nor contradicts the proposed mechanism about obesity-driven hypercoagulability affecting stroke outcomes.",
          "key_findings": "Irisin levels decrease with age and are associated with various aging-related diseases (metabolic diseases such as obesity and type 2 diabetes, cardiovascular diseases including stroke, and nervous system diseases including stroke). Irisin is proposed to improve energy metabolism, autophagy, mitochondrial quality control, reduce ROS, and mitigate inflammation. No data or statements are provided about coagulation, hypercoagulability, or thrombolytic response in the context of obesity or stroke.",
          "pmid": "35793739",
          "title": "Irisin, an exercise-induced bioactive peptide beneficial for health promotion during aging process.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines MRI markers of covert vascular brain injury and their associations with future stroke, dementia, and death. It does not assess obesity, hypercoagulability, or response to thrombolytic therapy, nor does it stratify outcomes by obesity or coagulation status. Therefore, it neither supports nor contradicts the proposed mechanism linking obesity-related hypercoagulability to stroke severity or thrombolytic response.",
          "key_findings": "Extensive white matter hyperintensities, MRI-defined covert brain infarcts, and cerebral microbleeds are each associated with increased risks of incident stroke (ischemic and hemorrhagic), dementia (including Alzheimer disease), and death. Data on perivascular spaces suggest possible increased risk but are insufficient for meta-analysis. No data on obesity, coagulation status, or thrombolytic treatment are presented.",
          "pmid": "30422209",
          "title": "Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on obesity, aldosterone/mineralocorticoid receptor activation, and clinical outcomes in heart failure across BMI strata, as well as response to finerenone. It does not address hypercoagulability, stroke severity, or response to thrombolytic therapy, nor any coagulation-related endpoints. Therefore, it neither supports nor contradicts the proposed mechanism linking obesity-associated hypercoagulability to stroke severity and thrombolytic response.",
          "key_findings": "Obesity is associated with excess adipocyte-derived aldosterone and worse heart failure outcomes (higher risk of cardiovascular death and worsening HF events in obesity class II\u2013III vs normal weight). Finerenone reduced the primary composite outcome similarly across BMI categories, with a possibly greater benefit at higher BMI when BMI is treated as a continuous variable. No data on coagulation markers, stroke incidence/severity, or thrombolytic treatment response are presented.",
          "pmid": "39665701",
          "title": "Finerenone, Obesity, and Heart\u00a0Failure\u00a0With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "weight",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Adipose tissue is metabolically active, producing inflammatory mediators that can affect stroke recovery.",
        "evidence_level": "speculative"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (weight OR BMI OR obesity OR \"body mass\" OR \"pharmacokinetics\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"metabolically\" OR \"inflammatory\" OR \"mediators\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 0,
      "neutral_count": 19,
      "support_percentage": 5.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions that sex hormones affect energy metabolism, body composition, vascular function, and inflammatory responses, and that endocrine imbalances relate to unfavorable cardiometabolic traits. However, it does not specifically discuss adipose tissue as a metabolically active source of inflammatory mediators, nor does it link adipose-derived inflammation to stroke recovery outcomes. Thus, it is related to inflammation and metabolic status but does not address the proposed mechanism in a specific or mechanistic way.",
          "key_findings": "Sex hormones impact energy metabolism, body composition, vascular function, and inflammatory responses; endocrine imbalances are linked to adverse cardiometabolic traits; women with diabetes have greater increases in cardiovascular risk and stroke mortality than men. No direct discussion of adipose tissue\u2013derived inflammatory mediators or their role in stroke recovery.",
          "pmid": "27159875",
          "title": "Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on tirzepatide\u2019s effects on glycaemic control, body weight, and cardiovascular safety in type 2 diabetes. It does not discuss adipose tissue as a metabolically active source of inflammatory mediators, nor does it examine inflammation, stroke, or stroke recovery outcomes. Therefore it neither supports nor contradicts the proposed mechanism about adipose-derived inflammatory mediators affecting stroke recovery.",
          "key_findings": "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, significantly reduces HbA1c and body weight in type 2 diabetes, is more effective than semaglutide and basal insulin for these endpoints, improves insulin sensitivity and insulin secretion, and appears cardiovascularly safe (no increased risk of MACE-4). No measurements or discussion of inflammatory mediators, adipose tissue inflammatory activity, or stroke recovery are provided.",
          "pmid": "36050763",
          "title": "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses adipose-tissue\u2013related, low-grade systemic inflammation in PCOS and its cardiovascular implications, but it does not address stroke, stroke outcomes, or how adipose-derived inflammatory mediators influence stroke recovery. Thus it is mechanistically related to adipose inflammation but does not provide direct evidence for or against effects on stroke recovery.",
          "key_findings": "PCOS is associated with low-grade chronic inflammation characterized by elevated CRP, IL-18, TNF-\u03b1, IL-6, WBC, MCP-1, MIP-1\u03b1, AGEs/RAGE, and markers of endothelial dysfunction and thrombosis (e.g., ADMA, PAI-1, VEGF); this inflammatory state is aggravated by obesity and hyperinsulinemia and is linked to cardiovascular risk and pregnancy complications, but stroke recovery is not mentioned or studied.",
          "pmid": "33917519",
          "title": "Chronic Low Grade Inflammation in Pathogenesis of PCOS.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obstructive sleep apnoea, cardiovascular disease, and heterogeneous risk factors including obesity and inflammation, but it does not specifically address adipose tissue as a metabolically active source of inflammatory mediators or their direct impact on stroke recovery outcomes.",
          "key_findings": "The abstract notes that OSA is associated with increased risk of hypertension, stroke, myocardial infarction, heart failure, arrhythmias, sudden death, and all-cause mortality, and that OSA heterogeneity involves anatomical, physiological, inflammatory, and obesity-related risk factors. It does not mention adipose tissue-derived mediators nor mechanisms of stroke recovery.",
          "pmid": "36899115",
          "title": "Obstructive sleep apnoea heterogeneity and cardiovascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on the pathophysiology, diagnosis, and management of disseminated intravascular coagulation, emphasizing inflammatory cytokines, coagulation pathways, fibrinolysis, endothelial dysfunction, and extracellular DNA/histones. It does not mention adipose tissue, its metabolic activity, or its role in producing inflammatory mediators affecting stroke recovery, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "DIC is driven by inflammatory cytokine-induced activation of tissue factor-dependent coagulation, impaired anticoagulant pathways, and PAI-1-mediated suppression of fibrinolysis, leading to endothelial dysfunction and microvascular thrombosis; extracellular DNA and histones also play a role. No discussion of adipose tissue or stroke recovery is provided.",
          "pmid": "27250996",
          "title": "Disseminated intravascular coagulation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses glycolipid metabolism disorders, their pathological links (including chronic inflammatory response), and the use of multi-omics to find biomarkers. It does not mention adipose tissue, its metabolic activity, inflammatory mediator production, or any connection to stroke or stroke recovery, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Highlights that glycolipid metabolism disorders involve factors such as neuroendocrine axis dysfunction, insulin resistance, oxidative stress, chronic inflammatory response, and gut microbiota dysbiosis, and reviews how multi-omics approaches can identify biomarkers for these disorders; no reference to adipose tissue or stroke outcomes.",
          "pmid": "36382190",
          "title": "Advances in multi-omics study of biomarkers of glycolipid metabolism disorder.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that HFpEF is a multisystem disorder involving adipose tissue and immune/inflammatory signaling, but it does not describe adipose tissue as a metabolically active source of inflammatory mediators or link adipose-derived inflammation to stroke recovery. It focuses on heart failure mechanisms, not post-stroke recovery pathways.",
          "key_findings": "HFpEF is described as a multisystem disorder involving adipose tissue and immune and inflammatory signalling; however, no details are given about inflammatory mediators produced by adipose tissue, nor any connection to stroke or stroke recovery outcomes.",
          "pmid": "33432192",
          "title": "Cellular and molecular pathobiology of heart failure with preserved ejection fraction.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that adipose tissue dysfunction\u2014including inflammatory processes and release of pro\u2011inflammatory, diabetogenic and atherogenic signals\u2014serves as a mechanistic link between obesity and adverse health outcomes, including stroke. It also notes that altered signals from adipose tissue can directly affect the brain, liver, vasculature and other organs, aligning with the proposed mechanism that metabolically active adipose tissue produces inflammatory mediators impacting stroke-related outcomes.",
          "key_findings": "1) Dysfunction of adipose tissue, rather than excess fat mass alone, may be the mechanistic link between obesity and adverse health outcomes. 2) Mechanisms of impaired adipose tissue function include inflammatory processes and release of pro-inflammatory, diabetogenic and atherogenic signals. 3) People at high risk for obesity-related complications show higher central fat deposition, more immune cells in adipose tissue, and altered signals released from adipose tissue that can directly affect the brain and vasculature. 4) Obesity is epidemiologically linked to increased risk of stroke among other cardiometabolic diseases.",
          "pmid": "40069923",
          "title": "An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates associations between diabetes/fasting blood glucose and risk of vascular events (including stroke), but it does not assess adipose tissue activity, inflammatory mediators from adipose tissue, or stroke recovery outcomes. It focuses on incident vascular risk, not post-stroke recovery mechanisms or adipose-driven inflammation.",
          "key_findings": "Diabetes approximately doubles risk of coronary heart disease and increases risk of ischemic, hemorrhagic, and unclassified stroke; these associations are largely independent of conventional risk factors and are not materially altered by adjusting for lipid, inflammatory, or renal markers. Fasting blood glucose is non-linearly associated with vascular risk but adds little predictive value beyond conventional factors.",
          "pmid": "20609967",
          "title": "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on sleep apnea pathophysiology, intermittent hypoxemia, and their cardiovascular, metabolic, and neurocognitive sequelae. While it mentions inflammatory effects on resistance vessels and impacts on insulin sensitivity and glucose regulation, it does not discuss adipose tissue as a metabolically active source of inflammatory mediators or link adipose-derived inflammation to stroke recovery. Therefore, it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Severe obstructive sleep apnea is associated with daytime systemic hypertension, potentially mediated by enhanced chemoreceptor sensitivity, increased sympathetic activity, overproduction of superoxide ion, and inflammatory effects on resistance vessels. OSA-related intermittent hypoxemia and sleep disruption negatively impact insulin sensitivity and glucose regulation. Neurocognitive impairments arise from hypoxia-induced neural injury. Adipose tissue and stroke recovery mechanisms are not addressed.",
          "pmid": "20086074",
          "title": "Pathophysiology of sleep apnea.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses mechanisms of salt-dependent hypertension, salt sensitivity, obesity, and cardiovascular risk, but does not address adipose tissue as a metabolically active organ producing inflammatory mediators, nor any impact of adipose-derived inflammation on stroke recovery. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "High salt intake increases risk of hypertension and related cardiovascular diseases; salt reduction lowers blood pressure. Mechanisms mentioned include volume expansion, renal function changes, RAAS alterations, sympathetic nervous system activation, and possible inflammatory processes, with increased salt sensitivity in obesity and metabolic syndrome. Stroke is referenced only as an outcome of hypertension, not in relation to adipose tissue inflammation or recovery mechanisms.",
          "pmid": "27757935",
          "title": "Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses inflammatory mediators, obesity as a risk factor, and impaired wound healing in venous leg ulcers, but it does not address adipose tissue as a metabolically active source of inflammatory mediators nor any effects on stroke recovery. The proposed mechanism involves adipose-driven inflammation influencing stroke outcomes, which is outside the scope of this paper on venous ulcer pathophysiology and treatment.",
          "key_findings": "The abstract reports that venous leg ulcer pathogenesis and healing involve endothelial injury, leukocyte infiltration, inflammatory cytokines, matrix metalloproteinases, reactive oxygen and nitrogen species, and other biomolecules. It notes that obesity is associated with prolonged healing time of recalcitrant venous leg ulcers. However, it does not examine adipose tissue as an inflammatory organ or its systemic effects on stroke recovery.",
          "pmid": "33374372",
          "title": "Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses neuroinflammatory responses after ischemic stroke, HPA axis activation, altered energy metabolism, and antidepressant (SSRI) anti-inflammatory actions in relation to post-stroke depression. It does not mention adipose tissue, obesity, or adipose-derived inflammatory mediators, nor does it link peripheral adipose inflammation to stroke recovery. Therefore it neither supports nor contradicts the specific mechanism involving metabolically active adipose tissue affecting stroke recovery.",
          "key_findings": "1) Post-stroke depression (PSD) is common and worsens functional outcomes and rehabilitation response after ischemic stroke. 2) Proposed mechanisms for PSD include neuroinflammatory response to acute ischemic stroke, HPA axis stress activation, impaired neurogenesis, and mitochondrial dysfunction. 3) SSRIs may act via anti-inflammatory effects and enhanced neurogenesis, potentially supported by improved mitochondrial energy metabolism. 4) Future treatments may target anti-cytokine modulators for depression, especially in inflammatory states. No role of adipose tissue or adipose-derived inflammatory mediators is described.",
          "pmid": "29128343",
          "title": "Post-stroke depression: Mechanisms and pharmacological treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on serum albumin, its anti-inflammatory and antioxidant properties, and its association with cardiovascular diseases and stroke risk/prognosis. It does not discuss adipose tissue, adipokines, or how inflammatory mediators from adipose tissue might influence stroke recovery. Thus it neither supports nor contradicts the proposed adipose-tissue-based mechanism.",
          "key_findings": "Low serum albumin levels are epidemiologically linked to increased incidence and poorer prognosis of cardiovascular diseases including stroke, independent of BMI and inflammation; serum albumin has anti-inflammatory, antioxidant, anticoagulant, and antiplatelet activities, and hypoalbuminemia may be a modifiable risk factor.",
          "pmid": "29680174",
          "title": "Human serum albumin in cardiovascular diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links obesity and aging to systemic inflammation in cardiometabolic HFpEF but does not identify adipose tissue as the specific source of inflammatory mediators, nor does it address stroke or stroke recovery. Thus it neither directly supports nor contradicts the proposed mechanism about adipose-derived inflammation affecting stroke recovery.",
          "key_findings": "Obesity and aging are said to promote systemic inflammation that is integral to cardiometabolic HFpEF pathophysiology; immune cell accumulation in the heart and altered metabolome contribute to cardiac inflammation and fibrosis; broad anti-inflammatory therapy has not significantly improved outcomes in HFpEF.",
          "pmid": "39357068",
          "title": "Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions obesity as a shared condition linked to both migraine and stroke but does not discuss adipose tissue as a metabolically active organ, nor its production of inflammatory mediators or their impact on stroke recovery. No mechanistic or outcome-related evidence about adipose-derived inflammation and stroke recovery is presented.",
          "key_findings": "Obesity is listed among several conditions (e.g., PFO, atrial fibrillation, dyslipidemia) that are linked to both migraine and stroke, but the abstract does not explore mechanisms involving adipose tissue inflammation or its influence on post-stroke recovery.",
          "pmid": "39979846",
          "title": "Migraine and stroke: correlation, coexistence, dependence - a modern perspective.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on berberine\u2019s effects on metabolic syndrome (anti-obesity, anti-inflammatory, lipid-lowering, neuroprotective, anticancer) but does not discuss adipose tissue as an active endocrine/inflammatory organ affecting stroke recovery, nor any outcomes related to stroke or post-stroke recovery.",
          "key_findings": "Berberine reduces insulin resistance, inhibits adipogenesis, has anti-inflammatory effects via COX-2 and PGE2 inhibition, improves metabolic parameters in schizophrenic patients, and shows anti-atherosclerotic, neuroprotective, and anticancer properties. Stroke or stroke recovery and adipose-derived inflammatory mediators in that context are not addressed.",
          "pmid": "35209140",
          "title": "Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that adipose tissue is metabolically active and produces inflammatory mediators that affect vascular/endothelial function in obesity, but it does not address stroke, brain injury, or stroke recovery outcomes. Thus it is consistent with but does not provide direct evidence for adipose-driven inflammatory effects on stroke recovery.",
          "key_findings": "Obesity is associated with low-grade chronic inflammation originating in adipose tissue; dysregulated adipocyte-derived endocrine and paracrine factors, altered adipo-cytokine profiles in perivascular adipose tissue, increased oxidative stress, and pro-inflammatory cytokines contribute to endothelial dysfunction and cardiovascular risk. Various therapies (e.g., liraglutide, RAAS-targeted drugs, SGLT2 inhibitors) modulate these adipose-related inflammatory and vascular mechanisms. No stroke- or recovery-specific data are presented.",
          "pmid": "39287863",
          "title": "Endothelial Dysfunction in Obesity and Therapeutic Targets.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links body mass index, lipid metabolism, and inflammatory/immune pathways to ALS risk and survival via DNA methylation, but it does not examine adipose tissue itself, its inflammatory mediator production, or any effect on stroke recovery. The disease context is ALS, not stroke, and no mechanistic pathway from adipose-derived inflammation to recovery from stroke is addressed.",
          "key_findings": "Blood-based DNA methylation changes in ALS patients were enriched in metabolic, cholesterol biosynthesis, and immune pathways; methylation-derived proxies for HDL cholesterol, BMI, white blood cell proportions, and alcohol intake were associated with ALS; cholesterol biosynthesis may be causally related to ALS; certain methylation markers and inferred blood cell proportions associated with ALS survival.",
          "pmid": "35196023",
          "title": "Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a methodological guideline on assays for monitoring autophagy and does not address adipose tissue, inflammatory mediators, stroke, or stroke recovery. Therefore it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Provides guidance on the use and interpretation of assays to monitor autophagy; no mention of adipose tissue, inflammation, or stroke-related outcomes.",
          "pmid": "26799652",
          "title": "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "sbprand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Elevated systolic pressure increases the risk of intracranial hemorrhage and reduces effective cerebral perfusion during treatment.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (\"systolic blood pressure\" OR \"blood pressure\" OR \"hypertension\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"intracranial\" OR \"hemorrhage\" OR \"treatment\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 1,
      "neutral_count": 18,
      "support_percentage": 5.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract only notes that infarct size and neurological severity depend in part on systemic blood pressure, without specifying whether elevated systolic pressure increases intracranial hemorrhage risk or reduces effective cerebral perfusion during treatment. It does not describe BP levels, directions of effect, or treatment-related hemodynamics, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Infarct size and neurological severity after ischemic stroke depend on multiple factors including time since occurrence, severity of ischemia, systemic blood pressure, venous systems, and infarct location, but no detailed relationship between elevated systolic pressure, hemorrhage risk, or cerebral perfusion during treatment is provided.",
          "pmid": "34878154",
          "title": "Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions blood pressure lowering as part of bundled care for intracerebral haemorrhage but does not discuss how elevated systolic pressure mechanistically increases hemorrhage risk or reduces cerebral perfusion during treatment, nor does it detail the physiological consequences of different systolic pressure levels.",
          "key_findings": "For intracerebral haemorrhage, the abstract states that prompt bundled care including immediate anticoagulation reversal, simultaneous blood pressure lowering, and stroke unit protocols can improve outcomes; no specific data or mechanistic explanation about elevated systolic pressure, hemorrhage risk, or effective cerebral perfusion is provided.",
          "pmid": "38759664",
          "title": "Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ischemic stroke management, reperfusion therapies, and secondary prevention including general blood pressure control, but does not address how elevated systolic pressure specifically affects risk of intracranial hemorrhage or cerebral perfusion during treatment.",
          "key_findings": "Focus on thrombolysis and thrombectomy time windows, use of perfusion imaging, and general mention of blood pressure control as part of secondary prevention. No data or claims about elevated systolic pressure altering intracranial hemorrhage risk or effective cerebral perfusion during treatment.",
          "pmid": "31601801",
          "title": "Ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses guidelines for treating cerebral edema and intracranial pressure using hyperosmolar agents, corticosteroids, and non-pharmacologic therapies. It does not address the role of elevated systolic blood pressure, its impact on risk of intracranial hemorrhage, or its effect on cerebral perfusion during treatment. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The guideline concludes that hyperosmolar therapy may reduce ICP elevations or cerebral edema in various neurologic conditions, that corticosteroids help in bacterial meningitis but not intracerebral hemorrhage, and that differences in efficacy and safety exist between hypertonic saline and mannitol. No data are presented on systemic blood pressure, systolic pressure levels, risk of intracranial hemorrhage related to blood pressure, or changes in cerebral perfusion associated with blood pressure during treatment.",
          "pmid": "32227294",
          "title": "Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions 'aggressive management of blood pressure' as part of treatment for intracerebral hemorrhage but does not specify systolic pressure levels, how elevated systolic pressure changes risk of hemorrhage, or its impact on effective cerebral perfusion during treatment. No mechanistic data or outcome comparisons based on systolic pressure levels are provided.",
          "key_findings": "The abstract states that treatment approaches for intracerebral hemorrhage include aggressive management of blood pressure and that such coordinated, specialty care can improve outcomes, but it does not detail the relationship between elevated systolic pressure and intracranial hemorrhage risk or cerebral perfusion.",
          "pmid": "19427958",
          "title": "Intracerebral haemorrhage.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract compares ischemic stroke patients and stroke mimics, noting that mimics have lower (nearly normal) blood pressure and a much lower rate of intracranial hemorrhage after thrombolysis. However, it does not analyze systolic pressure as a causal determinant of hemorrhage risk or cerebral perfusion during treatment, nor does it examine how varying levels of elevated systolic pressure affect these outcomes. The observed association (higher hemorrhage rate in true strokes, who also tend to have higher BP and more risk factors) is confounded by underlying disease severity and stroke status, so it cannot be taken as direct mechanistic evidence for or against the proposed pathway.",
          "key_findings": "1) Stroke mimics have lower (nearly normal) blood pressure compared with ischemic stroke patients.\n2) Overall intracranial hemorrhage was 9.4% in ischemic stroke vs. 0.7% in stroke mimics.\n3) Stroke patients had worse outcomes and higher mortality than mimics.\n4) The study does not directly examine the mechanistic effect of elevated systolic pressure on intracranial hemorrhage risk or cerebral perfusion during treatment.",
          "pmid": "34656244",
          "title": "Ischemic stroke mimics: A comprehensive review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension as a modifiable risk factor for cerebral hemorrhage and emphasizes its treatment in prevention, but it does not address how elevated systolic pressure specifically alters intracranial hemorrhage risk during treatment or its effect on effective cerebral perfusion. No mechanistic or treatment-phase hemodynamic details are provided.",
          "key_findings": "Hypertension is identified as an important risk factor for ischemic stroke and cerebral hemorrhage, and treatment of hypertension is highlighted as a key strategy for both primary and secondary prevention of cerebral hemorrhage.",
          "pmid": "32299593",
          "title": "Primary and Secondary Prevention of\u00a0Ischemic Stroke and Cerebral\u00a0Hemorrhage: JACC Focus Seminar.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports overall stroke epidemiology, risk factor prevalence (including hypertension), treatment modalities, and rates of intracranial hemorrhage during thrombolysis and thrombectomy, but it does not analyze the relationship between elevated systolic pressure and intracranial hemorrhage risk or cerebral perfusion during treatment. No blood pressure levels, stratified analyses, or mechanistic data on hemodynamics are presented.",
          "key_findings": "The report notes: (1) high prevalence and poor control of hypertension in China; (2) distribution of stroke subtypes (including 14.9% ICH); (3) incidence of intracranial hemorrhage during IVT (3.2%), MT (7.7%), and bridging therapy (12.9%); and (4) mortality, disability, and recurrence rates after stroke. None of these findings link systolic blood pressure levels to intracranial hemorrhage occurrence or to changes in cerebral perfusion during treatment.",
          "pmid": "37468952",
          "title": "China stroke surveillance report 2021.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares higher versus lower systolic blood pressure treatment targets in older adults and reports clinical outcomes (stroke, serious cardiovascular events, mortality, withdrawals). It does not examine intracranial hemorrhage specifically, nor does it analyze cerebral perfusion or how elevated systolic pressure during treatment might increase hemorrhage risk or reduce effective cerebral perfusion. The findings that lower BP targets reduce stroke and serious cardiovascular events are outcome-based and not mechanistic with respect to intracranial hemorrhage or perfusion dynamics.",
          "key_findings": "In older adults (\u226565 years), treatment to lower BP targets (\u2264140/90 mmHg or 110\u2013130 mmHg systolic) versus higher targets (150\u2013160/95\u2013105 mmHg): (1) results in little to no difference in all-cause mortality (RR 1.14, 95% CI 0.95\u20131.37; low-certainty); (2) reduces stroke (RR 1.33 favoring lower target, 95% CI 1.06\u20131.67; high-certainty); (3) likely reduces total serious cardiovascular adverse events (RR 1.25 favoring lower target, 95% CI 1.09\u20131.45; moderate-certainty); and (4) likely does not increase withdrawals due to adverse effects (RR 0.99, 95% CI 0.74\u20131.33; moderate-certainty). Intracranial hemorrhage and cerebral perfusion are not specifically measured or discussed.",
          "pmid": "39688187",
          "title": "Higher blood pressure targets for hypertension in older adults.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The trial shows that in patients with hemorrhagic stroke, early reduction of elevated systolic blood pressure improves functional outcome, consistent with elevated systolic pressure increasing risk/severity of intracranial hemorrhage; conversely, in ischemic stroke, early BP lowering worsens outcome, consistent with elevated systolic pressure helping to maintain effective cerebral perfusion. Thus, the study provides direct, differential evidence that high systolic BP is harmful in hemorrhage and protective for perfusion in ischemia, aligning with both components of the proposed mechanism.",
          "key_findings": "Among 2404 suspected acute stroke patients randomized in the ambulance with systolic BP \u2265150 mm Hg, early BP lowering to a target of 130\u2013140 mm Hg versus usual care produced: (1) No overall difference in functional outcome at 90 days in the entire undifferentiated cohort. (2) In the hemorrhagic stroke subgroup, prehospital BP reduction decreased odds of poor functional outcome (common OR 0.75; 95% CI, 0.60\u20130.92), implying that persistently higher systolic pressure is detrimental in intracranial hemorrhage. (3) In the cerebral ischemia subgroup, the same BP reduction increased odds of poor functional outcome (common OR 1.30; 95% CI, 1.06\u20131.60), implying that elevated systolic pressure supports cerebral perfusion in ischemic stroke and that lowering it reduces effective perfusion.",
          "pmid": "38752650",
          "title": "Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses secondary stroke prevention and vascular risk factor control, including hypertension in general terms, but it does not address how elevated systolic pressure specifically affects intracranial hemorrhage risk or cerebral perfusion during treatment.",
          "key_findings": "Mentions control of vascular risk factors such as hypertension as a goal in stroke reduction; discusses various stroke mechanisms and corresponding preventive strategies, but provides no data or statements on systolic pressure effects on intracranial hemorrhage or cerebral perfusion in the treatment context.",
          "pmid": "26300647",
          "title": "Secondary stroke prevention: challenges and solutions.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The mechanism proposes that elevated systolic pressure increases intracranial hemorrhage risk and reduces effective cerebral perfusion during treatment. In this trial, the higher systolic BP target group (140\u2013180 mm Hg) did not have increased symptomatic intracerebral hemorrhage compared with the lower target group (<140 mm Hg), and in fact had better functional outcomes. This directly contradicts the idea that higher systolic BP in this post-EVT setting worsens outcomes via increased hemorrhage or reduced effective perfusion.",
          "key_findings": "Among post-EVT patients, intensive BP lowering (SBP <140 mm Hg) vs conventional BP (SBP 140\u2013180 mm Hg) for 24 hours resulted in: (1) lower functional independence at 3 months in the intensive group (39.4% vs 54.4%; adjusted OR 0.56, P = .03); (2) similar rates of symptomatic intracerebral hemorrhage (9.0% vs 8.1%; adjusted OR 1.10, P = .82); and (3) no statistically significant difference in stroke-related death at 3 months (7.7% vs 5.4%). Thus, higher allowed systolic pressures were not associated with greater hemorrhage risk and were associated with better functional outcome.",
          "pmid": "37668619",
          "title": "Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses uncertainty about whether lowering high blood pressure after ischemic stroke improves outcome or worsens cerebral perfusion, and notes that large BP-lowering trials have not changed outcomes. It does not provide direct evidence that elevated systolic pressure specifically increases intracranial hemorrhage risk or reduces effective cerebral perfusion during treatment; these mechanisms are mentioned only as theoretical concerns (e.g., aberrant autoregulation, collateral effects on cerebral perfusion and platelets) without supporting or refuting data.",
          "key_findings": "High BP after ischemic stroke is associated with poor functional outcome and increased mortality; large BP-lowering trials have failed to change outcome; there is concern that BP lowering might worsen cerebral perfusion due to aberrant autoregulation; management may need to be individualized (lower, maintain, or raise BP) in different clinical scenarios such as thrombolysis and thrombectomy.",
          "pmid": "35291822",
          "title": "Blood Pressure Management for Ischemic Stroke in the First 24 Hours.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports changes in pulmonary artery systolic pressure and intracranial hemorrhage incidence during catheter-directed fibrinolysis for pulmonary embolism, but it does not analyze how elevated systemic (systolic) blood pressure affects risk of intracranial hemorrhage or cerebral perfusion. No data are presented on systemic blood pressure levels, cerebral perfusion, or their relationship to intracranial bleeding, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In patients with massive or submassive pulmonary embolism treated with ultrasound-facilitated, catheter-directed low-dose tPA, pulmonary artery systolic pressure decreased significantly (51.4 to 36.9 mm Hg), RV/LV ratio improved, and there were no intracranial hemorrhages; bleeding events were limited to one severe groin hematoma with transient hypotension and several moderate bleeds. Systemic systolic blood pressure and cerebral outcomes beyond intracranial hemorrhage incidence were not evaluated in relation to blood pressure.",
          "pmid": "26315743",
          "title": "A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links hypertension, arterial stiffness, and blood pressure variability with increased risk of ischemic and hemorrhagic stroke, but it does not specifically address elevated systolic pressure during treatment, its acute impact on intracranial hemorrhage risk, or its effect on effective cerebral perfusion under therapeutic conditions. It remains general and mechanistic about chronic hypertension and pulsatility rather than the proposed treatment-context mechanism.",
          "key_findings": "Hypertension is associated with over 50% of ischemic and 70% of hemorrhagic strokes; late-life hypertension is characterized by increasing systolic and falling diastolic pressures with increased arterial stiffness and aortic pulsatility; blood pressure variability independently predicts risk of ischemic and intracerebral hemorrhage; cerebral small vessel disease is linked to increased large-vessel pulsatility and reduced CO2 reactivity. No data are provided on how elevated systolic pressure during treatment acutely alters intracranial hemorrhage risk or cerebral perfusion.",
          "pmid": "35255709",
          "title": "New Insights Into Cerebrovascular Pathophysiology and Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions perioperative blood pressure control as part of intraoperative strategies to reduce stroke risk but does not provide data or specific statements about elevated systolic pressure increasing intracranial hemorrhage risk or reducing effective cerebral perfusion during treatment.",
          "key_findings": "The statement reviews perioperative stroke risk factors and discusses blood pressure control as one strategy among others; however, no explicit mechanistic or outcome-based evidence regarding elevated systolic pressure, intracranial hemorrhage, or cerebral perfusion is described in the abstract.",
          "pmid": "33827230",
          "title": "Perioperative Neurological Evaluation and Management to Lower the Risk of Acute Stroke in Patients Undergoing Noncardiac, Nonneurological Surgery: A Scientific Statement From the American Heart Association/American Stroke Association.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract states that hypertension is an important modifiable risk factor for stroke and that reducing blood pressure is essential for stroke prevention, but it does not specifically discuss systolic pressure effects on intracranial hemorrhage risk or on effective cerebral perfusion during treatment. It addresses overall stroke risk and prevention, not the proposed detailed mechanism.",
          "key_findings": "Hypertension is described as the most important modifiable risk factor for stroke; efficacious reduction of blood pressure is emphasized as essential for stroke prevention, with attention to earlier treatment initiation in high-risk groups. No mention is made of intracranial hemorrhage specifically or of cerebral perfusion dynamics during treatment.",
          "pmid": "25573327",
          "title": "Stroke prevention--medical and lifestyle measures.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses intracerebral hemorrhage epidemiology, mechanisms of injury, imaging, and general management, but it does not mention systolic blood pressure levels, their modulation during treatment, intracranial hemorrhage risk related to elevated systolic pressure, or effects on cerebral perfusion. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The review summarizes AHA 2022 guidelines on ICH, including causes (e.g., small vessel disease, hypertension-related arteriopathy), mechanisms of harm (edema, inflammation, blood product toxicity), and imaging sensitivity of CT/MRI, but provides no specific data or statements about elevated systolic pressure influencing ICH risk or cerebral perfusion during treatment.",
          "pmid": "35870549",
          "title": "Essential Topics About the Imaging Diagnosis and Treatment of Hemorrhagic Stroke: A Comprehensive Review of the 2022 AHA Guidelines.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a broad review of neurocritical care in ischemic stroke and mentions blood pressure goals and hemorrhagic conversion in general terms, but it does not present specific data or statements about elevated systolic pressure increasing intracranial hemorrhage risk or reducing effective cerebral perfusion during treatment.",
          "key_findings": "The article reviews ICU management of ischemic stroke, including blood pressure goals by treatment type and management of hemorrhagic conversion, but provides no explicit mechanistic or outcome data linking elevated systolic blood pressure to intracranial hemorrhage risk or cerebral perfusion changes.",
          "pmid": "36333037",
          "title": "Neurocritical Care Aspects of Ischemic Stroke Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates overall efficacy and safety of more intensive blood pressure lowering on major cardiovascular, renal outcomes, and serious adverse events, but it does not report intracranial hemorrhage rates, cerebral perfusion measures, or stroke subtype analysis that would directly address whether elevated systolic pressure increases intracranial hemorrhage risk or reduces effective cerebral perfusion during treatment.",
          "key_findings": "Intensive blood pressure lowering (mean 133/76 vs 140/81 mm Hg) reduced major cardiovascular events and stroke overall, with a small increase in severe hypotension and serious adverse events, but no detailed data on intracranial hemorrhage, cerebral perfusion, or differential stroke subtypes are provided.",
          "pmid": "26559744",
          "title": "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "sbprand",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Aggressive hypertension can destabilize plaques, promoting secondary stroke incidents.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (\"systolic blood pressure\" OR \"blood pressure\" OR \"hypertension\") AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"hypertension\" OR \"destabilize\" OR \"aggressive\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 1,
      "neutral_count": 18,
      "support_percentage": 5.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes hypertension as a modifiable risk factor for stroke and discusses general prevention by treating hypertension, but it does not address the specific mechanistic claim that aggressive blood pressure lowering can destabilize atherosclerotic plaques and thereby promote secondary strokes.",
          "key_findings": "Hypertension is listed as a common, modifiable risk factor for both ischemic and hemorrhagic stroke, and treating hypertension is mentioned as a prevention strategy. No discussion is provided about plaque stability, effects of aggressive blood pressure control, or secondary stroke incidents linked to such destabilization.",
          "pmid": "28154098",
          "title": "Stroke Risk Factors, Genetics, and Prevention.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The proposed mechanism suggests that more aggressive blood pressure lowering in hypertension can destabilize plaques and promote secondary stroke incidents. This review instead finds that lower (more aggressive) blood pressure targets in older adults reduce stroke and serious cardiovascular events, with no clear increase in adverse effects, which contradicts the idea that aggressive hypertension management promotes stroke via plaque destabilization.",
          "key_findings": "In hypertensive adults \u226565 years, lower BP targets (<140/90 mmHg or 110\u2013130 mmHg systolic) compared to higher targets (<150\u2013160/95\u2013105 mmHg) over 2\u20134 years: (1) reduce stroke (RR 1.33, 95% CI 1.06\u20131.67; high-certainty evidence, in favor of lower targets), (2) likely reduce total serious cardiovascular adverse events (RR 1.25, 95% CI 1.09\u20131.45; moderate-certainty), (3) show little to no difference in all-cause mortality (RR 1.14, 95% CI 0.95\u20131.37; low-certainty), and (4) likely do not increase withdrawals due to adverse effects (RR 0.99, 95% CI 0.74\u20131.33; moderate-certainty). No signal is reported that more aggressive BP lowering increases stroke risk.",
          "pmid": "39688187",
          "title": "Higher blood pressure targets for hypertension in older adults.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes hypertension as the most important vascular risk factor for CNS small vessel disease and stroke but does not discuss aggressive hypertension, plaque destabilization, or secondary stroke incidents via plaque rupture. It focuses on small vessel pathology and risk-factor control in general, not on the specific mechanism of hypertension-mediated plaque destabilization.",
          "key_findings": "Hypertension is identified as a key risk factor for CNS small vessel disease and stroke, and intensive control of vascular risk factors (especially hypertension) is recommended. No mention is made of plaque instability, aggressive blood pressure levels, or a mechanistic link between hypertension and plaque destabilization causing secondary strokes.",
          "pmid": "31142635",
          "title": "CNS small vessel disease: A clinical review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses blood pressure management after ischemic stroke, including whether and how to lower high blood pressure, but it does not specifically address plaque destabilization or link aggressive hypertension to plaque rupture and secondary strokes. It focuses on functional outcomes, mortality, cerebral perfusion, and treatment timing, not on plaque stability as a mechanistic pathway.",
          "key_findings": "High blood pressure after ischemic stroke is associated with poor functional outcome and increased mortality; large trials of blood pressure lowering in the acute phase have not clearly changed outcomes; optimal management likely varies by patient subgroup, cause, timing, and treatment context. No mention is made of plaque destabilization or hypertension-induced secondary stroke via plaque rupture.",
          "pmid": "35291822",
          "title": "Blood Pressure Management for Ischemic Stroke in the First 24 Hours.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract states that hypertension promotes stroke via shear stress, endothelial dysfunction, large artery stiffness, small-vessel disease, hypoperfusion, and BBB permeability, but it does not mention plaque destabilization, plaque rupture, or secondary stroke incidents specifically attributable to aggressive hypertension. Thus it does not directly support or refute the proposed mechanism.",
          "key_findings": "Hypertension is described as the most important modifiable risk factor for stroke and promotes stroke through increased shear stress, endothelial dysfunction, and large artery stiffness that transmits pulsatile flow to the cerebral microcirculation. It also promotes cerebral small vessel disease via hypoperfusion, diminished autoregulatory capacity, and increased blood-brain barrier permeability. These mechanisms alter the pathophysiology of ischemic stroke and response to acute ischemia, but plaque destabilization is not discussed.",
          "pmid": "30198826",
          "title": "The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses magnesium\u2019s role in blood pressure regulation and associations between low magnesium and hypertension, stroke, and cardiovascular disease, but it does not address the specific mechanistic claim that aggressive hypertension destabilizes plaques to promote secondary strokes. No data on plaque stability, plaque rupture, or secondary stroke incidents in the context of aggressive hypertension are presented.",
          "key_findings": "Magnesium is involved in vasomotor tone and blood pressure regulation; low magnesium levels are associated with hypertension, cardiovascular disease, and cerebrovascular accident (stroke). The review emphasizes magnesium\u2019s role in disease prevention and overall health but provides no mechanistic information on hypertension-induced plaque destabilization or secondary strokes.",
          "pmid": "23674807",
          "title": "Magnesium in disease prevention and overall health.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links hypertension, arterial stiffness, and blood pressure variability to increased risk of ischemic and hemorrhagic stroke, but it does not discuss plaque biology, plaque destabilization, or secondary stroke incidents mediated by plaque rupture. Therefore it neither supports nor contradicts the specific mechanism that aggressive hypertension destabilizes plaques.",
          "key_findings": "Hypertension is associated with over 50% of ischemic and 70% of hemorrhagic strokes; blood pressure variability independently predicts risk of ischemic and intracerebral hemorrhage; increased arterial stiffness and aortic/cerebral pulsatility and impaired cerebrovascular reactivity are implicated in cerebrovascular disease. No mention is made of plaque destabilization or mechanisms of recurrent stroke via plaque rupture.",
          "pmid": "35255709",
          "title": "New Insights Into Cerebrovascular Pathophysiology and Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cardiovascular complications and hypertension management after acute ischemic stroke, but it does not address whether aggressive hypertension itself destabilizes atherosclerotic plaques or promotes secondary stroke incidents via plaque destabilization. The focus is on brain\u2013heart axis dysregulation, hemodynamic instability, and recommended blood pressure control agents, not on a mechanistic link between high blood pressure and plaque destabilization.",
          "key_findings": "1) Acute ischemic stroke patients are vulnerable to severe cardiac complications due to brain\u2013heart axis dysregulation involving sympathetic hyperactivity, HPA axis, immune/inflammatory responses, and gut dysbiosis. 2) Major causes of mortality after AIS include heart attack, heart failure, hemodynamic instability, arrhythmias, and cardiac arrest. 3) Labetalol, nicardipine, and nitroprusside are recommended for control of hypertension during AIS; beta blockers are suggested for preventing chronic remodeling and treating arrhythmias. 4) The review aims to describe pathophysiological mechanisms of brain\u2013heart interaction and provide cardiovascular management recommendations, but it does not discuss plaque destabilization or secondary stroke via aggressive hypertension.",
          "pmid": "32317013",
          "title": "Brain-heart interaction after acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions hypertension as a risk factor that can interact with migraine to increase stroke risk but does not discuss aggressive blood pressure levels, plaque stability, or mechanisms of plaque destabilization leading to secondary strokes. Therefore it neither supports nor contradicts the specific mechanistic claim about aggressive hypertension destabilizing plaques.",
          "key_findings": "The abstract states that migraine, particularly with aura, is an independent risk factor for stroke and that this risk is higher when combined with other factors such as smoking or hypertension. It discusses shared processes between migraine and stroke (cortical spreading depression, endothelial dysfunction, vasculopathy, genetic factors, PFO, atrial fibrillation, etc.), but does not address plaque destabilization or the specific effects of aggressive hypertension on plaque stability or secondary stroke incidents.",
          "pmid": "39979846",
          "title": "Migraine and stroke: correlation, coexistence, dependence - a modern perspective.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses early aggressive bundled care in intracerebral hemorrhage, including blood pressure control, as beneficial for limiting hematoma expansion and improving outcomes. It does not address whether aggressive hypertension itself destabilizes atherosclerotic plaques or promotes secondary (recurrent) stroke incidents, nor does it discuss plaque biology or stroke recurrence mechanisms.",
          "key_findings": "Early, aggressive, bundled care for intracerebral hemorrhage (including time-based blood pressure control and anticoagulation reversal) is associated with better outcomes and reduced hematoma expansion; lack of early aggressive care is associated with worse outcomes. No mention is made of plaque destabilization or secondary stroke mechanisms due to aggressive hypertension.",
          "pmid": "38099439",
          "title": "Code ICH: A Call to Action.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension as a cellular stressor that promotes endothelial cell senescence, blood-brain barrier dysfunction, microvascular dysfunction, and worsened stroke outcomes, but it does not address plaque destabilization or secondary stroke incidents. It focuses on microvascular/BBB mechanisms rather than atherosclerotic plaque stability, so it neither supports nor contradicts the specific mechanism that aggressive hypertension destabilizes plaques to promote secondary strokes.",
          "key_findings": "Senescent endothelial cells, which can be induced by hypertension and diabetes, accumulate with age and alter tight junctions, increase transcytosis, and disrupt the extracellular matrix, leading to increased blood-brain barrier permeability. These changes can impair angiogenesis and vascular remodeling, potentially increasing the risk of hemorrhagic transformation and worsening outcomes in ischemic stroke, and contribute to microvascular dysfunction and vascular cognitive impairment. The abstract does not discuss plaque stability, atherosclerosis, or secondary stroke events due to plaque destabilization.",
          "pmid": "39541552",
          "title": "Endothelial Cell Senescence Effect on the Blood-Brain Barrier in Stroke and Cognitive Impairment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates whether adding folic acid to enalapril reduces first stroke in hypertensive adults. It does not analyze the effects of aggressive versus less aggressive blood pressure control, plaque stability, or secondary stroke events. The mechanism about aggressive hypertension destabilizing plaques and promoting secondary strokes is not addressed.",
          "key_findings": "In hypertensive Chinese adults without prior stroke or MI, enalapril plus folic acid reduced risk of first stroke (HR 0.79), first ischemic stroke (HR 0.76), and composite cardiovascular events (HR 0.80) compared with enalapril alone, with no significant differences in hemorrhagic stroke, MI, or all-cause mortality.",
          "pmid": "25771069",
          "title": "Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses prevalence of hypertension as a risk factor and differences in stroke etiology and outcomes across regions and ethnic groups, but it does not examine whether aggressive hypertension destabilizes atherosclerotic plaques or leads to secondary stroke incidents. No blood pressure intensity, plaque stability, or recurrent/secondary stroke mechanisms are evaluated.",
          "key_findings": "Hypertension is common among young ischemic stroke patients, particularly in Black and Asian groups; large vessel atherosclerosis and small vessel disease are more frequent causes of stroke in high\u2011income countries; patients in low\u2011 and middle\u2011income countries are younger, have fewer vascular risk factors, yet higher 3\u2011month mortality. None of these findings address plaque destabilization by aggressive hypertension or secondary stroke mechanisms.",
          "pmid": "34906974",
          "title": "Global Differences in Risk Factors, Etiology, and Outcome of Ischemic Stroke in Young Adults-A Worldwide Meta-analysis: The GOAL Initiative.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions hypertension only as a vascular risk factor to be identified and modified in migraine patients but does not discuss aggressive hypertension, plaque stability, or secondary stroke incidents, nor any mechanistic link between blood pressure levels and plaque destabilization.",
          "key_findings": "Migraine, particularly with aura, is associated with ischaemic and haemorrhagic stroke; potential mechanisms discussed include cortical spreading depression, vascular/inflammatory/endothelial factors, PFO, hormones, smoking, vasoconstrictor medications, and rare genetic diseases. The abstract recommends identifying and modifying vascular risk factors such as hypertension but does not examine how aggressive hypertension might destabilize plaques or influence secondary strokes.",
          "pmid": "28989805",
          "title": "Migraine and stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links hypertension to coagulation abnormalities and thromboembolic complications but does not address plaque destabilization, atherosclerotic plaque biology, or secondary stroke events. It focuses on coagulation markers and vascular remodeling in hypertension, not on whether aggressive hypertension destabilizes plaques to promote secondary strokes.",
          "key_findings": "Hypertensive individuals have elevated D-dimer and fibrinogen levels, which increase with hypertension severity and duration; increased blood pressure is associated with changes in prothrombin time and aPTT; P-selectin, suPAR, thrombomodulin, tissue factor, vWF, and other markers are implicated in hypertension-related coagulation, inflammation, and vascular remodeling. Thromboembolic complications in hypertension are mentioned generally, without specific evidence for plaque destabilization or secondary stroke mechanisms.",
          "pmid": "37561240",
          "title": "Irregularities of Coagulation in Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links lacunar stroke and small deep infarctions to arterial hypertension and atherosclerosis and notes that these lesions predict future hemorrhagic and ischemic stroke, but it does not address whether aggressive blood pressure levels or blood pressure\u2013lowering strategies destabilize plaques or promote secondary strokes. No mechanism of plaque destabilization by aggressive hypertension or its temporal relationship to recurrent stroke is described.",
          "key_findings": "Lacunar stroke is most often associated with cerebral microangiopathy due to arterial hypertension and tandem atherosclerosis; small deep infarctions and diffuse white matter pathology contribute to cognitive impairment and vascular dementia; asymptomatic small deep infarctions are predictors of severe hemorrhagic and ischemic stroke in patients with hypertension and atherosclerosis.",
          "pmid": "31825358",
          "title": "[Lacunar stroke].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links hypertension and blood pressure patterns with increased risk of TIA and subsequent stroke, but it does not address the specific mechanistic claim that aggressive hypertension destabilizes atherosclerotic plaques, nor does it discuss plaque stability or secondary stroke via plaque rupture.",
          "key_findings": "Hypertension is described as the most important modifiable risk factor for stroke and TIA; there is a strong relationship between hypertension and incidence of TIA and short-term stroke risk; diurnal blood pressure patterns may influence subsequent stroke risk; blood pressure remains poorly controlled after TIA and chronotherapy may improve control. No mention is made of plaque destabilization or a mechanistic pathway involving plaque rupture.",
          "pmid": "19659823",
          "title": "Hypertension and TIA.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension as a risk factor for several cardiovascular and cerebrovascular conditions and focuses on the role of biomarkers for diagnosis and prognosis. It does not address the specific mechanistic claim that aggressive hypertension destabilizes atherosclerotic plaques to promote secondary stroke incidents, nor does it discuss plaque stability or stroke recurrence mechanisms.",
          "key_findings": "Systemic arterial hypertension is described as a major risk factor for secondary diseases such as ischemic stroke, intracerebral hemorrhage, transient ischemic attack, acute myocardial infarction, angina pectoris, and chronic kidney disease. The review centers on the potential use of biomarkers in hypertension and related disorders for diagnosis, prognosis, risk assessment, and therapy management, without mechanistic discussion of plaque destabilization or secondary stroke events.",
          "pmid": "36154587",
          "title": "Biomarkers in Hypertension and Hypertension-related Disorders.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links hypertensive disorders of pregnancy with increased maternal stroke risk but does not discuss aggressive blood pressure levels, plaque stability, or plaque-mediated mechanisms of secondary stroke. It focuses on epidemiologic risk and pregnancy-related physiology rather than on hypertension-induced plaque destabilization.",
          "key_findings": "Hypertensive disorders of pregnancy (gestational hypertension, preeclampsia) are identified as major risk factors for maternal stroke and adverse pregnancy outcomes. The immediate postpartum period is described as the highest-risk time for maternal stroke. However, no mention is made of atherosclerotic plaque, plaque destabilization, or secondary stroke mechanisms related to aggressive hypertension.",
          "pmid": "35133313",
          "title": "Maternal Stroke Associated With Pregnancy.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly states that in highly anxious patients, alpha-adrenergic vasoconstriction causes hypertension that favors plaque rupture. This directly links elevated blood pressure (hypertension) to plaque rupture, which is a key component of the proposed mechanism that aggressive hypertension can destabilize plaques and promote secondary vascular events such as stroke. While stroke is not specifically mentioned, the mechanistic link between hypertension and plaque destabilization/rupture is clearly supported.",
          "key_findings": "The abstract notes that in highly anxious patients, alpha-adrenergic vasoconstriction 'also causes hypertension, favoring plaque rupture.' It further discusses how anxiety-related hemostatic and vascular changes contribute to cardiovascular and thrombotic diseases, indicating that hypertension induced by anxiety-related vasoconstriction promotes plaque rupture.",
          "pmid": "29723894",
          "title": "Anxiety-Related Bleeding and Thrombosis.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "sbprand",
      "mechanism": {
        "mechanism_type": "statistical",
        "description": "Reflects underlying cardiovascular comorbidities impacting stroke outcomes.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (\"systolic blood pressure\" OR \"blood pressure\" OR \"hypertension\") AND (\"independent predictor\" OR \"confounding\" OR \"interaction effect\") AND (\"cardiovascular\" OR \"comorbidities\" OR \"underlying\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiological associations between alcohol consumption and various cardiovascular diseases and methodological issues, but it does not analyze stroke outcomes in relation to pre\u2011existing cardiovascular comorbidities or describe statistical adjustment showing that underlying cardiovascular disease explains stroke outcomes. Therefore it neither supports nor contradicts the proposed mechanism about underlying cardiovascular comorbidities impacting stroke outcomes.",
          "key_findings": "Alcohol has complex, often non-linear associations with multiple cardiovascular diseases including stroke; methodological issues such as confounding and exposure classification are highlighted; large longitudinal studies with extensive assessment of genetic and confounding variables are needed. No direct data or analysis is provided on how underlying cardiovascular comorbidities statistically account for stroke outcomes.",
          "pmid": "34684419",
          "title": "Alcohol's Impact on the Cardiovascular System.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns cardiovascular comorbidities affecting stroke outcomes, whereas the abstract evaluates how blood pressure variability predicts incident cardiovascular events and mortality, including stroke. It does not analyze stroke prognosis, outcomes after stroke, or the mediating role of existing cardiovascular comorbidities on stroke outcomes, so it neither supports nor contradicts the specific mechanistic claim.",
          "key_findings": "Increased long-term variability in systolic blood pressure is associated with higher risk of all-cause mortality (HR 1.15), cardiovascular mortality (HR 1.18), cardiovascular events (HR 1.18), coronary heart disease (HR 1.10), and stroke (HR 1.15). Mid- and short-term daytime systolic blood pressure variability are also associated with all-cause mortality. These associations are independent of mean blood pressure.",
          "pmid": "27511067",
          "title": "Blood pressure variability and cardiovascular disease: systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that peri- and postmenopausal women with PCOS have higher prevalence of stroke and various cardiometabolic comorbidities, and that many cardiometabolic outcomes are driven by weight excess. However, it does not specifically analyze stroke outcomes in relation to underlying cardiovascular comorbidities as mediators, nor does it statistically dissect whether these comorbidities account for stroke outcome differences. Thus it does not directly test or quantify the proposed statistical mechanism.",
          "key_findings": "Women with PCOS \u226545 years showed increased odds of stroke (OR 1.75), myocardial infarction, hypertension, diabetes, and adverse metabolic markers compared with controls; many cardiometabolic comorbidities were attributed to coexisting weight excess. The study does not specifically evaluate how underlying cardiovascular comorbidities impact stroke outcomes or the extent to which they explain stroke risk differences.",
          "pmid": "37353908",
          "title": "PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how different levels of alcohol consumption relate to various cardiovascular disease outcomes, but it does not analyze stroke outcomes as a function of underlying cardiovascular comorbidities or use comorbidities statistically to explain stroke prognosis. It addresses alcohol\u2013CVD risk associations, not the proposed statistical mechanism in which underlying cardiovascular comorbidities drive stroke outcomes.",
          "key_findings": "Low alcohol intake (1\u20132 drinks/day) is associated with no risk to possible risk reduction for coronary artery disease, stroke, sudden death, and possibly heart failure; effects on atrial fibrillation at this level are unknown. Heavy drinking (\u22653 drinks/day or binge drinking) is consistently associated with worse outcomes across studied cardiovascular diseases. Most evidence is observational and prone to confounding, and more randomized trials are needed.",
          "pmid": "40485439",
          "title": "Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews pathophysiological mechanisms of HFpEF (e.g., diastolic dysfunction, vascular function, autonomic tone) and their relation to risk factors like aging, obesity, and hypertension, but it does not analyze stroke outcomes, statistical adjustment, or explicitly frame cardiovascular comorbidities as confounders or mediators of stroke prognosis. Thus it neither supports nor contradicts the proposed statistical mechanism about cardiovascular comorbidities impacting stroke outcomes.",
          "key_findings": "HFpEF accounts for about half of heart failure cases; it is pathophysiologically heterogeneous with multiple coexisting mechanisms (diastolic dysfunction, systolic reserve limitations, vascular dysfunction, nitric oxide bioavailability, chronotropic reserve, right heart and left atrial function, autonomic tone, peripheral impairments); and these mechanisms relate to risk factors including aging, obesity, and hypertension. No findings regarding stroke incidence or outcomes are presented.",
          "pmid": "24958077",
          "title": "The pathophysiology of heart failure with preserved ejection fraction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines LOX-1\u2013related biomarkers (sLOX-1, LAB, LOX index) as risk markers for atherosclerotic disease and ischemic stroke, but does not address whether measured stroke outcomes are influenced by underlying cardiovascular comorbidities in a way that would clarify a statistical mechanism. It reports associations with incident events and risk factors, not how cardiovascular comorbidities statistically shape stroke outcomes.",
          "key_findings": "Serum LAB is positively associated with carotid intima-media thickness independent of LDL-C; LAB and the LOX index are significantly associated with incidence of coronary artery disease and ischemic stroke after adjusting for confounders including non-HDL cholesterol; sLOX-1 may be a better biomarker for early diagnosis of acute coronary syndrome than traditional biomarkers; LAB is associated with several atherosclerotic risk factors such as smoking, obesity, diabetes, diastolic hypertension, hypertriglyceridemia, and metabolic syndrome.",
          "pmid": "25463747",
          "title": "LOX-1 in atherosclerotic disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antihypertensive therapy, blood pressure reduction, and cardiovascular outcomes, but it does not analyze stroke outcomes in relation to underlying cardiovascular comorbidities or use statistical adjustment/mediation to show that comorbid cardiovascular disease explains stroke results. Thus it neither supports nor contradicts the proposed statistical mechanism.",
          "key_findings": "Antihypertensive therapy reduces incidence of stroke, heart failure, and renal failure; benefits for coronary events are smaller than expected and may relate to trial duration or drug side effects. Absolute cardiovascular risk is influenced by age, gender, race, and other cardiovascular risk factors, and LVH is an independent predictor for coronary disease. However, no specific analysis links underlying cardiovascular comorbidities to stroke outcome differences.",
          "pmid": "7729325",
          "title": "Goals of antihypertensive therapy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns stroke outcomes being influenced by underlying cardiovascular comorbidities as a statistical factor. The abstract evaluates pulse pressure, systolic, and diastolic blood pressure as independent predictors of stroke occurrence and mortality in the general population, not as statistical markers or confounders reflecting pre-existing cardiovascular comorbidities on stroke outcomes. It does not analyze stroke prognosis after occurrence or explicitly link these blood pressure parameters to underlying comorbidity burden as the pathway of effect.",
          "key_findings": "A 10 mmHg increase in pulse pressure was associated with higher risk of stroke (pooled HR 1.046, 95% CI 1.025\u20131.068). Systolic and diastolic blood pressure were also significant predictors of stroke. Pulse pressure was not significantly associated with all-cause mortality, while systolic blood pressure was. The study focuses on blood pressure measures as independent risk factors for stroke incidence and mortality, not as proxies for cardiovascular comorbidities affecting stroke outcomes.",
          "pmid": "26902972",
          "title": "Pulse pressure as an independent predictor of stroke: a systematic review and a meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism is about heart rate acting as a statistical proxy for underlying cardiovascular comorbidities that impact stroke outcomes, with unknown effect direction. The abstract shows that elevated resting heart rate is an independent predictor of cardio- and cerebrovascular morbidity and mortality, even after adjustment for major cardiovascular risk factors, implying heart rate has prognostic value beyond comorbidities. It does not specifically analyze heart rate as merely a reflection of underlying comorbidities or focus on stroke outcomes per se, so it neither directly supports nor contradicts the proposed statistical-mechanism framing.",
          "key_findings": "Increased heart rate is consistently associated with higher cardiovascular, cerebrovascular, and all-cause mortality; this association is stronger in men; elevated heart rate often accompanies higher blood pressure and metabolic disturbances; after adjustment for major cardiovascular risk factors, heart rate remains an independent predictor of adverse cardiovascular and cerebrovascular events.",
          "pmid": "29355923",
          "title": "Heart rate as a predictor of cardiovascular risk.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that proteinuria is an independent predictor of incident stroke even after adjustment for hypertension and other cardiovascular risk factors. The proposed mechanism concerns statistical adjustment for underlying cardiovascular comorbidities as drivers of stroke outcomes. While the paper directly examines confounding by hypertension, it does not demonstrate that proteinuria\u2019s association with stroke is merely a reflection of broader underlying cardiovascular comorbidities; instead, it suggests an independent effect or shared susceptibility. Thus it neither clearly supports nor clearly contradicts the specific mechanism that stroke outcomes simply reflect underlying cardiovascular comorbidities.",
          "key_findings": "In a meta-analysis of 38 studies (1,735,390 participants; 26,405 strokes), any proteinuria was associated with increased stroke risk (crude RR 2.00, 95% CI 1.63\u20132.46). After adjustment for established cardiovascular risk factors, including various levels of blood pressure control/measurement, the association persisted (pooled adjusted RR 1.72, 95% CI 1.51\u20131.95). More thorough adjustment for hypertension (single BP measure, history/treated hypertension, or multiple BP measures) did not substantially attenuate the association (adjusted RRs ~1.68\u20131.92). Authors conclude that proteinuria is strongly and independently associated with stroke risk, suggesting a shared renal\u2013cerebral vascular susceptibility not fully explained by traditional vascular risk factors.",
          "pmid": "31935154",
          "title": "Proteinuria as an independent predictor of stroke: Systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns underlying cardiovascular comorbidities influencing stroke outcomes, whereas the abstract evaluates whether assisted reproductive technology use is associated with long-term cardiovascular events (including stroke) compared with controls. It reports adjusted effect sizes for incident cardiovascular outcomes but does not analyze how pre-existing cardiovascular comorbidities modify stroke outcomes or mediate stroke prognosis. Thus, it neither supports nor contradicts the specific mechanistic claim.",
          "key_findings": "In a meta-analysis of 10 studies including 500,664 women undergoing ART and 36,395,240 controls, ART was not associated with a significant increase in major adverse cardiovascular events, coronary heart disease, stroke (ES 1.21, 95% CI 0.92\u20131.59), venous thromboembolism, hypertension, or diabetes; ART was associated with a lower risk of heart failure (ES 0.75, 95% CI 0.60\u20130.94). Outcomes were adjusted for confounding factors, but the study did not address how underlying cardiovascular comorbidities impact stroke outcomes.",
          "pmid": "39710934",
          "title": "Cardiovascular safety of assisted reproductive technology: a meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on diet and nutrition as modifiable risk factors for cardiovascular diseases and stroke, but it does not analyze how underlying cardiovascular comorbidities statistically influence stroke outcomes. It discusses risk and prevention, not outcome differences attributable to pre-existing cardiovascular conditions or their role as confounders in stroke outcome analysis.",
          "key_findings": "Dietary sodium increases blood pressure; potassium lowers risk of hypertension and stroke; fruits and vegetables protect against hypertension, CHD, and stroke; certain dietary patterns (DASH, Mediterranean, prudent) reduce risk of hypertension and CHD. The abstract emphasizes methodological issues like confounding but does not provide data or specific analysis on cardiovascular comorbidities impacting stroke outcomes.",
          "pmid": "14972059",
          "title": "Diet, nutrition and the prevention of hypertension and cardiovascular diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns underlying cardiovascular comorbidities driving stroke outcomes. This meta-analysis evaluates pulse pressure and mean pressure as predictors of total, cardiovascular, coronary, and fatal stroke mortality in hypertensive patients, but it does not examine pre\u2011existing cardiovascular comorbidities as mediators of stroke outcomes or provide mechanistic insight into how such comorbidities impact stroke prognosis. Stroke outcomes are included only as one endpoint among others and are not linked to underlying comorbid burden, so the abstract neither supports nor contradicts the specific mechanism.",
          "key_findings": "In hypertensive trial control-group patients, a 10 mmHg higher baseline pulse pressure was independently associated with approximately 6\u20137% increased risk of total, cardiovascular, and coronary mortality; a similar (6%) but statistically non\u2011significant increase in fatal stroke risk was observed due to few stroke events. Mean arterial pressure was not an independent predictor of these outcomes overall. Age modified prognostic power: pulse pressure predicted fatal stroke more strongly at older ages, and mean pressure predicted coronary mortality more strongly at younger ages.",
          "pmid": "11791038",
          "title": "Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses remote ischaemic conditioning as a neuroprotective intervention, its mechanisms (neural, hormonal, inflammatory), protocols, and ongoing trials, but does not analyze or even mention cardiovascular comorbidities as statistical confounders or determinants of stroke outcome. It provides no data or arguments about whether observed stroke outcomes reflect underlying cardiovascular comorbidities, so it neither supports nor contradicts the proposed statistical mechanism.",
          "key_findings": "Remote ischaemic conditioning may provide systemic protection against ischaemia and shows promising effects in acute ischaemic stroke and related conditions; numerous clinical trials are ongoing to clarify efficacy, optimal protocols, and mechanisms, but comorbid cardiovascular conditions as drivers of stroke outcomes are not addressed.",
          "pmid": "33903181",
          "title": "Remote ischaemic conditioning for stroke: unanswered questions and future directions.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns statistical confounding of stroke outcomes by underlying cardiovascular comorbidities. This abstract examines whether occupational noise exposure is associated with cardiovascular disease incidence and mortality; it does not analyze stroke outcomes in relation to pre\u2011existing cardiovascular comorbidities as confounders or mediators, nor does it address statistical adjustment for such comorbidities in a way that informs this specific mechanism.",
          "key_findings": "The meta-analysis reports relative risks for incident and fatal ischemic heart disease, stroke, and hypertension associated with high (\u226585 dBA) versus low (<85 dBA) occupational noise exposure. Evidence for incident IHD is classified as \u2018limited evidence of harmfulness,\u2019 while evidence for stroke and hypertension outcomes is judged \u2018inadequate evidence of harmfulness.\u2019 The abstract does not discuss how underlying cardiovascular comorbidities statistically impact stroke outcomes.",
          "pmid": "33612311",
          "title": "The effect of occupational exposure to noise on ischaemic heart disease, stroke and hypertension: A systematic review and meta-analysis from the WHO/ILO Joint Estimates of the Work-Related Burden of Disease and Injury.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on anesthetic strategy (local anesthesia, conscious sedation, general anesthesia) and peri-procedural hemodynamics during endovascular stroke treatment. It does not analyze or attribute stroke outcomes to underlying cardiovascular comorbidities or their statistical impact, nor does it adjust for or examine comorbidity burden as a mechanism affecting outcomes.",
          "key_findings": "Endovascular treatment has improved outcomes in large vessel occlusion stroke. Anesthetic strategies vary, with small RCTs showing no difference or favoring general anesthesia, while large observational studies favor conscious sedation or local anesthesia. Meta-analysis of observational studies found no difference in functional outcome between local anesthesia and other strategies. Local anesthesia is associated with shorter door-to-groin time and less intraprocedural hypotension, both known to affect functional outcome. The optimal anesthetic strategy remains unclear, and multicenter RCTs are needed.",
          "pmid": "35787587",
          "title": "Anesthetic considerations for endovascular treatment in stroke therapy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates aspirin for primary cardiovascular prevention in non-endstage CKD and its effects on cardiovascular events, mortality, and bleeding. It does not analyze stroke outcomes specifically, nor does it investigate how underlying cardiovascular comorbidities statistically influence stroke prognosis or outcomes. Therefore it neither supports nor contradicts the proposed mechanism about cardiovascular comorbidities impacting stroke outcomes.",
          "key_findings": "In a meta-analysis of three trials (4468 CKD participants, 16,740 person-years), aspirin did not significantly reduce major cardiovascular events (RR 0.92, 95% CI 0.49\u20131.73) or all-cause mortality (RR 0.74, 95% CI 0.55\u20131.00), but increased major bleeding (RR 1.98, 95% CI 1.11\u20133.52). The authors conclude there is no clear benefit of aspirin for primary prevention of cardiovascular events in CKD and that data are insufficient to recommend universal use or avoidance.",
          "pmid": "27341534",
          "title": "Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The proposed mechanism is statistical, about underlying cardiovascular comorbidities explaining stroke outcomes. The abstract lists cardiovascular risk factors for stroke (e.g., mitral annular calcification, diabetes, hypertension, hyperlipidemia, obesity) and discusses mechanisms of thromboembolism and therapies, but it does not analyze stroke outcomes as being statistically driven by comorbidities versus other factors, nor does it quantify their impact on stroke outcomes. Thus it neither directly supports nor contradicts the specific statistical mechanism.",
          "key_findings": "The abstract states that common risk factors for stroke in mitral stenosis include mitral annular calcification, diabetes mellitus, male gender, hypertension, hyperlipidemia, and obesity, and that mitral annular calcification is an independent predictor of stroke. It also describes pathophysiologic mechanisms (endothelial damage, hypercoagulability, blood stasis) and reviews pharmacological (NOACs) and non-pharmacological stroke-prevention strategies, but without directly addressing whether stroke outcomes primarily reflect underlying cardiovascular comorbidities in a statistical sense.",
          "pmid": "35518523",
          "title": "Risk of Stroke With Mitral Stenosis: The Underlying Mechanism, Treatment, and Prevention.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns underlying cardiovascular comorbidities influencing stroke outcomes via statistical confounding. The abstract instead discusses morning blood pressure surge as a physiological and prognostic factor for cardiovascular events, including stroke, and methodological confounding with other 24\u2011hour BP profile features. It does not analyze stroke outcomes in relation to broader cardiovascular comorbidities as statistical confounders, nor does it address stroke prognosis conditional on such comorbidities.",
          "key_findings": "The abstract states that: (1) morning hours show the highest incidence of major cardiovascular events (myocardial infarction, sudden death, stroke); (2) activation of the sympathetic nervous system in the morning leads to a morning blood pressure surge (MBPS); (3) excessive MBPS may be causally involved in the pathogenesis of cardiovascular events by inducing hemodynamic stress; (4) studies support an independent relationship between MBPS and organ damage, cerebrovascular complications, and mortality, though with heterogeneity; (5) heterogeneity may be due to ethnic differences, methodological issues, and confounding with other 24\u2011hour BP parameters such as nocturnal dipping or BP variability; and (6) long\u2011acting antihypertensive drugs can affect MBPS. None of these findings specifically evaluate underlying cardiovascular comorbidities as statistical determinants of stroke outcomes.",
          "pmid": "29872338",
          "title": "Morning blood pressure surge: pathophysiology, clinical relevance and therapeutic aspects.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates daytime and nighttime blood pressure, and their ratio, as prognostic markers for mortality and cardiovascular events in hypertensive patients, but it does not analyze or attribute these prognostic effects to underlying cardiovascular comorbidities nor examine how such comorbidities impact stroke outcomes specifically. It remains focused on blood pressure metrics as independent predictors rather than on comorbid disease burden as the mechanism driving stroke prognosis.",
          "key_findings": "In hypertensive patients without major cardiovascular disease at baseline, both daytime and nighttime systolic blood pressure predicted all-cause and cardiovascular mortality, coronary heart disease, and stroke, independent of office blood pressure and confounders. When daytime and nighttime BP were modeled together, nighttime systolic BP remained predictive of all outcomes whereas daytime BP lost prognostic value. The systolic night\u2013day blood pressure ratio predicted all outcomes, with its prognostic value persisting only for all-cause mortality after adjusting for 24-hour BP. These findings indicate nighttime BP is generally a better predictor of outcomes than daytime BP but do not address underlying cardiovascular comorbidities as the explanatory mechanism.",
          "pmid": "18039980",
          "title": "Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "antiplat_rand",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Antiplatelets inhibit platelet activity, complementing alteplase by facilitating more effective fibrinolysis.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (antiplatelet OR aspirin OR clopidogrel OR \"platelet inhibition\") AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"complementing\" OR \"antiplatelets\" OR \"fibrinolysis\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 0,
      "neutral_count": 19,
      "support_percentage": 5.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions antiplatelets only in the context of drug\u2013drug interactions with antiseizure medications in stroke survivors and does not address their pharmacologic effect on platelet activity in relation to alteplase or fibrinolysis. No data or discussion is provided on how antiplatelets might complement alteplase-mediated thrombolysis.",
          "key_findings": "The review discusses seizures and epilepsy after stroke, risk factors, biomarkers, and management considerations, including that drug\u2013drug interactions between antiseizure medications and anticoagulants or antiplatelets influence treatment decisions. It does not examine antiplatelets\u2019 mechanistic role in enhancing alteplase-induced fibrinolysis.",
          "pmid": "33619704",
          "title": "Seizures and Epilepsy After Stroke: Epidemiology, Biomarkers and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a broad overview of stroke pharmacogenomics and mentions rtPA, antiplatelets, and warfarin but does not discuss how antiplatelets interact mechanistically with alteplase, nor whether they facilitate fibrinolysis. No data or statements address the complementary role of antiplatelets with alteplase on platelet activity or fibrinolysis.",
          "key_findings": "The paper reviews principal drugs in stroke (rtPA for acute treatment, antiplatelets and warfarin for secondary prophylaxis) in the context of genetic influences on drug response, but provides no mechanistic or outcome data on antiplatelets enhancing alteplase-mediated fibrinolysis.",
          "pmid": "19925046",
          "title": "Stroke pharmacogenomics.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ximelagatran (a direct thrombin inhibitor) and its clinical efficacy and safety compared with warfarin and heparins, and mentions antiplatelets only in the context of acute coronary syndromes and combination with aspirin. It does not address how antiplatelet therapy interacts with alteplase, nor whether antiplatelets facilitate fibrinolysis when combined with thrombolytics. No mechanistic data on platelet inhibition enhancing alteplase-mediated fibrinolysis are presented.",
          "key_findings": "1) Warfarin is described as the standard for long-term thromboembolism prevention, with antiplatelets preferred in acute coronary syndromes. 2) Ximelagatran is an oral direct thrombin inhibitor comparable in efficacy to warfarin and low molecular weight heparin for various thromboembolic indications. 3) When combined with aspirin, ximelagatran was more effective than aspirin alone at preventing major cardiovascular events after myocardial infarction. 4) Bleeding risk with ximelagatran is similar or lower compared with standard anticoagulants. None of these findings examine or mention antiplatelet effects on alteplase-induced fibrinolysis.",
          "pmid": "16511607",
          "title": "Ximelagatran.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses dual antiplatelet therapy and addition of oral anticoagulants after acute coronary syndrome, focusing on clinical outcomes (cardiovascular death, MI, stroke, stent thrombosis) and bleeding risk. It does not examine interactions with alteplase, fibrinolysis efficacy, or platelet inhibition as a mechanism to enhance thrombolytic action. Thus it neither supports nor refutes the specific mechanism of antiplatelets complementing alteplase-mediated fibrinolysis.",
          "key_findings": "Dual antiplatelet therapy is standard after ACS but residual risk of events remains; adding NOACs (dabigatran, apixaban, rivaroxaban, darexaban) to DAPT increases bleeding, with potential efficacy signal for apixaban and rivaroxaban. Low-dose rivaroxaban (2.5 mg bid) combined with DAPT improves composite cardiovascular outcomes but with dose-dependent major bleeding. No mention of alteplase or thrombolytic enhancement mechanisms.",
          "pmid": "24136072",
          "title": "Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews emergency reversal of antiplatelet agents in intracranial hemorrhage and notes that prehospital antiplatelet use is associated with increased ICH risk and volume, and that evidence on outcomes is conflicting. It does not study or discuss how antiplatelets interact with alteplase or their role in facilitating fibrinolysis, so it neither supports nor contradicts the proposed mechanism about complementing alteplase.",
          "key_findings": "Prehospital antiplatelet use is associated with increased risk of ICH and increased hematoma volume; data on the relationship between prehospital antiplatelet use and ICH outcomes are conflicting; only one retrospective study assessed outcomes after platelet transfusion for reversal; there is insufficient evidence to determine whether platelet transfusion mitigates hematoma enlargement or improves outcomes. No data are presented on interactions between antiplatelets and alteplase or on facilitation of fibrinolysis.",
          "pmid": "21492561",
          "title": "Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The trial compares two antiplatelet agents (ticagrelor vs clopidogrel) in STEMI patients treated with fibrinolysis and reports similar efficacy and bleeding outcomes, but it does not test or quantify whether antiplatelet therapy per se enhances alteplase-mediated fibrinolysis versus no antiplatelet use, nor does it assess platelet activity or fibrinolytic parameters mechanistically. Thus it neither directly supports nor refutes the proposed mechanism that antiplatelets facilitate more effective fibrinolysis.",
          "key_findings": "In 3,799 STEMI patients <75 years treated with fibrinolytic therapy, ticagrelor did not significantly reduce the composite of cardiovascular death, MI, or stroke vs clopidogrel (6.7% vs 7.3%; HR 0.93; 95% CI 0.73\u20131.18; p=0.53). An extended composite outcome including other ischemic events was also not significantly different (8.0% vs 9.1%; HR 0.88; 95% CI 0.71\u20131.09; p=0.25). Major, fatal, and intracranial bleeding rates were similar between groups. The study does not compare antiplatelet therapy to no antiplatelet therapy, nor does it measure fibrinolytic efficacy directly.",
          "pmid": "30898608",
          "title": "Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how cardiovascular drugs, including aspirin, modulate fibrinolysis via endothelial\u2013platelet interactions and platelet-derived antifibrinolytic factors (e.g., PAI-1), but it does not specifically evaluate antiplatelet agents as adjuncts to alteplase or demonstrate that platelet inhibition complements alteplase-mediated fibrinolysis in thrombolytic therapy.",
          "key_findings": "Platelets release antifibrinolytic factors such as PAI-1 and thus participate in regulation of fibrinolysis; major cardiovascular drugs (including aspirin) can have profibrinolytic and antithrombotic effects via modulation of endothelium\u2013platelet interactions and the NO/PGI2 pathway. No data are presented on combination therapy with alteplase or direct enhancement of t-PA-based thrombolysis by antiplatelets.",
          "pmid": "26321270",
          "title": "Pharmacological modulation of fibrinolytic response - In vivo and in vitro studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses vorapaxar, an antiplatelet PAR-1 antagonist, in the context of atherosclerotic disease, but it does not involve alteplase, thrombolysis, or fibrinolysis, nor does it evaluate how antiplatelet therapy might complement alteplase-mediated fibrinolysis. Therefore, it neither supports nor contradicts the specific proposed mechanism about antiplatelets enhancing alteplase effectiveness.",
          "key_findings": "Vorapaxar, used with aspirin and/or clopidogrel, reduced composite cardiovascular events in secondary prevention but not in non\u2013ST-elevation MI, and increased major/minor bleeding and intracranial hemorrhage. No data are presented on interaction with alteplase or effects on fibrinolysis.",
          "pmid": "25680760",
          "title": "Vorapaxar in atherosclerotic disease management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on milvexian, a factor XIa inhibitor anticoagulant, including its use in addition to dual antiplatelet therapy, but does not investigate or describe the mechanistic role of antiplatelets in facilitating alteplase-mediated fibrinolysis or any interaction with alteplase. No data on alteplase, fibrinolysis enhancement by antiplatelets, or their mechanistic complementarity with thrombolysis are presented.",
          "key_findings": "Milvexian is described as a factor XIa inhibitor with a favorable pharmacokinetic profile and low bleeding risk. In acute non-cardioembolic ischemic stroke or high-risk TIA, milvexian added to dual antiplatelet therapy appears effective and safe, particularly regarding intracranial hemorrhage. There is no mention of alteplase, thrombolytic therapy, or antiplatelet effects on fibrinolysis.",
          "pmid": "39215446",
          "title": "Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antiplatelet therapy, anticoagulants (including asundexian), bleeding risk, and dual\u2011pathway inhibition in stroke prevention, but it does not examine or report on how antiplatelets interact with alteplase or whether they facilitate fibrinolysis when combined with alteplase. No data are presented on platelet activity in the context of thrombolysis or alteplase efficacy, so the specific proposed mechanism is neither supported nor refuted.",
          "key_findings": "1) Antiplatelets and oral anticoagulants are standard for ischemic stroke prevention but increase bleeding risk; 2) Asundexian, a factor XIa inhibitor, has a favorable pharmacokinetic profile and may be beneficial in non\u2011cardioembolic ischemic stroke as part of dual\u2011pathway inhibition with antiplatelets; 3) Clinical trials of asundexian showed safety for bleeding even when combined with antiplatelet therapy; 4) No mention of alteplase, fibrinolysis enhancement, or mechanistic interaction between antiplatelets and thrombolytic therapy.",
          "pmid": "39257338",
          "title": "A pharmacokinetic and pharmacodynamic evaluation of asundexian: a novel factor XIa inhibitor for stroke prevention.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates argatroban (a direct thrombin inhibitor) added to antiplatelet therapy in ischemic stroke but does not involve alteplase, fibrinolysis, or how antiplatelets might mechanistically complement alteplase-mediated clot lysis. It reports clinical outcomes of combining anticoagulation with antiplatelets, not the specific pharmacological mechanism of antiplatelets enhancing alteplase fibrinolysis.",
          "key_findings": "Argatroban plus antiplatelet therapy (SAPT or DAPT) versus antiplatelets alone in acute ischemic stroke: improved odds of favorable functional outcome (mRS 0\u20132 and 0\u20131), reduced early neurological deterioration, greater NIHSS improvement, and no significant increase in intracranial hemorrhage, symptomatic ICH, stroke recurrence, or mortality. Subgroup analysis suggests greatest benefit with dual antiplatelet therapy. Alteplase or fibrinolytic mechanisms are not studied or mentioned.",
          "pmid": "40392513",
          "title": "Exploring the Efficacy and Safety of Argatroban as an Adjunct to Antiplatelet Therapy in Ischemic Stroke Patients: A Systematic Review and Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews clinical efficacy and bleeding risks of various antiplatelet agents in cardiovascular disease but does not mention alteplase, fibrinolysis, or any interaction between antiplatelet therapy and thrombolytic agents. It focuses on outcomes like death, MI, and stroke, not on mechanistic effects on fibrinolysis or synergy with alteplase.",
          "key_findings": "Dual antiplatelet therapy (aspirin + clopidogrel) and newer agents (prasugrel, ticagrelor) reduce cardiovascular events but increase bleeding risk; no discussion of alteplase or enhancement of fibrinolysis.",
          "pmid": "24213473",
          "title": "Updates in antiplatelet agents used in cardiovascular diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly states a pharmacodynamic, additive and beneficial effect of aspirin when used concomitantly with thrombolysis, implying that antiplatelet therapy enhances the clinical effect of thrombolytic agents without excessive bleeding. While it does not detail the molecular mechanism (e.g., facilitation of fibrinolysis via platelet inhibition), it does support the core idea that antiplatelet drugs complement thrombolytic therapy such as alteplase.",
          "key_findings": "1) Thrombolytic agents interact pharmacodynamically with platelet aggregation and coagulation, which may be important for synergistic interactions with antiplatelet drugs. 2) The abstract reports that concomitant aspirin therapy with thrombolysis has an additive and beneficial effect without excessive bleeding rates. 3) It notes frequent comedication with antiplatelet agents (aspirin, clopidogrel, ticlopidine) during thrombolytic therapy, highlighting clinically relevant interactions, though data are lacking for ticlopidine and clopidogrel specifically.",
          "pmid": "11085346",
          "title": "Thrombolytics: drug interactions of clinical significance.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study examines effects of remote ischemic preconditioning on platelet-derived extracellular vesicles and global coagulation/fibrinolytic markers in patients already on antiplatelet therapy, but it does not evaluate how antiplatelet agents themselves modulate platelet activity to complement alteplase-mediated fibrinolysis, nor does it assess interactions with thrombolytic therapy or fibrinolytic efficacy.",
          "key_findings": "In a randomized controlled trial of 60 patients with coronary disease (all on at least one antiplatelet agent), remote ischemic preconditioning reduced circulating platelet-derived EVs (CD41+ and CD61+) but did not change overall hemostatic potential or plasma levels of tPA, urokinase, PAI-1, or plasminogen. Statin use and certain comorbidities modified some EV responses. No data were presented on alteplase use or on enhancement of fibrinolysis by antiplatelet therapy.",
          "pmid": "34196106",
          "title": "Circulating platelet-derived extracellular vesicles are decreased after remote ischemic preconditioning in patients with coronary disease: A randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates baseline troponin levels and 90\u2011minute ST\u2011segment resolution as predictors of 30\u2011day cardiovascular mortality in STEMI patients receiving fibrinolysis (in a trial where clopidogrel was adjunctive), but it does not assess how antiplatelet therapy mechanistically interacts with alteplase to enhance fibrinolysis or platelet inhibition per se. No comparison of antiplatelet vs no antiplatelet, no specific analysis of platelet activity, and no mechanistic inference about antiplatelets facilitating fibrinolysis are presented.",
          "key_findings": "Higher baseline troponin levels and less 90\u2011minute ST\u2011segment resolution are independently associated with higher 30\u2011day cardiovascular mortality in STEMI patients treated with fibrinolysis, and adding these measures to clinical risk factors improves risk discrimination.",
          "pmid": "20569707",
          "title": "Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The study shows that ticagrelor produces stronger and more prolonged platelet inhibition than clopidogrel in STEMI patients treated with fibrinolysis and undergoing PCI, but it does not measure or report any outcomes related to fibrinolysis effectiveness, clot lysis, reperfusion, or interaction between antiplatelet therapy and alteplase/tenecteplase. Thus, it informs the degree of platelet inhibition but does not provide direct evidence that antiplatelet-induced platelet inhibition complements alteplase by facilitating more effective fibrinolysis.",
          "key_findings": "In STEMI patients who received tenecteplase, aspirin, and clopidogrel, randomization to additional ticagrelor versus clopidogrel showed: (1) ticagrelor produced greater reductions in platelet reactivity units (PRU) from baseline through 4 h, 24 h, and long-term follow-up, whereas clopidogrel showed significant PRU reduction only from baseline to 4 h; (2) a higher proportion of patients on ticagrelor achieved adequate platelet inhibition (PRU < 208) at long-term follow-up compared with clopidogrel (100% vs. 82.6%, p = 0.038). No data on fibrinolytic efficacy or enhanced clot lysis were reported.",
          "pmid": "29170875",
          "title": "Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses plasminogen activators (tPA, scuPA), their mutants, chimeras, and conjugates with antifibrin or antiplatelet monoclonal antibodies to improve thrombolytic potency. It does not address the use of pharmacological antiplatelet drugs, nor does it examine platelet inhibition as a means of complementing alteplase-mediated fibrinolysis. Targeting plasminogen activators to clots with antiplatelet antibodies is a different mechanism than systemic antiplatelet inhibition.",
          "key_findings": "Plasminogen activators can be engineered (mutants, chimeras, antibody conjugates) to alter pharmacokinetics and thrombolytic potency; conjugation with antifibrin or antiplatelet monoclonal antibodies increases thrombolytic potency 5- to 10-fold by targeting clots, but no data are presented on pharmacologic antiplatelet agents enhancing alteplase via platelet inhibition.",
          "pmid": "1309056",
          "title": "Remaining perspectives of mutant and chimeric plasminogen activators.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines effects of low-dose warfarin, aspirin\u2013warfarin combinations, and dose-adjusted warfarin on markers of thrombogenesis, fibrinolysis, and endothelial dysfunction in chronic atrial fibrillation. It does not involve alteplase, thrombolytic therapy, or the specific concept of antiplatelets facilitating alteplase-mediated fibrinolysis. Therefore, it neither supports nor contradicts the proposed mechanism regarding antiplatelets complementing alteplase.",
          "key_findings": "In AF patients, low-dose warfarin alone or combined with 300 mg aspirin did not significantly reduce fibrin D-dimer, fibrinogen, or vWf over 8 weeks, whereas conventional dose-adjusted warfarin (INR 2.0\u20133.0) significantly reduced fibrin D-dimer and fibrinogen. PAI-1 increased in one low-dose combination group. No thrombolytic or alteplase therapy was studied.",
          "pmid": "10753983",
          "title": "Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns risk prediction for adverse clinical events in atrial fibrillation with stable coronary artery disease and notes antiplatelet use as a predictor variable, but it does not examine how antiplatelets interact mechanistically with alteplase, nor does it assess their impact on fibrinolysis effectiveness. No data on thrombolytic therapy or platelet-mediated modulation of alteplase activity are presented.",
          "key_findings": "A machine-learning-based and Cox-regression-derived risk score for net adverse clinical events (all-cause death, myocardial infarction, stroke, or major bleeding) was developed and validated in AF patients with stable CAD receiving antithrombotic therapy. Antiplatelet use was one of several clinical variables used in the model, but the study did not analyze mechanistic effects of antiplatelets on fibrinolysis or on alteplase activity.",
          "pmid": "37173099",
          "title": "Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical efficacy and bleeding risk of dabigatran versus warfarin with and without concomitant antiplatelet therapy in atrial fibrillation. It does not involve alteplase, fibrinolysis enhancement, or mechanistic assessment of how antiplatelets might facilitate fibrinolysis. The findings concern outcomes (stroke/systemic embolism and bleeding) under different antithrombotic regimens, not the proposed mechanism of antiplatelets complementing alteplase-mediated fibrinolysis.",
          "key_findings": "Concomitant antiplatelet therapy (aspirin or clopidogrel) was used in 38.4% of RE-LY patients. Dabigatran 110 mg BID remained noninferior to warfarin for stroke/systemic embolism with fewer major bleeds, regardless of antiplatelet use. Dabigatran 150 mg BID showed reduced stroke/systemic embolism versus warfarin, with possible attenuation of benefit among antiplatelet users. Concomitant single and dual antiplatelet therapy increased major bleeding risk (HR 1.60 and 2.31 respectively). The study did not examine interactions with alteplase or fibrinolytic processes.",
          "pmid": "23271794",
          "title": "Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "antiplat_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Inhibition of platelets reduces micro-thrombosis risk, maintaining penumbral regions post-treatment.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (antiplatelet OR aspirin OR clopidogrel OR \"platelet inhibition\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"maintaining\" OR \"inhibition\" OR \"thrombosis\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study evaluates adding aspirin (a platelet inhibitor) to existing oral anticoagulation in chronic coronary syndrome and reports clinical outcomes (composite ischemic events, death, bleeding), but it does not assess micro-thrombosis, penumbral tissue preservation, or post-acute treatment tissue-level effects. Therefore it neither supports nor contradicts the specific mechanistic claim about platelet inhibition reducing micro-thrombosis to maintain penumbral regions.",
          "key_findings": "In patients with chronic coronary syndrome on long-term oral anticoagulation, adding aspirin 100 mg daily increased the risk of the composite efficacy outcome (HR 1.53), all-cause death (HR 1.72), and major bleeding (HR 3.35) compared with placebo, leading to early trial termination. No measurements of micro-thrombosis, penumbral regions, or related mechanistic endpoints were reported.",
          "pmid": "40888725",
          "title": "Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns platelet inhibition reducing micro-thrombosis to preserve penumbral brain regions (a cerebrovascular/neuroprotection context). The abstract evaluates different durations of dual antiplatelet therapy vs clopidogrel monotherapy in acute coronary syndrome patients after PCI, focusing on composite cardiovascular and bleeding outcomes. It does not assess micro-thrombosis, penumbral tissue, or neuroprotection, nor does it mechanistically link platelet inhibition to preservation of at-risk tissue. Thus it neither supports nor conflicts with the specific mechanism.",
          "key_findings": "In ACS patients post-PCI, 1\u20132 months of DAPT followed by clopidogrel monotherapy was not noninferior to 12 months of DAPT for a composite of cardiovascular and bleeding events; shorter DAPT showed numerically more cardiovascular events but less bleeding. No data on micro-thrombosis, penumbral regions, or brain tissue preservation are reported.",
          "pmid": "35234821",
          "title": "Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial examines the effects of rivaroxaban (an anticoagulant) with or without aspirin (an antiplatelet) on major cardiovascular and limb events and bleeding in stable peripheral/carotid artery disease. It does not investigate micro-thrombosis, cerebral penumbral tissue, or post-treatment (e.g., post-stroke or reperfusion) tissue preservation. Outcomes are macro-level clinical events (MI, stroke, major limb events), not microvascular thrombosis or penumbral maintenance, so the specific proposed mechanism is neither directly supported nor contradicted.",
          "key_findings": "In patients with peripheral artery disease, low-dose rivaroxaban plus aspirin reduced the composite endpoint of cardiovascular death, MI, or stroke and reduced major adverse limb events vs aspirin alone, but increased major bleeding. Rivaroxaban alone did not significantly reduce the primary cardiovascular composite but reduced major adverse limb events and increased major bleeding. No data were reported on micro-thrombosis, penumbral regions, or post-treatment neurovascular outcomes.",
          "pmid": "29132880",
          "title": "Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study compares low-dose anticoagulation with dual antiplatelet therapy after left atrial appendage occlusion and reports composite clinical outcomes (bleeding, thromboembolic events, device-related thrombosis). It does not assess micro-thrombosis in the cerebral circulation, penumbral tissue preservation, or platelet inhibition\u2013specific effects on brain microvasculature after acute treatment (e.g., stroke therapy). Therefore, it neither directly supports nor refutes the proposed mechanism about platelet inhibition reducing micro-thrombosis to maintain penumbral regions.",
          "key_findings": "Low-dose apixaban after LAAO resulted in fewer composite primary endpoint events (4.5% vs 21.7%; HR 0.19, 95% CI 0.04\u20130.88) and lower device-related thrombosis (0% vs 8.7%) compared with dual antiplatelet therapy, with no difference in clinical thromboembolic events (no strokes or systemic emboli in either group). The trial setting is post-LAAO atrial fibrillation patients, not acute cerebrovascular penumbral protection or micro-thrombus formation in the brain.",
          "pmid": "39110427",
          "title": "Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses intracranial branch atheromatous disease, its pathophysiology, and the lack of established effective treatments, but it does not mention platelet inhibition, micro-thrombosis, or preservation of penumbral regions, nor does it provide data on how antiplatelet therapy affects micro-thrombotic risk or penumbral maintenance.",
          "key_findings": "BAD is caused by occlusion of large perforating branches by atherosclerotic plaque-based thrombus; it is refractory to standard treatments for atherothrombotic or lacunar infarction and tends to show progressive worsening; multiple acute treatment combinations have been explored but no therapy with proven efficacy exists.",
          "pmid": "37183021",
          "title": "Pathophysiology and Optimal Treatment of Intracranial Branch Atheromatous Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that dual antiplatelet therapy (clopidogrel plus aspirin) reduces the risk of new stroke versus aspirin alone when initiated up to 72 hours after mild ischemic stroke or TIA, with an increased bleeding risk. However, it does not investigate micro-thrombosis, penumbral tissue preservation, or imaging/biological markers related to maintaining the ischemic penumbra. The data are clinical outcome\u2013based and do not directly test or describe the proposed mechanism of reduced micro-thrombosis preserving penumbral regions.",
          "key_findings": "Dual antiplatelet therapy initiated within 72 hours after mild ischemic stroke or TIA lowered 90-day new stroke risk compared with aspirin alone across all time windows studied, with similar relative increases in moderate-to-severe bleeding. No measurements of micro-thrombosis, penumbral viability, or related mechanistic biomarkers were reported.",
          "pmid": "39240565",
          "title": "Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns platelet inhibition reducing micro-thrombosis to preserve penumbral tissue (a cerebrovascular/penumbral concept). This trial evaluates different antiplatelet regimens after coronary stenting, focusing on major bleeding, composite cardiovascular events, stent thrombosis, and revascularization. It does not assess micro-thrombosis, penumbral regions, or tissue preservation, nor mechanisms related to microvascular thrombus burden.",
          "key_findings": "In 6002 post-PCI patients, prasugrel monotherapy (aspirin-free) vs dual antiplatelet therapy showed: (1) no superiority for major bleeding at 1 month (4.47% vs 4.71%; HR 0.95, 95% CI 0.75\u20131.20); (2) noninferiority for composite cardiovascular events (4.12% vs 3.69%; HR 1.12, 95% CI 0.87\u20131.45); and (3) higher rates of unplanned coronary revascularization and subacute definite/probable stent thrombosis in the aspirin-free group. No data on micro-thrombosis or penumbral tissue preservation were reported.",
          "pmid": "37994553",
          "title": "An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a broad primer on atrial fibrillation epidemiology and management. It does not mention platelet inhibition, micro-thrombosis, penumbral regions, or post-treatment tissue preservation, so it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Describes AF as a common arrhythmia with increased stroke risk and outlines general management strategies (stroke prevention, rate and rhythm control) without specifying platelet-targeted mechanisms or micro-thrombotic processes.",
          "pmid": "27159789",
          "title": "Atrial fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares two dual antiplatelet regimens after coronary stenting and reports composite ischemic and bleeding outcomes, but it does not examine micro-thrombosis, penumbral tissue preservation, or any microvascular/penumbral imaging or surrogate markers. While it confirms that platelet inhibition regimens can affect clinical thrombosis and bleeding risk, it does not provide mechanistic data about maintaining penumbral regions post-treatment.",
          "key_findings": "Indobufen plus clopidogrel was noninferior and appeared superior to aspirin plus clopidogrel for a 1-year composite endpoint (HR 0.73, 95% CI 0.56\u20130.94), mainly due to reduced BARC 2\u20135 bleeding (2.97% vs 4.71%, HR 0.63). Rates of cardiovascular death, nonfatal MI, ischemic stroke, and stent thrombosis were similar between regimens. No data on micro-thrombosis or penumbral region maintenance were presented.",
          "pmid": "36335890",
          "title": "Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions antithrombotic drugs such as aspirin and clopidogrel and states that randomized controlled trials show they reduce major adverse events in peripheral artery disease, but it does not discuss micro-thrombosis in penumbral regions, preservation of penumbra, or a mechanistic link between platelet inhibition and maintenance of at-risk ischemic tissue after treatment.",
          "key_findings": "Peripheral artery disease is common and associated with major adverse events. Established treatments include antithrombotic drugs (aspirin, clopidogrel) and risk factor\u2013modifying medications, and randomized controlled trials show these reduce major adverse events. The abstract does not describe effects on micro-thrombosis, penumbral regions, or tissue preservation mechanisms.",
          "pmid": "34997200",
          "title": "Update on the pathophysiology and medical treatment of peripheral artery disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares different antithrombotic regimens after left atrial appendage occlusion in terms of device-related thrombosis, thromboembolic events, bleeding, and mortality, but it does not investigate platelet inhibition as a mechanism for reducing micro-thrombosis or preserving penumbral brain regions post-treatment. Outcomes are clinical and device-related, not microvascular or penumbral-tissue based, and no mechanistic platelet\u2013microthrombosis\u2013penumbra pathway is evaluated.",
          "key_findings": "Dual antiplatelet therapy, DOAC, DOAC plus single antiplatelet therapy, and VKA were superior to no therapy in preventing device-related thrombosis. DOAC showed lower all-cause mortality than VKA. Compared with single antiplatelet therapy, dual antiplatelet therapy reduced thromboembolic events without increasing major bleeding. DOAC monotherapy ranked best for reducing thromboembolic events and major bleeding. These results relate to overall thromboembolism and device-related thrombosis, not specifically to micro-thrombosis in penumbral regions.",
          "pmid": "37611779",
          "title": "Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares long-term clopidogrel vs aspirin monotherapy after PCI and reports differences in composite thrombotic and bleeding outcomes. It does not assess micro-thrombosis, penumbral tissue, or any neurovascular/ischemic territory preservation, nor does it mechanistically link platelet inhibition to maintaining penumbral regions. Thus it neither directly supports nor contradicts the specific proposed mechanism.",
          "key_findings": "In a post hoc analysis of the HOST-EXAM Extended trial (n=3974), clopidogrel monotherapy after an event-free period on DAPT was associated with lower rates of a thrombotic composite endpoint and lower bleeding compared with aspirin, regardless of high bleeding risk status or PCI complexity. Outcomes reported were macro-level cardiovascular events (CV death, MI, stroke, ACS readmission, stent thrombosis) and bleeding (BARC 2\u20135), without evaluation of micro-thrombosis or penumbral region preservation.",
          "pmid": "39602157",
          "title": "Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The mechanism concerns platelet inhibition reducing micro-thrombosis to preserve penumbral tissue, a concept specific to microvascular/penumbral protection (typically in ischemic brain or similar settings). This trial compares a direct factor Xa inhibitor (rivaroxaban) with an antiplatelet agent (ASA) for macro-thromboprophylaxis after Fontan surgery in children and reports rates of clinical thrombotic events and bleeding. It does not assess micro-thrombosis, penumbral regions, or mechanistic platelet effects on tissue preservation, nor does it focus on a post-reperfusion/penumbral context. Thus it is related to thrombosis prevention generally but neither tests nor informs the specific proposed mechanism.",
          "key_findings": "In children post-Fontan, rivaroxaban (an anticoagulant) had similar bleeding rates but fewer clinically evident thrombotic events (1 pulmonary embolism; ~2% event rate) compared with ASA (1 ischemic stroke and 2 venous thromboses; ~9% event rate), though differences were not statistically significant. No data on micro-thrombosis, penumbral tissue, or platelet-specific mechanisms were provided.",
          "pmid": "34558312",
          "title": "Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antiphospholipid syndrome, its thrombotic manifestations, and standard treatments (long\u2011term oral anticoagulation, aspirin, heparin), but it does not specifically address inhibition of platelets as a means to reduce micro-thrombosis or preserve penumbral regions after any treatment. No data on micro-thrombosis, penumbra, or platelet-specific mechanisms in this context are provided.",
          "key_findings": "APS is characterized by venous and/or arterial thromboses and pregnancy morbidity in the presence of antiphospholipid antibodies. APS patients with thrombosis are treated with long-term oral anticoagulation, and obstetric complications are prevented using aspirin and heparin. The abstract is a general clinical and therapeutic overview without mechanistic detail on platelet inhibition and micro-thrombosis in penumbral tissue.",
          "pmid": "28262233",
          "title": "Antiphospholipid syndrome.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study evaluates clinical outcomes (composite of death, MI, stent thrombosis, stroke, and major bleeding) with different antiplatelet regimens after coronary stenting, but it does not assess micro-thrombosis, penumbral tissue preservation, or any mechanistic measures related to maintaining penumbral regions. It focuses on macro-level cardiovascular events and bleeding, not on the specific micro-thrombosis/penumbra mechanism described.",
          "key_findings": "In acute coronary syndrome patients with drug-eluting stents, stopping aspirin within 1 month and continuing ticagrelor monotherapy was noninferior and statistically superior to 12 months of ticagrelor-based dual antiplatelet therapy for a 1-year composite outcome (2.8% vs 5.2%; HR 0.54), mainly due to less major bleeding (1.2% vs 3.4%; HR 0.35). Micro-thrombosis or penumbral region preservation were not measured or discussed.",
          "pmid": "37878786",
          "title": "Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses perioperative stroke mechanisms and mentions antiplatelet and anticoagulant therapy only as proposed modifiable risk factors, without presenting data on whether platelet inhibition reduces micro-thrombosis or preserves penumbral regions. No mechanistic or outcome evidence related to platelet inhibition and micro-thrombosis in penumbra is provided.",
          "key_findings": "The review describes diverse pathophysiologic mechanisms of perioperative stroke (thrombotic, cardioembolic, hypoxic) and lists risk factors such as age, cerebrovascular disease, ischemic heart disease, heart failure, atrial fibrillation, and renal disease. It notes that the role of modifiable factors including perioperative anticoagulation and antiplatelet therapy remains to be clarified, indicating a lack of definitive evidence rather than supportive or conflicting data regarding platelet inhibition reducing micro-thrombosis or maintaining penumbral regions.",
          "pmid": "26391795",
          "title": "Perioperative stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions antiplatelet drugs as part of guideline-based medical therapy for carotid stenosis but does not examine how platelet inhibition affects micro-thrombosis, penumbral tissue, or post-treatment brain viability. No mechanistic or outcome data are provided that link platelet inhibition to preservation of penumbral regions after acute stroke treatment.",
          "key_findings": "Antiplatelet drugs are listed among recommended medical treatments for symptomatic and high-risk asymptomatic carotid stenosis, alongside antihypertensives and lipid-lowering drugs, but the abstract does not report specific effects on micro-thrombosis, penumbra preservation, or detailed platelet-related mechanisms.",
          "pmid": "39832540",
          "title": "The diagnosis and treatment of asymptomatic and symptomatic patients with carotid artery stenosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions use of antiplatelet agents (aspirin, aspirin/dipyridamole, clopidogrel) for prevention of recurrent noncardioembolic ischemic stroke, but it does not discuss micro-thrombosis, penumbral tissue, or post-treatment tissue preservation. It addresses clinical stroke prevention broadly, not the specific mechanism of preserving penumbra via reduced micro-thrombosis.",
          "key_findings": "Antiplatelet agents are recommended for secondary prevention after noncardioembolic ischemic stroke, with aspirin or aspirin/dipyridamole as first-line and clopidogrel for specific patient groups; other drug classes (antihypertensives, antidiabetics, statins, antithrombotics including warfarin) are also effective for stroke risk reduction.",
          "pmid": "14579620",
          "title": "[Stroke prevention].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the general role of platelet inhibitors and anticoagulants in preventing arterial and venous thrombosis, but it does not address micro-thrombosis, penumbral brain regions, or post-treatment tissue preservation. There is no mechanistic or outcome data specifically linking platelet inhibition to reduced micro-thrombosis and maintenance of penumbral regions.",
          "key_findings": "Platelet inhibitors (aspirin, thienopyridines) are indicated for prevention of arterial thrombi in conditions such as myocardial infarction, certain strokes, and critical limb ischemia; anticoagulants (VKAs, NOACs) are used for venous clots and atrial fibrillation. The abstract focuses on individualized antithrombotic therapy selection, not on microvascular thrombosis or penumbral tissue maintenance.",
          "pmid": "25597592",
          "title": "Individualized antithrombotic therapy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aspirin and other antiplatelet drugs, their pharmacodynamics, and drug\u2013drug interactions in the context of secondary stroke prevention, but it does not present data or specific mechanistic evidence about reducing micro-thrombosis or maintaining penumbral brain regions post-treatment.",
          "key_findings": "Low-dose aspirin is recommended for secondary prevention after ischemic stroke/TIA; some NSAIDs can interfere with aspirin\u2019s platelet COX-1 inhibition; SSRIs may have synergistic platelet inhibition with antiplatelet agents; aspirin\u2019s straightforward pharmacokinetics limit clinically relevant DDIs. No mention of micro-thrombosis or penumbral region preservation.",
          "pmid": "27765537",
          "title": "Aspirin, stroke and drug-drug interactions.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "antiplat_rand",
      "mechanism": {
        "mechanism_type": "behavioral",
        "description": "The use of antiplatelets may correlate with substantial pre-treatment medical care, influencing post-treatment compliance and outcomes.",
        "evidence_level": "speculative"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (antiplatelet OR aspirin OR clopidogrel OR \"platelet inhibition\") AND (\"antiplatelets\" OR \"substantial\" OR \"influencing\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses guideline recommendations for PFO closure and the use of antiplatelet therapy versus anticoagulation, but it does not address patients\u2019 prior medical care utilization, treatment adherence, or how antiplatelet use might serve as a marker of substantial pre-treatment care that influences subsequent compliance or outcomes.",
          "key_findings": "The guideline recommends PFO closure plus antiplatelet therapy for selected patients with PFO-associated stroke, suggests against long-term anticoagulation unless otherwise indicated, and notes evidence levels for different age groups and PFO characteristics. No data are presented on correlations between antiplatelet use and pre-treatment medical care intensity, adherence behavior, or behavioral determinants of post-treatment outcomes.",
          "pmid": "38752755",
          "title": "European Stroke Organisation (ESO) Guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses efficacy, adherence, genetic polymorphisms, and racial differences in response to antiplatelet therapy, but it does not examine or mention associations between antiplatelet use and the extent of pre-treatment medical care, nor does it link such pre-treatment care to post-treatment compliance or outcomes. Thus, it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "The review reports: (1) strong evidence for aspirin and clopidogrel in secondary stroke prevention; (2) higher efficacy of combined therapy in the first 21 days post-stroke but increased hemorrhage risk with long-term dual therapy; (3) antiplatelet treatment failure influenced by poor adherence and genetic polymorphisms; and (4) potential differential benefit of cilostazol in certain racial groups. It does not address pre-treatment medical care patterns or their relationship to later compliance and outcomes.",
          "pmid": "35094598",
          "title": "Antiplatelet Use in Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares two aspirin doses in patients with established cardiovascular disease and reports clinical outcomes and dose switching, but it does not assess pre-treatment medical care intensity, healthcare utilization patterns, or how such factors might influence post-treatment compliance or outcomes. The mechanism about antiplatelet use serving as a marker of substantial prior medical care and thereby affecting later compliance/outcomes is not tested or discussed.",
          "key_findings": "Randomized, open-label trial of 81 mg vs 325 mg aspirin in 15,076 patients with atherosclerotic cardiovascular disease; most patients were already on aspirin pre-randomization (96%, mostly 81 mg). No significant difference in the composite outcome of death, MI, or stroke between doses (HR 1.02, 95% CI 0.91\u20131.14) and no significant difference in major bleeding (HR 1.18, 95% CI 0.79\u20131.77). Higher dose switching and fewer days at assigned dose in the 325 mg group. The study does not analyze or attribute outcomes to prior healthcare engagement or pre-treatment care patterns associated with antiplatelet use.",
          "pmid": "33999548",
          "title": "Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that drug\u2013drug interactions between antiseizure medications and anticoagulants or antiplatelets influence treatment decisions, but it does not examine whether antiplatelet use correlates with greater pre-treatment medical care, nor whether such a correlation affects post-treatment compliance or outcomes. No behavioral or care-pattern mechanisms related to antiplatelet use are evaluated.",
          "key_findings": "The abstract states that management of post-stroke seizures/epilepsy must consider drug\u2013drug interactions, especially between antiseizure medications and anticoagulants or antiplatelets, and that treatment decisions are influenced by age, comorbidities, and co-medications. It does not present data or discussion on how antiplatelet use reflects prior medical care intensity or impacts subsequent treatment adherence or outcomes.",
          "pmid": "33619704",
          "title": "Seizures and Epilepsy After Stroke: Epidemiology, Biomarkers and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses recommended secondary stroke prevention strategies, including antiplatelet use as part of best medical therapy, but does not address whether antiplatelet use correlates with greater pre-treatment medical care, nor does it examine how such a correlation might influence post-treatment compliance or outcomes.",
          "key_findings": "Antiplatelets are recommended as part of best medical therapy for intracranial large artery atherosclerosis and lacunar stroke, along with high-dose statins, aggressive vascular risk factor control, and lifestyle modifications; however, no data or statements are provided about patient care history, adherence, or behavioral outcomes related to antiplatelet use.",
          "pmid": "26300647",
          "title": "Secondary stroke prevention: challenges and solutions.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical outcomes (stroke recurrence, atrial fibrillation, adverse events) between PFO closure plus antiplatelets, anticoagulation, and antiplatelet therapy alone in a randomized trial. It does not analyze or report on patients\u2019 prior medical care utilization, pre-treatment healthcare engagement, or subsequent adherence/compliance behaviors as potential explanations for outcome differences. Thus it neither supports nor contradicts the proposed behavioral mechanism that antiplatelet use may correlate with substantial pre-treatment medical care influencing post-treatment compliance and outcomes.",
          "key_findings": "In a randomized trial of 663 patients with cryptogenic stroke attributed to PFO and high-risk features, PFO closure plus antiplatelet therapy was associated with no recurrent strokes versus 14 strokes in the antiplatelet-only group (HR 0.03, 95% CI 0\u20130.26). Anticoagulation showed fewer strokes than antiplatelets alone (3 vs 7 events). PFO closure had a higher rate of atrial fibrillation and some procedural complications. The study does not assess or report on pre-treatment medical care intensity or post-treatment compliance patterns related to antiplatelet use.",
          "pmid": "28902593",
          "title": "Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the efficacy and bleeding risks of aspirin in primary and secondary prevention using randomized trials, focusing on clinical vascular outcomes and adverse events. It does not analyze or report on patterns of pre-treatment medical care, patient behavior, or post-treatment compliance, nor does it examine whether antiplatelet use correlates with prior healthcare engagement or influences subsequent adherence or outcomes through such behavioral pathways.",
          "key_findings": "Low-dose aspirin reduces serious vascular events (particularly non-fatal myocardial infarction) but increases major gastrointestinal and extracranial bleeding; net benefit is clear in secondary prevention and uncertain in primary prevention. Similar proportional benefits are seen in men and women. Main coronary risk factors also predict bleeding risk. No data are presented on prior healthcare utilization, treatment-seeking behavior, or adherence-related outcomes.",
          "pmid": "19482214",
          "title": "Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares outcomes of IV thrombolysis versus best medical therapy and reports that results are unchanged in subgroups including patients using antiplatelets, but it does not examine whether antiplatelet use serves as a marker of greater pre-treatment medical care, nor does it analyze how such care might influence post-treatment compliance or outcomes. Thus it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "In this meta-analysis of 20 studies (13,397 patients) with minor ischemic stroke, IV thrombolysis showed no significant benefit over best medical therapy in functional outcomes or mortality, but increased risks of symptomatic intracranial hemorrhage and hemorrhagic transformation. Subgroup analysis indicated that the lack of improvement in excellent functional outcome (mRS 0\u20131) remained unchanged in patients with nondisabling deficits and in those using antiplatelets. No data were presented on pre-treatment medical care intensity, adherence, or behavioral factors linked to antiplatelet use.",
          "pmid": "38465591",
          "title": "Intravenous Alteplase Versus Best Medical Therapy for Patients With Minor Stroke: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses pharmacologic efficacy, bleeding risk, and general factors influencing choice of antiplatelet/anticoagulant therapy (including compliance), but it does not analyze whether antiplatelet use specifically correlates with greater pre-treatment medical care or how that might behaviorally influence post-treatment compliance or outcomes.",
          "key_findings": "The review states that antiplatelets and anticoagulants are key for secondary stroke prevention; short-term dual antiplatelet therapy is more effective than single therapy for certain patients; prolonged dual therapy increases bleeding risk; and treatment choice depends on stroke mechanism, genetic polymorphisms, bleeding risk, compliance, tolerance, and resistance. No data or discussion links antiplatelet use to prior medical care intensity or to subsequent adherence-related outcomes.",
          "pmid": "37037980",
          "title": "Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions secondary prevention with short-term dual antiplatelet therapy but does not discuss patients\u2019 prior medical care, its correlation with antiplatelet use, or how such pre-treatment care influences post-treatment compliance or outcomes. No behavioral or adherence-related mechanisms are evaluated.",
          "key_findings": "The review covers advances in acute ischemic stroke management, including emergency care protocols, thrombolysis, thrombectomy, physiologic management, and recent updates in secondary prevention such as short-term dual antiplatelet therapy after stroke. It does not address patterns of prior medical care or patient compliance.",
          "pmid": "32054610",
          "title": "Management of acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical efficacy and safety outcomes of anticoagulation versus antiplatelet therapy in cervical artery dissection but does not address pre-treatment medical care intensity, subsequent treatment compliance, or how antiplatelet use might correlate with broader healthcare engagement or behavioral outcomes. Therefore, it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "Meta-analysis of 11 studies (5039 patients) found that anticoagulation, compared with antiplatelets, was associated with lower ischemic stroke risk (RR 0.63) but higher major bleeding risk (RR 2.25), with similar risks of death and symptomatic intracranial hemorrhage; data on dual antiplatelet therapy and direct oral anticoagulants were insufficient.",
          "pmid": "38847098",
          "title": "Anticoagulation Versus Antiplatelets in Spontaneous Cervical Artery Dissection: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical outcomes between anticoagulants and antiplatelets in cervical artery dissection but does not examine pre-treatment medical care intensity, patient behavior, treatment adherence, or compliance-related outcome differences. Randomization and balanced baseline characteristics minimize differences in prior care and behavior, and no behavioral or compliance mechanisms are analyzed.",
          "key_findings": "Two RCTs (444 patients) comparing anticoagulants vs antiplatelets in cervical artery dissection showed: (1) no statistically significant difference in the composite primary endpoint of stroke, death, or major bleeding at 90 days; (2) fewer strokes but more bleeding events with anticoagulation vs aspirin; (3) baseline characteristics were balanced between groups. No data on pre-treatment medical care utilization or post-treatment compliance were reported.",
          "pmid": "38739383",
          "title": "Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical outcomes across different antithrombotic regimens after LAAO but does not assess patients\u2019 prior medical care intensity, adherence behavior, or how use of antiplatelets might serve as a proxy for substantial pre-treatment medical care. No data on compliance patterns or behavioral factors influencing post-treatment outcomes are presented, so the proposed behavioral mechanism is neither supported nor contradicted.",
          "key_findings": "Network meta-analysis of 41 studies (12,451 patients) found that DAPT, DOAC, DOAC+SAPT, and VKA were superior to no therapy in preventing device-related thrombosis; DOAC was associated with lower all-cause mortality than VKA; DAPT had fewer thromboembolic events than SAPT without increased major bleeding; DOAC monotherapy ranked best for lowering thromboembolic events and major bleeding. The abstract does not report on pre-treatment care intensity or adherence/compliance behaviors.",
          "pmid": "37611779",
          "title": "Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the clinical effectiveness and evidence base of antiplatelets (and other therapies) for cerebral venous thrombosis, but it does not address patterns of prior medical care, treatment-seeking behavior, adherence/compliance, or how antiplatelet use might correlate with broader pre-treatment healthcare utilization or post-treatment outcomes. Thus it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "Antiplatelets currently have little evidence for prevention or management of CVT; LMWH and unfractionated heparin are considered safe and effective first-line therapies; warfarin and DOACs have varying levels of supporting evidence. No information is provided about patients\u2019 prior medical care, healthcare utilization, or treatment adherence related to antiplatelet use.",
          "pmid": "39492709",
          "title": "Treatment of cerebral venous thrombosis: a review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares apixaban vs aspirin efficacy and bleeding risk across CHA2DS2-VASc strata in subclinical atrial fibrillation, but does not report on patterns of prior medical care, treatment adherence/compliance, or how antiplatelet use correlates with broader pre-treatment healthcare engagement or post-treatment outcomes. Thus it neither supports nor contradicts the proposed behavioral mechanism.",
          "key_findings": "Apixaban reduced stroke/systemic embolism compared with aspirin, particularly in patients with CHA2DS2-VASc >4, at the cost of increased major bleeding; in lower-risk groups (<4 or =4), net benefit was smaller or uncertain. No data on healthcare utilization, prior medical care intensity, adherence, or behavioral factors linked to antiplatelet use are provided.",
          "pmid": "39019530",
          "title": "Apixaban vs Aspirin According to CHA<sub>2</sub>DS<sub>2</sub>-VASc Score in Subclinical Atrial\u00a0Fibrillation: Insights From ARTESiA.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses evolving management strategies for atrial fibrillation, including limitations of aspirin, use of oral anticoagulants, risk stratification, and new antiarrhythmic or non-pharmacologic options. It does not address patterns of antiplatelet use as a marker of prior medical care, nor does it discuss how such use affects post-treatment compliance or clinical outcomes.",
          "key_findings": "The abstract highlights: (1) limitations of aspirin and increasing use of new oral anticoagulants versus warfarin; (2) a shift in stroke risk stratification to identify low-risk patients who may not need antithrombotic therapy; (3) introduction of new antiarrhythmic drugs and ablation as management options; and (4) management increasingly driven by symptoms. No data are presented on correlations between antiplatelet use, pre-treatment medical care intensity, or subsequent adherence and outcomes.",
          "pmid": "22166900",
          "title": "Atrial fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses guideline development for thrombolytic use in veterinary patients and briefly notes combination with antiplatelet drugs, but it does not examine or report data on whether antiplatelet use correlates with more extensive pre-treatment medical care or how that might influence post-treatment compliance or outcomes. No behavioral or care-pattern mechanisms are analyzed.",
          "key_findings": "The paper systematically reviews evidence on thrombolytics in dogs and cats with thrombosis, evaluates efficacy and safety, and generates guidelines. It notes that thrombolytics may be combined with anticoagulant or antiplatelet drugs, but provides no data on patient care history, treatment adherence, or outcome differences related to prior or concurrent antiplatelet use.",
          "pmid": "35881647",
          "title": "2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares early versus delayed initiation of aspirin after intracerebral haemorrhage surgery and reports clinical efficacy and safety outcomes. It does not analyze patients\u2019 broader pre-treatment medical care patterns, treatment adherence/compliance behaviors, or how antiplatelet use might correlate with such behaviors and influence outcomes. Therefore, it neither supports nor conflicts with the proposed behavioral mechanism about antiplatelet use serving as a proxy for substantial prior medical care and subsequent compliance.",
          "key_findings": "Early initiation of acetylsalicylic acid (day 3 post-surgery) versus late initiation (day 30) reduced 90-day major ischaemic cardiovascular/cerebrovascular/peripheral vascular events (20% vs 31%, OR 0.56 [95% CI 0.32\u20130.98]) without increasing intracranial bleeding (1% vs 3%). Non-bleeding serious adverse events were similar between groups (42% vs 42%). No data on pre-treatment care intensity or post-treatment compliance behavior are reported.",
          "pmid": "39577920",
          "title": "Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions antiplatelets as a main preventive therapy for recurrent cryptogenic stroke but does not discuss their relationship to the extent of pre-treatment medical care, patient compliance, or how such behavioral factors influence outcomes. Thus it neither supports nor refutes the proposed behavioral mechanism.",
          "key_findings": "In cryptogenic stroke, risk factor control, statins, and antiplatelets are described as the main therapeutic measures to prevent recurrent stroke; no behavioral or healthcare utilization/compliance aspects related to antiplatelet use are addressed.",
          "pmid": "25597418",
          "title": "Cryptogenic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses acute stroke treatments including early dual antiplatelet therapy but does not address patients\u2019 prior medical care, baseline healthcare engagement, or how antiplatelet use might correlate with pre-treatment care and influence post-treatment compliance or outcomes.",
          "key_findings": "Large trials have informed acute stroke care on topics such as expanding the thrombolysis window, alternatives to alteplase dosing, early dual antiplatelet therapy after minor ischemic stroke, and blood pressure management in intracerebral hemorrhage; the abstract does not mention prior care patterns or adherence-related behavioral mechanisms.",
          "pmid": "30229395",
          "title": "Acute Treatment of Stroke (Except Thrombectomy).",
          "analysis_method": "llm"
        }
      ]
    }
  ]
}